UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________
FORM 10-K
(Mark One)
☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the fiscal year ended: September 28, 2024
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 1-36214
__________________________________________________________
HOLOGIC, INC.
(Exact name of registrant as specified in its charter)
Delaware
04-2902449
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer Identification No.)
250 Campus Drive, Marlborough, Massachusetts 01752
(Address of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including Area Code (508) 263-2900
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock, $0.01 par value
HOLX
The NASDAQ Global Select Market
Securities registered pursuant to Section 12(g) of the Act: None
__________________________________________________________
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act. Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the
Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be
submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer,
smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one).
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act.
☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the
effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.
§7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements
of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of
incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period
pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.) Yes ☐ No ☒
The aggregate market value of the registrant's Common Stock held by non-affiliates of the registrant as of March 30,
2024 was $18,056,688,950 based on the price of the last reported sale on NASDAQ Global Select Market on that date.
As of November 21, 2024, 226,941,217 shares of the registrant’s Common Stock, $0.01 par value, were outstanding.
__________________________________________________________
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s Proxy Statement for the registrant’s annual meeting of stockholders to be filed within 120 days
of the end of its fiscal year ended September 28, 2024 are incorporated into Part III (Items 10, 11, 12, 13 and 14) of this Annual
Report on Form 10-K where indicated.
HOLOGIC, INC.
ANNUAL REPORT ON FORM 10-K
For the Fiscal Year Ended September 28, 2024
TABLE OF CONTENTS
Page
PART I
Item 1.
Business
6
Item 1A.
Risk Factors
19
Item 1B.
Unresolved Staff Comments
31
Item 1C.
Cybersecurity
32
Item 2.
Properties
33
Item 3.
Legal Proceedings
33
Item 4.
Mine Safety Disclosures
33
PART II
Item 5.
Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of
Equity Securities
34
Item 6.
Reserved
35
Item 7.
Management's Discussion and Analysis of Financial Condition and Results of Operations
36
Item 7A.
Quantitative and Qualitative Disclosures About Market Risk
52
Item 8.
Financial Statements and Supplementary Data
53
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
53
Item 9A.
Controls and Procedures
53
Item 9B.
Other Information
57
Item 9C
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
57
PART III
Item 10.
Directors, Executive Officers and Corporate Governance
58
Item 11.
Executive Compensation
58
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
58
Item 13.
Certain Relationships and Related Transactions, and Director Independence
58
Item 14.
Principal Accounting Fees and Services
59
PART IV
Item 15.
Exhibits and Financial Statement Schedules
60
Item 16.
Form 10-K Summary
66
3
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Some of the statements contained in this report and documents incorporated by reference herein are forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements involve known and unknown
risks, uncertainties and other factors which may cause our or our industry’s actual results, performance or achievements to be
materially different from any future results, performance or achievements expressed or implied by the forward-looking
statements. Forward-looking statements may include, but are not limited to, statements regarding:
• the development of new or improved competitive technologies and products;
• the anticipated development of markets we sell our products into and the success of our products in these markets;
• our ability to predict accurately the demand for our products, and products under development and to develop strategies to
address markets successfully;
• the anticipated performance and benefits of our products;
• business strategies;
• the effect of consolidation in the healthcare industry;
• the ability to execute acquisitions and the impact and anticipated benefits of completed acquisitions and acquisitions we
may complete in the future;
• the coverage and reimbursement decisions of third-party payors;
• the uncertainty of the impact of cost containment efforts and federal healthcare reform legislation on our business and
results of operations;
• the guidelines, recommendations, and studies published by various organizations relating to the use of our products;
• our ability to obtain and maintain regulatory approvals and clearances for our products, including the implementation of the
European Union Medical Device and In Vitro Diagnostic Regulation requirements, and maintain compliance with complex
and evolving regulations and quality standards, as well as the uncertainty of costs required to obtain and maintain
compliance with such regulatory and quality matters;
• the possibility that products may contain undetected errors or defects or otherwise not perform as anticipated;
• the impact and costs and expenses of investigative and legal proceedings and compliance risks we may be subject to now or
in the future;
• potential negative impacts resulting from climate change or other environmental, social, and governance and sustainability
related matters;
• the impact of future tax legislation;
• the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, such as inflation,
bank failures, rising interest rates and availability of capital markets, wars, conflicts, other economic disruptions and U.S.
and global recession concerns, on our customers and suppliers and on our business, financial condition, results of
operations and cash flows and our ability to draw down our revolver;
• the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulations and
tariffs, that may adversely impact the cost and sale of our products in certain countries, or increase the costs we may incur
to purchase materials, parts and equipment from our suppliers;
• conducting business internationally;
• potential cybersecurity threats and targeted computer crime;
• the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and
components, as well as cost inflation in materials, packaging and transportation;
• the possibility of interruptions or delays at our manufacturing facilities, or the failure to secure alternative suppliers if any
of our sole source third-party manufacturers fail to supply us;
• the ability to consolidate certain of our manufacturing and other operations on a timely basis and within budget, without
disrupting our business and to achieve anticipated cost synergies related to such actions;
• our ability to meet production and delivery schedules for our products;
• the effect of any future public health pandemic or other crises, including the timing, scope and effect of U.S. and
international governmental, regulatory, fiscal, monetary and public health responses to such crises;
• the ability to successfully manage ongoing organizational and strategic changes, including our ability to attract, motivate
and retain key employees and maintain engagement and efficiency in remote work environments;
4
• our ability to protect our intellectual property rights;
• anticipated trends relating to our financial condition or results of operations, including the impact of interest rate and
foreign currency exchange fluctuations;
• estimated asset and liability values;
• our compliance with covenants contained in our debt agreements; and
• our liquidity, capital resources and the adequacy thereof.
In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,”
“expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “likely,” “future,” “strategy,”
“potential,” “seeks,” “goal” and similar expressions intended to identify forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of
activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or
achievements expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue
reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions
only as of the date of this report. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking statement contained in this report to reflect any change in our
expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based.
Factors that could cause or contribute to differences in our future financial results include the cautionary statements set forth
herein and in our other filings with the Securities and Exchange Commission, including those set forth under “Risk Factors” set
forth in Part I, Item 1A of this Annual Report on Form 10-K (this “Annual Report”). We qualify all of our forward-looking
statements by these cautionary statements.
TRADEMARK NOTICE
Hologic is a trademark of Hologic, Inc. Other trademarks, logos, and slogans registered or used by Hologic and its
divisions and subsidiaries in the United States and other countries include, but are not limited to, the following: 3Dimensions,
3D Mammography, 3D, 3DQuorum, Acessa, Acessa ProVu, Affirm, Aptima, Aptima Combo 2, ATEC, BCI, BioZorb, Breast
Cancer Index, Brevera, CancerTYPE ID, Celero, Hologic Clarity HD, CoolSeal, C-View, DirectRay, Dimensions, Endomag,
Eviva, Faxitron, Fluent, Fluoroscan, Focal Therapeutics, Genius 3D, Genius, Genius AI, Hologic, Horizon, InSight, Intelligent
2D, ImageChecker, JustRight, LOCalizer, Magtrace, Magseed, MyoSure, NovaSure, Omni, Panther, Panther Fusion,
PreservCyt, Progensa, Quantra, Rapid Ffn, SecurView, Selenia, Sentimag, Sertera, SmartCurve, Smart-Depth, ThinPrep, and
Tomcat.
All other brand names or trademarks appearing in this Annual Report are the property of their respective owners.
Hologic’s use or display of other parties’ trademarks, trade dress or products in this Annual Report does not imply that Hologic
has a relationship with, or endorsement or sponsorship of, the trademark or trade dress owners.
5
PART I
Item 1. Business
Overview
We are a developer, manufacturer and supplier of premium diagnostics products, medical imaging systems, and surgical
products focused on women's health and well-being through early detection and treatment. We sell and service our products
through a combination of direct sales and service personnel and a network of independent distributors and sales representatives.
We operate in four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health.
Through our Diagnostics segment, we offer a wide range of diagnostic products, which are used primarily to aid in the
screening and diagnosis of human diseases. Our primary Diagnostics products include our molecular diagnostic assays, which
run on our advanced instrumentation systems (Panther and Panther Fusion), our ThinPrep cytology system, including our
Genius Digital Diagnostics System, and the Rapid Fetal Fibronectin Test. Our Aptima family of molecular diagnostic assays is
used to detect, among other things, the infectious microorganisms that cause common sexually transmitted diseases, or STDs,
such as chlamydia and gonorrhea, or CT/NG; certain high-risk strains of human papillomavirus, or HPV; Trichomonas
vaginalis, the parasite that causes trichomoniasis; Mycoplasma genitalium; and Herpes Simplex viruses 1 and 2. We also offer
viral load tests for the quantitation of Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, or HIV-1, and
human cytomegalo virus, or CMV, for use on our Panther instrument system. In addition, we offer bacterial vaginosis and
candida vaginitis assays for the diagnosis of vaginitis, a common and complex ailment affecting millions of women a year. Our
assay portfolio also includes diagnostic tests for a range of acute respiratory infections, including SARS-CoV-2, various strains
of influenza and parainfluenza, and respiratory syncytial virus, as well as a test for the detection of Group B Streptococcus, or
GBS, that are run on the Panther Fusion system, a field upgradeable instrument addition to the base Panther system. In response
to the COVID-19 pandemic, we developed and launched the Aptima SARS-CoV-2 assay and the Aptima SARS-CoV-2/Flu
assay (each of which runs on our standard Panther system) and the Panther Fusion SARS-CoV-2 assay and the Panther Fusion
SARS-CoV-2/Flu A/B/RSV assay (which run on our Panther Fusion system). In May 2022, we obtained CE-marking for two
new molecular assays, Panther Fusion EBV Quant assay for quantitation of Epstein-Barr virus, and the Panther Fusion BKV
Quant assay for quantitation of the BK virus. These two assays are the first quantitative real-time PCR assays on the Panther
Fusion system, and, together with the Aptima CMV Quant assay, expand our menu of transplant monitoring assays. The
ThinPrep System is primarily used in cytology applications, such as cervical cancer screening, and the Rapid Fetal Fibronectin
Test assists physicians in assessing the risk of pre-term birth. We also generate service revenues from our CLIA-certified
laboratory for testing related to breast cancer and all metastatic cancers.
Our Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology.
These solutions include 3D digital mammography systems, image analysis software utilizing artificial intelligence, reading
workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen
radiology systems. Our most advanced breast imaging platforms, Selenia 3D Dimensions and 3Dimensions systems, utilize
tomosynthesis to produce 3D images that show multiple contiguous slice images of the breast.
Our GYN Surgical products include our MyoSure hysteroscopic tissue removal system, our NovaSure endometrial
ablation system, our Fluent fluid management system, our Acessa ProVu laparoscopic radiofrequency ablation system, as well
as our CoolSeal vessel sealing portfolio and our JustRight surgical stapler. The MyoSure suite of devices offers four options to
provide incision-less removal of fibroids, polyps, and other pathology within the uterus. The NovaSure portfolio is comprised
of the NovaSure ADVANCED device and the NovaSure V5 device for the treatment of abnormal uterine bleeding. The Fluent
and Fluent Pro fluid management system provides liquid distention during diagnostic and operative hysteroscopic procedures.
The Acessa ProVu system is a fully integrated system that uses laparoscopic ultrasound, guidance mapping and radiofrequency
ablation to treat nearly all types of fibroids. The CoolSeal portfolio includes the CoolSeal Trinity, CoolSeal Reveal, and
CoolSeal Mini advanced bipolar vessel sealing devices. The JustRight 5 mm stapler features a smaller instrument profile and is
used for laparoscopic general and pediatric surgery.
Our Skeletal Health segment's products include the Horizon DXA, a dual energy x-ray system, which evaluates bone
density and performs body composition assessments, and the Fluoroscan Insight FD mini C-arm, which assists in performing
minimally invasive orthopedic surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot, and ankle.
Unless the context otherwise requires, references to “we”, “us”, “Hologic” or “the Company” refer to Hologic, Inc. and
its consolidated subsidiaries.
6
Available Information
Our internet website address is www.hologic.com. Through our website, we make available, free of charge, our annual
report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to those reports, as
well as proxy statements, and, from time to time, other documents as soon as reasonably practicable after we electronically file
such material with, or furnish it to, the Securities and Exchange Commission (SEC). These SEC reports can be accessed
through the investor relations section of our website. The information found on our website is not part of this or any other report
we file with or furnish to the SEC.
Investors and others should note that we announce material financial information to our investors using our investor
relations website (investors.hologic.com), SEC filings, press releases, public conference calls and webcasts. We use these
channels as well as social media to communicate with the public about our Company, our services and other issues. It is
possible that the information we post on social media could be deemed to be material information. Therefore, we encourage
investors, the media, and others interested in our Company to review the information we post on the social media channels
listed on our investor relations website. We have used, and intend to continue to use, our investor relations website, as well as
our X (formerly Twitter) account (@Hologic), as means of disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD. Additional corporate governance information, including our certificate of
incorporation, bylaws, governance guidelines, board committee charters, and code of business conduct and ethics, is also
available on our investor relations website under the heading “Governance.” The contents of our websites are not intended to be
incorporated by reference into this Annual Report or in any other report or document we file with the SEC, and any references
to our websites are intended to be inactive textual references only. Although we reference the availability of our U.S. Federal
Employment Information Report (EEO-1) on our website, our EEO-1 and any other materials on our website are not
incorporated by reference into this Annual Report or any of our other filings under the Securities Act of 1933, as amended, or
the Exchange Act. While matters discussed in such EEO-1, other website materials and our X and other social media accounts
may be significant, any significance should not be read as necessarily rising to the level of materiality used for the purposes of
our compliance with the U.S. federal securities law, even if we use the word “material” or “materiality” in such materials.
The SEC maintains an internet website that contains reports, proxy and information statements, and other information
regarding Hologic and other issuers that file electronically with the SEC. The SEC’s internet website address is www.sec.gov.
Products
We view our operations and manage our current business in four principal reporting segments: Diagnostics, Breast
Health, GYN Surgical and Skeletal Health. Financial information concerning these segments is provided in Note 16 to our
audited consolidated financial statements contained in Item 15 of this Annual Report. The following describes our principal
products in each of our segments.
Diagnostics Product Offerings
Molecular Diagnostic Instrumentation
We have developed and continue to develop instrumentation and software designed specifically for use with certain of
our molecular diagnostic assays. We also provide technical support and service to maintain these instrument systems in the
field. By placing our proprietary instrumentation in laboratories and hospitals, we can establish a platform for future sales of
our assays.
Our instrumentation includes the Panther instrument system, an integrated, fully automated testing instrument capable of
serving high-, medium- and low-volume laboratories. Our Panther Fusion system, including the related Fusion assays for flu,
respiratory, Group B Strep (GBS), and transplant testing, extends the capabilities of our Panther system by adding the flexibility
of polymerase chain reaction, or PCR, functionality to our existing Transcription Mediated Amplification, or TMA, based
technology. The Panther Fusion system is available as a modular in-lab upgrade to our base Panther system. In addition, our
instrumentation also includes the Tomcat instrument, a fully automated general-purpose instrument designed to improve pre-
analytical sample processing by eliminating the inefficient and error-prone activities associated with manually transferring
samples from one tube to another.
Molecular Diagnostic Assay Portfolio
We have a broad menu of assays available for sale in our primary markets that can be performed on the base Panther
System or on the combined Panther Fusion System as indicated in the table below. Our Aptima family of molecular diagnostic
assays integrates a number of proprietary core technologies, including our target capture technology, our TMA technology, and
our hybridization protection assay, or HPA, and dual kinetic assay, or DKA, technologies, to produce highly sensitive
amplification assays. Each of these technologies is described in greater detail below under the heading “Proprietary Core
7
Technologies”. Our Panther Fusion family of molecular diagnostic assays are performed on the Panther Fusion System and
utilize PCR technology to amplify target nucleic acid sequences for easier detection.
Unless otherwise noted, the assays shown in the table below have been approved or cleared for sale in the U.S. and are
available for sale in countries recognizing the CE-mark. Certain of the assays shown below are also available in certain other
markets such as Australia, Canada, China, Japan, New Zealand, South Korea and the United Kingdom.
Aptima-branded assays that are performed on
the base Panther System
Panther Fusion-branded assays that are
performed on the Panther Fusion System
Aptima HPV assay
Panther Fusion Flu A/B/RSV assay
Aptima HPV 16 18/45 Genotype assay
Panther Fusion Paraflu assay
Aptima HBV Quant assay
Panther Fusion AdV/hMPV/RV assay
Aptima CMV Quant assay
Panther Fusion SARS-CoV-2/Flu A/B/RSV assay
Aptima HIV-1 Quant Dx assay
Panther Fusion GBS assay
Aptima HCV Quant Dx assay
Panther Fusion MRSA assay2
Aptima Mycoplasma genitalium assay
Panther Fusion Bordetella assay2
Aptima Combo 2 assay (CT/NG)
Panther Fusion EBV Quant assay2
Aptima Chlamydia trachomatis assay (CT)
Panther Fusion BKV Quant assay2
Aptima Neisseria gonorrhoeae (NG)
Panther Fusion SARS-CoV-2 assay1,3
Aptima Trichomonas vaginalis assay
Aptima HSV 1 and 2 assay
Aptima CV/TV assay
Aptima BV assay
Aptima Zika assay1
Aptima SARS-CoV-2 assay1
Aptima SARS-CoV-2/Flu assay1
1 This assay is subject to an Emergency Use Authorization (EUA) in the U.S. that may be revoked upon notice by the Food and
Drug Administration (FDA).
2 This assay is available for sale in countries recognizing the CE-mark, and is not currently available for sale in the U.S.
3 This assay is not currently available for sale in countries recognizing the CE-mark.
Proprietary Core Technologies
Target Capture/Nucleic Acid Extraction Technology. The detection of target organisms that are present in small numbers
in a large-volume clinical sample requires that target organisms be concentrated to a detectable level. One way to accomplish
this is to isolate the particular nucleic acid of interest by binding it to a solid support. This support, with the target bound to it,
can then be separated from the original sample. We refer to such techniques as “target capture.” We have developed target
capture techniques to immobilize nucleic acids on magnetic beads by using a “capture probe” that binds to the bead and to the
target nucleic acid. We use magnetic separation to concentrate the target by drawing the magnetic beads to the sides of a sample
tube, while the remainder of the sample is removed from the tube. When used in conjunction with our amplification procedures,
target capture techniques concentrate the nucleic acid target(s) and also remove materials in the sample that might otherwise
interfere with amplification.
Transcription-Mediated Amplification (TMA) Technology. The goal of amplification technologies is to increase the copy
number of a target nucleic acid sequences that may be present in samples in small numbers. These copies can then be detected
using nucleic acid probes. Amplification technologies can yield results in only a few hours versus the several days or weeks
required for traditional culture methods. TMA is a transcription-based amplification system that uses two different enzymes to
drive the process. The first enzyme is a reverse transcriptase that creates a double-stranded DNA copy from an RNA or DNA
template. The second enzyme, an RNA polymerase, makes thousands of copies of the complementary RNA sequence, known
as the “RNA amplicon,” from the double-stranded DNA template. Each RNA amplicon serves as a new target for the reverse
transcriptase and the process repeats automatically, resulting in an exponential amplification of the original target that can
produce over a billion copies of the RNA amplicon in less than thirty minutes.
8
Hybridization Protection Assay (HPA) and Dual Kinetic Assay (DKA) Technologies. With our HPA technology, we have
simplified testing, further increased test sensitivity and specificity, and increased convenience. In the HPA process, the
acridinium ester, or AE, molecule is protected within the double-stranded helix that is formed when the probe binds to its
specific target. Prior to activating the AE molecule, known as “lighting off,” a chemical is added that destroys the AE molecule
on any unhybridized probes, leaving the label on the hybridized probes largely unaffected. When the “lighting off” or detection
reagent is added to the specimen, only the label attached to the hybridized probe is left to produce a signal indicating that the
target organism’s DNA or RNA is present. All of these steps occur in a single tube and without any wash steps, which were
required as part of conventional probe tests. Our DKA technology uses two types of AE molecules that can be differentiated
from each other — one that “flashes” and another one that “glows.” By using DKA technology, we have created nucleic acid
test, or NAT, assays that can detect two separate targets simultaneously.
ThinPrep System
The ThinPrep System is the most widely used method for cervical cancer screening in the U.S. The ThinPrep System has
multiple configurations, including one or more of the following: the ThinPrep 2000 Processor, ThinPrep 5000 Processor,
ThinPrep 5000 Processor with Autoloader, ThinPrep Genesis Processor, ThinPrep Imaging System, ThinPrep Integrated
Imager, and related reagents, filters and other supplies, such as the ThinPrep Pap Test and our ThinPrep PreservCyt Solution.
The ThinPrep Process. The ThinPrep process begins with the patient’s cervical sample being obtained by the physician
using a cervical sampling device that, rather than being smeared on a microscope slide as in a conventional Pap smear, is
inserted into a vial filled with our proprietary ThinPrep PreservCyt Solution. This enables most of the patient’s cell samples to
be preserved before the cells can be damaged by air drying. The ThinPrep specimen vial is then labeled and sent to a laboratory
equipped with a ThinPrep Processor for slide preparation. At the laboratory, the ThinPrep specimen vial is inserted into a
ThinPrep Processor, a proprietary sample preparation device, which automates the process of preparing cervical slides for
staining and microscopic examination. Additionally, an aliquot used for subsequent molecular testing can be produced using the
ThinPrep Genesis Processor.
In the case of manual screening, the cytotechnologist screens each Pap test slide with a microscope to first determine the
adequacy of the slide and then to examine the entire slide to differentiate diseased or abnormal cells from normal cells. With the
ThinPrep Imaging Systems, the screening process has been automated to combine the power of computer imaging technology
with human interpretive skills. Prior to human review, the ThinPrep Imaging Systems rapidly scan, locate and highlight areas of
interest for review. By directing the cytotechnologist to areas of interest on a slide, these systems may increase a cytology
laboratory’s screening productivity and diagnostic accuracy.
Additional Applications. In addition to serving as a replacement for the conventional Pap smear, the ThinPrep System can
also be used for non-gynecological cytology screening applications including fine-needle aspiration specimens (e.g., breast,
thyroid, lung or liver), body fluids (e.g., urine, pleural fluid, ascitic fluid or pericardial fluid), respiratory specimens (e.g.,
sputum or brushing of respiratory tracts) and ancillary testing (e.g., cell blocks, immunocytochemistry or special stains).
Genius Digital Diagnostics System
The Genius Digital Diagnostics System with the Genius Cervical AI Algorithm is the first CE-marked and FDA-cleared
digital cytology platform to combine a new artificial intelligence, or AI, algorithm with advanced volumetric imaging
technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cervical cancer cells in women. The
Genius Digital Diagnostics System consists of an advanced digital imager featuring volumetric imaging technology, a secure
image management server to store images, a deep learning-based AI algorithm that is designed to assist healthcare providers in
detecting pre-cancerous lesions and cervical cancer cells, and a high-resolution review station for local or remote case review.
The Genius Digital Diagnostics System can rapidly analyze all cells on a ThinPrep Pap test digital image, narrowing tens of
thousands of cells down to an AI-generated gallery of images that have been selected as the most diagnostically relevant
images, which gives healthcare providers additional critical information to help guide earlier detection and make better
treatment decisions for patients. The Genius Digital Diagnostics System was CE-marked for diagnostic use in the EU in
November 2020 and received marketing clearance from the FDA for diagnostic use in the U.S. in January 2024.
Rapid Fetal Fibronectin Test
The Rapid Fetal Fibronectin Test is a single-use disposable test used to determine a woman’s risk of pre-term birth by
detecting the presence of a specific protein, fetal fibronectin, in vaginal secretions during pregnancy. The test utilizes a single-
use, disposable cassette and is analyzed on our instrument, the TLi IQ System.
Oncology Product Offerings
Our Biotheranostics business offers two proprietary laboratory developed tests, or LDTs, that support physicians in the
treatment of cancer: the Breast Cancer Index test and the CancerTYPE ID test. The Breast Cancer Index, or BCI, test is a PCR-
9
based gene expression test used for determining which patients with early-stage, hormone-receptor positive, or HR+, breast
cancer are likely to benefit from extended endocrine therapy. In January 2021, the National Comprehensive Cancer Network
revised its clinical practice guidelines to include BCI as the only gene expression assay to predict benefit from extended
endocrine therapy for patients with early-stage HR+ breast cancer. In addition, in April 2022 the American Society of Clinical
Oncology updated its clinical practice guidelines, which now include BCI as the only genomic test to help guide extended
endocrine therapy decisions in early-stage, HR+ breast cancer patients. The CancerTYPE ID test is a PCR-based gene
expression test that is designed to identify the source of metastatic cancer in order to improve diagnostic accuracy and inform
treatment decisions. Both of these LDTs are offered as a service solely out of Biotheranostics' licensed, CLIA-certified, CAP-
accredited laboratory in San Diego, California.
Breast Health Products
Mammography Solutions
Our Dimensions platform includes the Selenia Dimensions and 3Dimensions systems capable of performing full field
digital mammography (2D) and digital breast tomosynthesis (3D) exams. When performing a 3D exam, each system acquires a
series of low dose x-ray images taken in a scanning motion at various angles. The images are mathematically reconstructed into
a series of small contiguous slices, allowing for visualization of the breast tissue through multiple layers. Our clinical results for
FDA approval demonstrated that full field digital mammography (2D) with the addition of our 3D Mammography is superior to
2D digital mammography alone for both screening and diagnostics. Hologic Clarity HD technology provides our highest
resolution imaging at 70 micron pixel size compared to the standard resolution technology of 100 micron pixel size. Our C-
View and Intelligent 2D software products generate 2D images that are mathematically synthesized from the tomosynthesis
data. These software products are FDA approved to replace full field digital mammography (2D) images within a 3D exam.
Synthesized 2D images eliminate the need for additional 2D exposure, reducing breast compression time and radiation exposure
compared to a “combo” exam, which includes a tomosynthesis (3D) exam and a full field digital mammography (2D) exam.
Our 3DQuorum technology is an artificial intelligence, or AI, powered algorithm that expedites mammography exam
reading time without compromising image quality, sensitivity or accuracy. The 3DQuorum technology uniquely reconstructs
Hologic Clarity HD 3D data to produce 6 mm “SmartSlices.” By utilizing 3DQuorum technology the number of 3D images to
review is reduced by two-thirds, saving an estimated average of one hour per eight hours of daily image interpretation time. The
3DQuorum technology also reduces the typical Hologic Clarity HD and Intelligent 2D study size by approximately 50%,
bringing the storage space and network impact back down to that of standard resolution 3D imaging.
The images captured by digital mammography systems are typically transmitted electronically for review by a radiologist
at a reading workstation. To address this process, we offer the SecurView DX workstation approved for interpretation of
mammograms as well as images from other diagnostic breast modalities including breast ultrasound and breast MRI. We also
offer image analytic products such as the Genius AI Detection solution (Hologic’s first artificial intelligence cancer detection
algorithm utilizing deep-learning technology for tomosynthesis), ImageChecker CAD-solution (provides markings of
suspicious areas of the breast that may be cancerous in 2D exams), and Quantra software (automates breast density
measurement for our mammography systems). These technologies provide reviewers with the potential to focus on key patients
that might otherwise be overlooked during the review process for additional diagnostic workups, thus potentially increasing
cancer detection.
Stereotactic Breast Biopsy Systems
We provide clinicians flexibility by offering two minimally invasive stereotactic breast biopsy guidance systems: the
Affirm prone and the Affirm upright breast biopsy guidance systems. The Affirm upright biopsy system is an attachment
designed to integrate with our Dimensions systems, transforming it into a versatile tool for both screening and tomosynthesis
biopsy. The Affirm prone biopsy system is a dedicated prone stereotactic biopsy system capable of both 2D and tomosynthesis-
guided procedures. These systems provide an alternative to open surgical biopsy and can be performed as an outpatient
procedure under local anesthesia, allowing shorter recovery times. The Affirm tomosynthesis option provides faster lesion
targeting and reduced patient procedure time compared to traditional stereotactic biopsy procedures. The Affirm system is pre-
programmed for use with our Brevera, Eviva and ATEC vacuum-assisted breast biopsy devices.
Breast Biopsy and Surgery Products
We offer a wide range of minimally invasive products for breast biopsy and breast surgery. Our breast biopsy portfolio
includes three types of tethered vacuum-assisted breast biopsy products: the Brevera, ATEC, and Eviva devices. Each tethered
device is powered by a console and utilizes our fluid management system. The ATEC device can be used under all standard
imaging guidance modalities (stereotactic x-ray, ultrasound, MRI and molecular breast imaging) whereas our Brevera and
Eviva devices are used exclusively under stereotactic x-ray guidance. We also offer non-tethered, spring-loaded, and vacuum-
assisted core biopsy devices, such as the Celero and Sertera, which are exclusively used under ultrasound guidance. We also
10
have products for surgical site marking, tissue localization, and sentinel lymph node biopsies, as well as specimen imaging
products for radiology, surgery and pathology. Our acquisition of Endomagnetics Ltd (Endomag) complements and diversifies
our expanding interventional breast health portfolio by adding wire-free breast surgery localization and lymphatic tracing
solutions, including the Magseed marker, the Magtrace lymphatic tracer and the Sentimag platform, to Hologic’s breast surgery
portfolio, providing breast surgeons and radiologists with an expanded range of options and enhanced user experience.
GYN Surgical Products
MyoSure
The MyoSure system is designed to provide efficient and effective hysteroscopic removal of tissue within the uterus,
including fibroids and polyps. Removal of fibroids can provide effective relief from heavy menstrual bleeding commonly
attributed to such pathology. Unlike other methods of tissue removal, the excavated tissue samples remain intact, which allows
them to be tested for abnormalities. The MyoSure system consists of a tissue removal device, control unit, and hysteroscope.
The MyoSure tissue removal device is single-use and features simultaneous tissue cutting and removal. The device incorporates
a rapidly rotating and reciprocating cutting blade. During the procedure, the tissue removal device is inserted through the Omni
hysteroscope. This tissue removal device is powered by a control unit, which features a simple user interface and is foot pedal
activated. We offer multiple handpiece devices that differ in size and are focused on addressing visualized tissue sampling and
different pathology types.
NovaSure
The NovaSure endometrial ablation system allows physicians to treat women suffering from abnormal uterine bleeding.
The system features Smart-Depth technology that continuously monitors and measures tissue impedance to provide a more
customized, reliable and reproducible depth of ablation for every patient. The NovaSure system consists of a disposable device
and a controller that delivers radiofrequency energy (heat) to ablate the endometrial lining of the uterus in order to eliminate or
reduce the patient’s abnormal bleeding. The NovaSure disposable device is a hand-held, single-use device that incorporates a
flexible gold-plated mesh electrode used to deliver the radiofrequency energy to the endometrial tissue. The NovaSure
ADVANCED and NovaSure V5 devices have a slim diameter designed to improve patient comfort and physician ease-of-use
while maintaining the clinical efficacy of the NovaSure system.
Fluent Fluid Management System
Our Fluent fluid management portfolio can be utilized for diagnostic and operative hysteroscopic procedures, including
MyoSure tissue removal. Both the Fluent and Fluent Pro systems feature an intuitive touch screen design, innovative FloPak
cartridge design, and a single waste bag design that eliminates the need for multiple canisters. Therefore, the Fluent and Fluent
Pro systems are designed for simplified setup and operation, and streamlined workflow for the operating room team.
Acessa ProVu System
The Acessa ProVu system is used by laparoscopic surgeons to treat fibroids using controlled radiofrequency energy to
cause coagulative necrosis. The treated tissue softens and shrinks over time, allowing fibroid symptoms to resolve without more
invasive treatment. The Acessa system includes an ultrasound probe to locate the fibroids, guidance mapping that provides
visual cues, and a percutaneous handpiece that deploys radiofrequency energy.
Advanced Energy and Surgical Stapling
The CoolSeal vessel sealing suite and JustRight surgical stapler bolster our laparoscopic surgical offerings with advanced
vessel sealing, dividing, dissection, and stapling tools. The CoolSeal Trinity and CoolSeal Reveal devices allow for dissection,
vessel sealing and dividing all in one tool. The ability to use a combination device improves surgical efficiency by reducing the
need for instrument exchanges. In addition, the CoolSeal Mini 3 mm sealer and the JustRight 5 mm stapler are designed for
small surgical spaces such as in pediatric cases, which can help reduce the need for larger, overpowered instruments.
Skeletal Health Products
Horizon DXA Systems
Bone densitometry is the measurement of bone density to assist in the diagnosis and monitoring of osteoporosis and other
metabolic bone diseases that can lead to frailty and debilitating bone fractures. Osteoporosis is a disease that is most prevalent
in post-menopausal women. Our Horizon line of x-ray bone densitometers incorporates advanced features designed for bone
health screening and body composition assessment. Body composition assessment is the precise measurement of bone, lean
mass, and fat mass within the body. These measurements provide value in diverse settings, from clinical cancer care, obesity
and diabetes medicine, and preventative healthcare, to athletic performance.
11
Fluoroscan Insight FD
Our Fluoroscan Insight FD is a mini C-arm imaging system that provides low intensity, real-time x-ray imaging, with
high-resolution images at radiation levels and at a cost below those of conventional x-ray and standard sized fluoroscopic
equipment. Mini C-arm systems are used primarily by orthopedic surgeons to assist in performing minimally invasive surgical
procedures on a patient’s extremities, such as the hand, wrist, knee, foot and ankle.
Marketing, Sales and Service
We sell and service our products through a combination of direct sales and service forces and a network of independent
distributors and sales representatives. In fiscal 2024, 2023, and 2022, no customer accounted for more than 10% of our
consolidated revenues.
Our U.S. sales force is structured to specifically target the customers in each of our business segments. We maintain
distinct teams focused on the Diagnostics, Breast Health, GYN Surgical, and Skeletal Health markets. Our end customers
include clinical laboratories, hospitals, healthcare providers and surgeons in both hospital and office settings, and we target
various specialists at healthcare entities who use our products, such as ob-gyns, radiologists and breast surgeons.
A critical element of our strategy in the U.S. for our Diagnostics, Breast Health, GYN Surgical, and Skeletal Health
divisions has been to utilize the results of our clinical trials and expanded FDA labeling to demonstrate safety, efficacy and
productivity improvements to our target customers. Our U.S. sales efforts also include the use of national account managers
focused on obtaining purchasing contracts from large purchasing entities, such as managed care organizations, integrated
delivery networks and government healthcare facilities. In addition, in certain regions of the U.S., we use a limited number of
independent dealers or distributors to sell and service certain of our products. Internationally, our products in all divisions are
marketed and sold through a combination of our direct sales force (primarily Western Europe, China, Japan, Australia, South
Korea and Canada) and a network of distributors.
Our service organization is responsible for installing our products and providing warranty and repair services,
applications training and biomedical training. Products sold by our direct sales force typically carry limited warranties covering
parts and labor for twelve months. Products sold through dealers also carry limited warranties that are typically for twelve
months and cover only parts and components. We also offer service contracts that generally cover equipment and maintenance
after the original warranty period from one to three years. We provide both repair services and routine maintenance services
under these arrangements, and also offer repair and maintenance services on a time and materials basis to customers that do not
have service contracts. Our Breast Health business generates a majority of our service revenue from service contracts for our
digital mammography portfolio. Internationally, generally in locations where we sell directly, we also perform maintenance
services for our products, and in other geographies we primarily use distributors, sales representatives and third parties to
provide maintenance services for our products.
Competition
The healthcare industry is highly competitive and characterized by continual change and improvements in technology.
This is particularly the case in the market segments in which we operate. A number of companies have developed or are
expected to develop products that compete or will compete with our products. Many of these competitors offer a broader
product portfolio and have greater brand recognition than we do, which may make these competitors more attractive to
hospitals, radiology clients, group purchasing organizations, laboratories, physicians and other potential customers. Competitors
may develop superior products or products of similar quality for sale at the same or lower prices. Moreover, our products could
be rendered obsolete by changes to industry standards or guidelines or advances in technology. We can give no assurance that
we will be able to compete successfully with existing or new competitors.
In the current environment of managed care, economically motivated buyers, consolidation among healthcare providers,
increased competition and declining reimbursement rates, we have been increasingly required to compete on the basis of price,
value, reliability and efficiency. We believe the current global economic conditions and healthcare reform measures are putting
additional competitive pressure on us, including on our average selling prices, overall procedure rates and market sizes.
As a provider of women’s health products and solutions designed to detect, diagnose and treat diseases across the care
continuum, we encounter significant competition across our product lines in each of the market segments in which we operate.
Most competition comes from larger companies that have greater financial, sales and marketing resources than we do in large
markets like diagnostics, imaging and surgery.
In our Diagnostics business, our primary competitors are Roche Diagnostics and Becton Dickinson, as well as a wide
range of diagnostics companies that sell a single or limited number of assays or products in only a specific market segment (i.e.,
Cytology, Acute Care, or Oncology Services).
12
In our Breast & Skeletal Health business, our primary competitors are large imaging companies such as Siemens
Healthineers and GE Healthcare, as well as a wide range of medical technology companies that sell a subset of technology
solutions into a specific market segment (i.e., Breast Biopsy, Breast Surgery).
In our GYN Surgical business, our primary competitors are large, full suite surgical solutions companies such as Johnson
& Johnson and Medtronic, as well as a wide range of single technology or solutions companies that sell into a specific market
segment or procedure (i.e., Hysterectomy). In addition, we also compete with alternative treatments to our NovaSure system,
such as drug therapy, intrauterine devices, hysterectomy, dilation and curettage and rollerball ablation. Because drug therapy is
an alternative to our NovaSure procedure, competitors to NovaSure also include many major pharmaceutical companies that
manufacture hormonal drugs for women.
In addition, our International team faces significant global and regional competition across our entire portfolio, with local
competition also playing a role in countries where local suppliers may be advantaged. We also face competition from non-
medical technology or diagnostics companies, which may offer alternative tests or therapies for illnesses and other health
conditions that could also be detected, diagnosed or treated by our products and solutions, or from companies offering
technologies that could augment, precede or replace procedures using our products.
We believe that the success of our products depends on our ability to differentiate ourselves and to demonstrate that our
products deliver the clinical and operational attributes that are most important and cost-effective to customers. These attributes
include, but are not limited to, superiority in efficacy, ease of use, reliability, accuracy, quality and cost. We believe our
continued success depends in large part upon our ability to invest in product enhancements and technologies that will help us
distinguish ourselves from our competitors.
Manufacturing
We purchase many of the components, subassemblies, and raw materials used in our products from numerous suppliers
worldwide. For reasons of quality assurance, scarcity and/or cost effectiveness, certain components, subassemblies, and raw
materials used in our products are available only from one or a limited number of suppliers. We work closely with our suppliers
to develop contingency plans to ensure continuity of quality and reliable supply. We have established long-term supply
contracts with many of our suppliers, and in other instances, we developed an in-house capability to offset potential shortages
caused by sole source suppliers. Due to the high standards and FDA requirements applicable to manufacturing our products,
such as the FDA's Quality System Regulation and Good Manufacturing Practices, we may not be able to quickly establish
additional or replacement sources for certain components or materials. In the event we are unable to obtain sufficient quantities
of raw materials or components or subassemblies on commercially reasonable terms or in a timely manner, our ability to
manufacture our products on a timely and cost-competitive basis may be compromised, which may have a material adverse
effect on our business, financial condition and results of operations.
Our current supplier of certain key raw materials for certain of our amplified NAT diagnostic assays is Roche, a direct
competitor of our Diagnostics business.
We have sole source third-party contract manufacturers for each of our molecular diagnostics instrument product lines
and for our Skeletal Health products. Stratec SE, or Stratec, is the only manufacturer of the Panther and Panther Fusion
instruments; and Flextronics Medical Sales and Marketing, LTD, or Flextronics, is the only manufacturer of our Skeletal Health
finished goods products. We are dependent on these sole source third-party manufacturers, and this dependence exposes us to
increased risks associated with production delays, delivery schedules, manufacturing capability, quality control, quality
assurance and costs. We have no firm long-term volume commitments with either Stratec or Flextronics. If Stratec, Flextronics
or any of our other third-party manufacturers experiences delays, disruptions, capacity constraints or quality control problems in
its development or manufacturing operations, curtails operations or otherwise fails to supply us with products in sufficient
quantities, instrument and equipment shipments to our customers could be delayed or cancelled, which would decrease our
revenues and may harm our competitive position and reputation. Further, because we place orders with our manufacturers based
on forecasts of expected demand for our molecular diagnostics instruments and Skeletal Health products, if we inaccurately
forecast demand, we may be unable to obtain adequate manufacturing capacity or adequate quantities of components to meet
our customers' delivery requirements.
We, and our contract manufacturers, manufacture our products at a limited number of different facilities located in the
U.S. and throughout the world. In most cases, the manufacturing of each of our products is concentrated in one or a few
locations. An interruption in manufacturing capabilities at any of these facilities, as a result of equipment failure or other
reasons, could reduce, delay or prevent the production of our products. Some of our manufacturing operations are located
outside of the U.S., including in Costa Rica and the United Kingdom. Those manufacturing operations are also subject to
additional challenges and risks associated with international operations described under the caption “Risk Factors” set forth in
Part I, Item 1A of this Annual Report.
13
From time to time new regulations are enacted that can affect the content and manufacturing of our products. We evaluate
the steps for compliance with regulations as they are enacted. For example, as a U.S. public company, we are subject to rules
requiring disclosures of the source of specified minerals, known as conflict minerals, which are necessary to the functionality or
production of products manufactured or contracted to be manufactured by us. Since our supply chain is complex, we may not be
able to sufficiently verify the origins of the relevant minerals used in our products through the due diligence procedures that we
implement, which may harm our reputation. In addition, we may encounter challenges to satisfy those customers who require
that all of the components of our products be certified as conflict-free, which could place us at a competitive disadvantage if we
are unable to do so.
Our operations are subject to numerous environmental laws regulating hazardous materials in products and chemical
usage. We maintain a chemical compliance program that includes policies, standards, systems and staff dedicated to overseeing
and maintaining compliance with these requirements. We also have processes and systems to support compliance with the
European Union (“EU”) Restriction of Hazardous Substances (“RoHS”) and Waste Electrical and Electronic Equipment
(“WEEE”) Directives; the China Administrative, the China Administrative Measures for the Restriction of Hazardous
Substances in Electrical and Electronic Products (“China RoHS”) regulation; the EU Registration, Evaluation, Authorization
and Restriction of Chemicals (“REACH”) regulation; EU Medical Device Regulation (“MDR”); EU In Vitro Diagnostic
Medical Devices Regulation (“IVDR”), and similar global and state laws that restrict chemical substances. Any failure to
comply with applicable environmental laws, regulations, and contractual obligations could increase product production lead
times, increase costs due to fines and could negatively affect our competitive position and brand.
Research and Development
The markets in which we participate are characterized by rapid technological change, frequent product introductions and
evolving customer requirements. Investment in research and development is critical to driving our future growth. Our research
and development efforts are focused on the further development and improvement of our existing products, the design and
development of new innovative medical technologies and regulatory compliance across all our business segments.
In addition to product development, our research and development personnel play an active role in the review of product
specifications, clinical protocols and FDA submissions, as well as ensuring that certain of our products conform to European
health, safety and environmental requirements, or CE-marking.
Patents and Proprietary Rights
We rely primarily on a combination of trade secrets, patents, copyrights, trademarks and confidentiality procedures to
protect our products and technology. Due to the rapid technological changes that characterize the markets we operate in, we
believe that trade secrets and other unpatented know-how relied upon in connection with the development of new products and
the enhancement of existing products are generally as important as patent protection in establishing and maintaining a
competitive advantage. Nevertheless, we have obtained patents and will continue to make efforts to obtain patents, when
available, in connection with our product development programs. We do not consider our business to be materially dependent
upon any individual patent.
We own numerous U.S. patents and have applied for numerous additional U.S. patents relating to our technologies. We
also own or have applied for corresponding patents in selected foreign countries. These patents relate to various aspects of most
of our products. We do not know if current or future patent applications will be issued with the full scope of the claims sought,
if at all, or whether any patents issued will be challenged or invalidated. There is a risk that our patent applications will not
result in granted patents or that granted patents will not provide significant protection for our products and technology. Third
parties may infringe, misappropriate or otherwise violate our intellectual property rights, or copy or reverse engineer portions of
our technology. Our competitors may independently develop similar or superior technology that our patents do not cover. In
addition, because patent applications in the U.S. are not generally publicly disclosed until eighteen months after the application
is filed, unpublished applications may have been filed by third parties that relate to our technology. Moreover, there is a risk
that foreign intellectual property laws will not protect our intellectual property rights to the same extent as intellectual property
laws in the U.S. The rights provided by a patent are finite in time. Over the coming years, certain patents relating to current
products will expire in the U.S. and abroad which may allow third parties to exploit those technologies. In the absence of
significant patent protection, we may be vulnerable to competitors who attempt to copy our products, processes or technology.
In addition to the patents we have been issued or we have acquired, we license patents from others on a variety of terms
and conditions.
We are engaged in intellectual property litigation, and we may be notified in the future of claims that we may be
infringing, misappropriating or otherwise violating the intellectual property rights of third parties. In connection with any such
claims, we may seek to enter into settlement and/or licensing arrangements. There is a risk in these situations that no license
14
will be available or that a license will not be available on reasonable terms. Alternatively, we may decide or be required to
litigate such claims. A successful claim against us may require us to remove the alleged infringing product from the market or
to design around the third party's patent, potentially resulting in less market demand for the product. Additionally, we may
initiate litigation against third parties who are infringing our intellectual property. There is a risk in these situations that we will
not obtain injunctive relief or receive damages sufficient to compensate for lost sales and the costs of the litigation.
Regulatory
The manufacture, sale, lease and service of medical diagnostic and surgical devices intended for commercial use are
subject to extensive governmental regulation by the FDA in the U.S. and by a variety of regulatory agencies in other countries.
Under the Federal Food, Drug and Cosmetic Act, known as the FD&C Act, manufacturers of medical products and devices
must comply with certain regulations governing the design, testing, manufacturing, packaging, distribution, servicing and
marketing of medical products. Some of our products are also subject to the Radiation Control for Health and Safety Act,
administered by the FDA, which imposes performance standards and record keeping, reporting, product testing and product
labeling requirements for devices that emit radiation, such as x-rays. FDA product approvals may be withdrawn or suspended if
compliance with regulatory standards is not maintained or if problems occur following initial marketing.
The FDA classifies medical devices into three classes based on risk. Regulatory control increases from Class I (lowest
risk) to Class III (highest risk). The FDA generally must clear or approve the commercial sale of new medical devices in
Classes II and III. Commercial sales of our Class II (except for Class II exempt devices) and Class III medical devices within
the U.S. must be preceded by either a pre-market notification filing pursuant to Section 510(k) of the FD&C Act (Class II) or
the granting of a pre-market approval, or PMA (Class III). Our Class I and Class II exempt medical devices must follow
Hologic’s internal Quality System processes prior to commercialization and throughout their product lifecycle. We must meet
requirements under FDA's quality system regulation (QSR), establishment registration, medical device listing, labeling and
medical device reporting (MDR) regulations. The FDA can authorize the emergency use of an unapproved medical product or
an unapproved use of an approved medical product, referred to as Emergency Use Authorization, or EUA, for certain
emergency circumstances after the Health and Human Services Secretary has made a declaration of emergency justifying
authorization of emergency use. An EUA allows use in an emergency to diagnose, treat, or prevent serious or life-threatening
diseases or conditions caused by emerging infectious disease threats when there are no adequate, approved, and available
alternatives. The FDA may also waive otherwise-applicable current good manufacturing practice (CGMP) requirements to
accommodate emergency response needs. In March 2020, the FDA granted EUA for our Panther Fusion SARS-CoV-2 assay
for testing for the COVID-19 virus. In May 2020, the FDA granted EUA for our Aptima SARS-CoV-2 assay for use on our
standard Panther instrument.
A 510(k) pre-market notification filing must contain information establishing that the device to be sold is substantially
equivalent to a device commercially distributed prior to May 28, 1976 or to a device that has been determined by the FDA to be
substantially equivalent. The PMA process involves a complex and lengthy testing process that is subject to review by the FDA
and may require several years to obtain. We may need to first obtain an investigational device exemption (for significant risk
devices), known as an IDE, in order to conduct extensive clinical testing of the device to obtain the necessary clinical data for
submission to the FDA. The FDA will approve a PMA only if after evaluating the supporting technical data it finds that the
PMA contains sufficient, valid scientific evidence to assure that the device is safe and effective for its intended use(s). This
approval may be granted with post-approval requirements including inspection of manufacturing facilities and/or additional
patient follow-up for an indefinite period of time.
Our Biotheranostics laboratory in San Diego, California and the laboratories that purchase certain of our products,
including the Aptima SARS-CoV-2 EUA, Aptima Flu Multiplex EUA, Fusion SARS-CoV-2 EUA, ThinPrep System, ThinPrep
Imaging System, Rapid Fetal Fibronectin Test, Aptima Combo 2, Aptima HPV tests and Aptima HIV-1 Quant, HCV Quant Dx,
HBV Quant, Aptima Trichomonas Vaginalis (Trich), Aptima Mycoplasma Genitalium (MGen), Aptima HSV 1 & 2, Aptima
BV, Aptima CV/TV, and Panther Fusion Assays are subject to extensive regulation under the Clinical Laboratory Improvement
Amendments of 1988, or CLIA, which requires laboratories to meet specified standards in the areas of personnel qualifications,
administration, participation in proficiency testing, patient test management, quality control, quality assurance and inspections.
Adverse interpretations of current CLIA regulations or future changes in CLIA regulations could have an adverse effect on
sales of any affected products or services. These laboratories are also licensed by the appropriate state agencies in the states in
which they operate, where such licensure is required. In addition, our laboratories hold state licenses or permits, as applicable,
from various states to the extent that they accept specimens from one or more of these states, each of which requires out-of-state
laboratories to obtain licensure. If a laboratory is out of compliance with CLIA or with state laws or regulations governing
licensed laboratories, penalties may include suspension, limitation or revocation of the license or CLIA certificate, assessment
of financial penalties or fines, or imprisonment. Loss of a laboratory's CLIA certificate or state license may also result in the
inability to receive payments from state and federal health care programs as well as private third-party payors.
15
Certain analyte specific reagents, referred to as ASR products, as with other Class I products, may be sold without 510(k)
clearance or PMA approval. However, ASR products are subject to significant restrictions. The manufacturer may not make
clinical or analytical performance claims for the ASR product, may not promote their use with specific laboratory equipment
and may only sell the ASR product to clinical laboratories that are qualified to run high complexity tests under CLIA. Each
laboratory must validate the ASR product for use in diagnostic procedures as a laboratory developed test.
We are also subject to a variety of federal, state and foreign laws which broadly relate to our interactions with healthcare
practitioners and other participants in the healthcare system, including, among others, the following:
•
anti-kickback and anti-bribery laws, such as the Foreign Corrupt Practices Act, or the FCPA, the U.K.’s Bribery Act
2010, or the U.K. Anti-Bribery Act;
•
laws regulating the confidentiality of sensitive personal information and the circumstances under which such
information may be released and/or collected, such as the Health Insurance Portability and Accountability Act of 1996,
or HIPAA, the Health Information Technology for Economic and Clinical Health Act, or HITECH Act, and the
European Union General Data Protection Regulation, or GDPR; and
•
healthcare reform laws, such as the Patient Protection and Affordable Care Act and the Health Care and Education
Affordability Reconciliation Act of 2010, which we refer to together as PPACA, which include new regulatory
mandates and other measures designed to constrain medical costs, as well as stringent new reporting requirements of
financial relationships between device manufacturers and physicians and teaching hospitals.
In addition, we are subject to numerous federal, state, foreign and local laws relating to safe working conditions,
manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous
substances, data privacy and protection among others. We may be required to incur significant costs to comply with these laws
and regulations in the future and complying with these laws may result in a material adverse effect upon our business, financial
condition and results of operations.
Sales of medical devices outside of the U.S. are subject to foreign requirements that vary widely from country to country.
For example, our ability to market our products outside of the U.S. is contingent upon maintaining our International Standards
Organization, or ISO, Quality System certification, complying with European directives and in some cases receiving specific
marketing authorization from the appropriate foreign regulatory authorities. Foreign registration is an ongoing process as we
register additional products and/or implement product modifications.
The time required to obtain approval from a foreign country to market and sell our products may be longer or shorter than
that required for FDA approval and the requirements may differ. In addition, we may be required to meet the FDA’s export
requirements or receive FDA export approval for the export of our products to foreign countries.
Our products are also subject to approval and regulation by foreign regulatory and safety agencies. For example, the EU
adopted the EU Medical Device Regulation (the “EU MDR”) and the In Vitro Diagnostic Regulation (the “EU IVDR”), each of
which impose stricter requirements for the marketing and sale of medical devices, including in the area of clinical evaluation
requirements, quality systems and post-market surveillance. The EU MDR and IVDR were amended in March 2023 to modify
deadlines for compliance. As such, manufacturers were required to demonstrate MDR-compliant Quality Management System
(QMS) and submit their MDR applications by May 2024. The EU IVDR has been applicable since May 2022. The March 2023
amendment to the EU IVDR deleted the sell-off provision, allowing continued availability of products placed on the market
before the end of the EU IVDR dates of application. Complying with the requirements of these regulations has required us to,
and may continue to require us to, incur significant expenditures. Failure to meet these requirements could adversely impact our
business in the EU and other regions that tie their product registrations to the EU requirements. In China, the recently rebranded
National Medical Products Administration (formerly CFDA), or the NMPA, has historically been conservative leading to
extended review times. However, more recently, the NMPA has been more interactive, which we attribute to its response to the
long delays in getting lifesaving medical devices into China. If this continues, this could favorably affect our ability to
introduce new products in the Chinese market.
The regulatory environment in China continues to evolve, and officials in the Chinese government exercise broad
discretion in deciding how to interpret and apply regulations. It is possible that the Chinese government's current or future
interpretation and application of existing or new regulations will negatively impact our China operations, result in regulatory
investigations or lead to fines or penalties.
We anticipate that governmental authorities will continue to scrutinize the healthcare industry closely and that changes in
laws, regulations or policies by governmental authorities may cause increases in uncertainties and compliance costs, exposure
to litigation and other adverse effects to our business and operations. Delays in receipt of, or failure to obtain, clearances or
16
approvals for future products could delay or preclude realization of product revenues from new products or result in substantial
additional costs which could decrease our profitability.
For additional information about the regulations to which our business is subject and the impact such regulations may
have on our business, see the disclosures under the captions “Manufacturing” and “Reimbursement” in this Item 1, and “Risk
Factors” in Item 1A below.
Reimbursement
Market acceptance of our medical products in the U.S. and other countries is dependent upon the purchasing and
procurement practices of our customers and patient need for our products and procedures and, the coverage and reimbursement
of patients’ medical expenses by government healthcare programs, private insurers or other healthcare payors. In the U.S., the
Centers for Medicare & Medicaid Services, known as CMS, establishes coverage policies and payment rates for Medicare
beneficiaries. CMS publishes payment rates for physician, hospital, laboratory and ambulatory surgical center services on an
annual basis. Under current CMS policies and regulations, varying payment levels have been established for tests and
procedures performed using our products. Coverage policies for Medicare patients may vary by regional Medicare contractor in
the absence of a national coverage determination and payment rates for procedures may vary based on the geographic price
index. Coverage policies and reimbursement rates for Medicaid patients are dependent on each state Medicaid plan and will
vary. Coverage policies and reimbursement rates for patients with private insurance are dependent on state and federal
requirements as well as individual private payor’s decisions. Moreover, private insurance carriers may choose not to follow the
CMS coverage policies or payment rates. The use of our products outside of the U.S. is similarly affected by reimbursement
policies adopted by foreign regulatory authorities and insurance carriers.
Healthcare policy and payment reform proposals and medical cost containment measures are being adopted in the U.S.
and in many foreign countries. The ability of our customers to obtain adequate reimbursement for our products and services
from private and governmental third-party payors is critical to the success of medical technology companies because it may
affect which products customers purchase and the prices they are willing to pay. Reimbursement and coverage vary by country
and can significantly impact acceptance of new products and technologies. Even if we develop a promising new product, we
may find limited demand for the product unless reimbursement approval and coverage is obtained from private and
governmental third-party payors. Further, ongoing legislative or administrative reform to the reimbursement system in the U.S.
and other countries may impact reimbursement for procedures using our medical products and/or limit coverage for those
procedures facilitated by our products. This includes price regulation, competitive bidding and tendering, coverage and payment
policies, comparative effectiveness of therapies, technology assessments and managed-care arrangements. These trends could
have a material adverse effect on our business, financial condition or results of operations.
Human Capital
We view human capital management and the strength of our employees as integral to the long-term success of our
business and the strengthening of our communities. We understand that we rely on our employees worldwide to propel our
organization forward with great ideas, innovations and leadership.
As of September 28, 2024, we had 7,063 full-time employees, including 2,208 in manufacturing operations, 1,774 in
sales and marketing, 1,472 in support services, 784 in research and development, and 825 in general administration.
Approximately 4,113 of these employees are in the U.S. and approximately 2,950 were outside the U.S. In various countries
outside the U.S., certain of our employees are unionized and, where local law requires, participate in works councils.
Employee Engagement and Development
Our goal is to develop and maintain a talented, engaged and diverse workforce that has a positive impact on our
performance, and on our customers and their patients. We have been conducting an annual engagement survey since 2015 in
which most of our employees regularly participate, as well as two other annual workplace surveys since 2021 that engage our
U.S. employees. We believe our foundation of employee engagement, our commitment to our employees, and their
commitment to each other fortifies our leaders and teams and improves their business performance. We also offer a range of
programs to develop our managers and enhance our leadership across the Company. Our professional development efforts are
aimed at increasing organizational talent and capabilities and identifying and developing potential successors for key leadership
positions.
17
Compensation and Benefits
Our compensation philosophy aims to attract and retain top talent for today and the future. To this end, we invest in the
physical, emotional and financial well-being of our employees through our robust compensation and benefit programs. These
programs (which vary by country/region) include a variety of health plan options, annual performance incentive opportunities,
employee stock purchase plan, and retirement savings programs, paid time off (including for charitable actions), leave
programs, employee assistance programs and other wellness offerings.
Equal pay for equal work is rooted in our values and foundational to fostering an inclusive environment. As such, we
regularly review pay for internal equity, considering factors such as an employee’s role, experience, skills and performance, and
aim to provide that our compensation structure is appropriate. We also engage outside counsel to evaluate compliance with pay
equity laws. When we identify any potential differences in pay for whatever reason, we research those differences and act if
appropriate. Employees are encouraged to share any pay equity concerns with management, Human Resources, or
confidentially through our reporting hotline, including anonymously. Hologic has a non-retaliation policy for raising any
workplace concerns, including around pay.
Diversity Drives Performance
We are committed to creating an inclusive and diverse work environment that promotes equal opportunity, dignity and
respect, starting with our Board and our Leadership team. Of our nine directors, five, representing 56% of the Board, are
women, one of our directors self-identifies as Asian and another self-identifies as Black. For each of the past 13 years, women
have comprised over 30% of our Board. Also, three of our directors were born outside of the United States, and two were
predominantly educated outside of the United States, which we believe promotes diverse perspectives for our Board.
We believe that our focus on the lives of women has helped us to attract a diverse workforce and build an inclusive ethos
where different perspectives are valued and respected. Building a diverse workforce begins with our hiring practices and
extends to our access to opportunities, strategic development and promotion of internal talent. We seek to identify and develop
high-potential individuals, including women and members of underrepresented ethnicities within the Company. In addition to
women holding several key roles within the Company (Chief Financial Officer; President, Diagnostic Solutions; Senior Vice
President, Global Human Resources; Corporate Vice President, Global Tax and Treasury; Vice President of Finance, Breast and
Skeletal Health; Vice President of Internal Audit; Vice President, Corporate Strategy and Development; Corporate Vice
President, Government Affairs and Corporate Communications; and Chief of Staff), persons of color have assumed important
leadership roles as Chief Operating Officer, Vice President, Investor Relations and Corporate Secretary. Additionally, given
that our commercial teams are an important pipeline for senior management, we are pleased that a significant number of our
commercial team members below the level of vice president are women and/or people of color.
We strive to hire the most talented person for the job and believe that, over time, this will lead to an increasingly diverse
workforce which reflects the communities in which we operate. As a part of finding the most qualified people, we seek to
identify and consider diverse slates of candidates for roles across the organization, from the boardroom and c-suite to all levels
of the workforce. We believe our focus on talent identification, development, engagement and succession planning has been
particularly successful in developing a deep and diverse talent pipeline. As part of our continued commitment to transparency
on diversity, our U.S. Federal Employment Information Report (EEO-1) is also publicly available on our website.
Health, Safety and Wellness
We seek to comply in letter and in spirit with applicable health and safety laws and regulations and implement programs,
policies and procedures to achieve compliance throughout the Company. We also establish our own environmental health and
safety standards in addition to those that are legally required. We employ management systems and procedures designed to
protect human safety, health, and the environment. In fact, during the COVID-19 pandemic, we took additional health and
safety measures. We seek to reduce risk and protect our employees and communities by employing safe technologies and
operating procedures, and by maintaining a business continuity program to stay prepared for emergencies. We have also
developed safety rules and procedures to address behaviors and work practices that can lead to accidents and injuries. Safety
performance is assessed throughout the year by management and during annual performance reviews.
In addition, we have developed several employee-focused initiatives to support the physical, mental, and financial well-
being of our employees. These initiatives include providing enhanced accident and critical illness insurance, access to telehealth
services, developing an employee assistance program that provides mental health therapy, wellness coaching, and medication
management, and offering subscriptions to self-care mobile apps.
Community Engagement and Volunteerism
We take the role we play as leaders in the communities where we live and work seriously. Our philanthropic and
charitable efforts are an important part of our culture and linked to our efforts to work to improve the health of our
18
communities, customers, patients and employees, and seek to ensure that the decisions we make today have a positive effect on
future generations. We center our giving efforts in three specific areas to maximize our impact in ways that align with the
values of our employees and customers: (i) women's health, and other healthcare fields in which Hologic operates; (ii) science,
technology, engineering, and math education (STEM), especially for students from underserved communities; and (iii) social
and racial equality, especially in healthcare.
We also support employees in giving back to community organizations through volunteering and matching donations. To
that end, we further expanded our support for local non-profit groups, by providing our U.S. colleagues an additional paid day
off to engage in community service. We also have continued to strengthen our scholarship funds. The Hologic Scholarship
Fund awards scholarships for employees' children and grandchildren. We also support students near our largest U.S. facilities
by providing scholarship funding to non-profit organizations that help students from underserved communities become the first
in their family to attend college.
Seasonality
Worldwide sales, including U.S. sales, do not reflect any significant degree of seasonality; however, customer purchases
of our GYN Surgical products have been historically lower in our second fiscal quarter compared to our other fiscal quarters.
Our respiratory infectious disease product line (including our assays for the detection of SARS-CoV-2) within our Diagnostics
segment is also subject to significant seasonal and year-over-year fluctuations. In addition, the summer months, which occur
during our fourth fiscal quarter, typically have had lower order rates internationally for most of our products.
Item 1A. Risk Factors
In evaluating our business, the risks described below, as well as other information contained in this Annual Report and in
our other filings with the SEC should be considered carefully. Additional risks not presently known to us or that we currently
deem immaterial may also adversely affect our business. The occurrence of any of these events or circumstances could
individually or in the aggregate have a material adverse effect on our business, financial condition, cash flow or results of
operations. This report contains forward-looking statements; please refer to the cautionary statements made under the heading
“Special Note Regarding Forward-Looking Statements” for more information on the qualifications and limitations on forward-
looking statements.
COMPETITION AND BUSINESS DEVELOPMENT
We face intense competition from other companies and may not be able to compete successfully.
The markets in which we sell our products are intensely competitive, subject to rapid technological change and may be
significantly affected by new product introductions and other market activities of industry participants, and these competitive
pressures may reduce the demand and prices for our products. Other companies may develop products that are superior to and/
or less expensive than our products. Improvements in existing competitive products or the introduction of new competitive
products, including an increase of artificial intelligence and machine learning capabilities, may reduce our ability to compete for
sales, particularly if those competitive products demonstrate better safety or effectiveness, clinical results, ease of use or lower
costs.
In addition, some companies may have significant competitive advantages over us, which may make them more attractive
to hospitals, clinics, radiology clients, group purchasing organizations, laboratories, and physicians, including:
•
greater brand recognition;
•
larger or more established distribution networks and customer bases;
•
a broader product portfolio, resulting in the ability to offer rebates or bundle products to offer discounts or incentives
to gain a competitive advantage;
•
higher levels of automation and greater installed bases of such equipment;
•
higher reimbursement coverage;
•
more extensive research, development, sales, marketing, and manufacturing capabilities and greater financial
resources; and
•
greater technical resources positioning them to continue to improve their technology in order to compete in an
evolving industry.
We also developed assays to detect COVID-19. As COVID-19 testing declines, and there is greater use of rapid tests and
at-home collection tests, continued decline in demand for our COVID-19 assays without a corresponding increase in our other
businesses or customers consolidating their molecular testing menu to high throughput, high automation platforms which may
further increase the competition our Panther and Panther Fusion instruments face could have a material, adverse effect on our
results of operations, cash flow and financial position.
19
Challenges in the development of our products could materially impact our long-term success.
Our growth depends in large part on our ability to identify and develop new products or new indications for or
enhancements of existing products. The development of new products and enhancement of existing products requires
significant investment in research and development, clinical trials and regulatory approvals. The results of our product
development efforts may be affected by a number of factors, including our ability to anticipate customer needs, innovate and
develop new products, complete clinical trials, obtain regulatory clearances and approvals and reimbursement in the U.S. and
abroad, manufacture products in a cost-effective manner, obtain, maintain, protect and enforce appropriate intellectual property
protection for our products, gain and maintain market approval of our products and access capital. If we are not able to
successfully enhance existing products or develop new products, our products may be rendered obsolete or uncompetitive by
changing technology or new industry standards. We cannot assure that any products now in development or that we may seek to
develop in the future will achieve technological feasibility, obtain regulatory approval or gain market acceptance, and we may
be unable to recover all or a meaningful part of our investment in such products and technologies. Additionally, our current
products utilize artificial intelligence, and future innovations in our products will likely continue to incorporate artificial
intelligence. As with many technological innovations, there are significant risks and challenges involved in maintaining and
deploying these technologies, and there can be no assurance that the use of such technologies will enhance our products or
services or be beneficial to our business. The use of artificial intelligence in healthcare products also poses certain clinical risks
resulting from potential misdiagnosis or misinformation provided from applications, diminishing critical judgment, or loss of
interpersonal care from clinicians. The regulatory landscape surrounding artificial intelligence is also evolving and may expose
us to an increased risk of regulatory enforcement and litigation. Such risks could have a material adverse effect on our results of
operations, financial position and cash flows.
The markets for our newly developed products and newly introduced enhancements to our existing products may not develop
as expected.
The successful commercialization of our newly developed products and newly introduced enhancements to our existing
products are subject to numerous risks, both known and unknown, including:
•
uncertainty of the development of a market for such product;
•
trends relating to, or the introduction or existence of, competing products or technologies that may be more effective,
safer or easier to use than our products or technologies;
•
the perception of our products as compared to other products;
•
recommendation and support for the use of our products by influential customers, such as highly regarded hospitals,
physicians and treatment centers;
•
the availability and extent of data demonstrating the clinical efficacy of our products or treatments;
•
competition, including the presence of competing products sold by companies with longer operating histories, more
recognizable names and more established distribution networks; and
•
other technological developments.
Often, the development of a significant market for a product will depend upon the establishment of a reimbursement code
or an advantageous reimbursement level for use of the product. Moreover, even if addressed, such reimbursement codes or
levels frequently are not established until after a product is developed and commercially introduced, which can delay the
successful commercialization of a product. If we are unable to successfully commercialize and create a significant market for
our newly developed products and newly introduced enhancements to our existing products our business and prospects could be
harmed.
If we cannot maintain our current corporate collaborations and enter into new corporate collaborations, our product
development could be delayed and our revenue or expenses could be adversely impacted.
We have relied and/or expect to rely on corporate collaborators for funding development, marketing, distribution, and the
commercialization of certain products. If we or any of our corporate collaborators were to breach, terminate, fail to renew our
agreements or otherwise fail to properly conduct their obligations in a timely manner, the development or commercialization
and subsequent marketing of the products contemplated by the collaboration could be delayed or terminated, and we could
incur additional charges or expenses. Further, we would be required to devote additional resources to product development or
marketing, to terminate some development programs or to seek alternative corporate collaborations with certain partners or
companies that could make it more difficult for us to enter into advantageous business transactions or relationships with others.
Any of the foregoing risks could harm our business and prospects.
Our long-term success will depend upon our ability to execute on business development activities and integrate acquired
businesses.
20
As part of our long-term strategy, we are engaged in business development activities including evaluating future
acquisitions, joint development opportunities, technology licensing arrangements and other opportunities to further expand our
presence in or diversify into priority growth areas by accessing new products and technologies. We may not be able to identify
appropriate business development activities or acquisition candidates, consummate transactions or obtain agreements with
favorable terms, if at all. We may also be subject to increasing regulatory scrutiny from competition and antitrust authorities in
connection with acquisitions. If we are successful in pursuing future acquisitions, we may face significant competition, be
required to expend significant funds, incur additional debt or other obligations, or issue additional securities, which may
negatively affect our operating results and financial condition. If we spend significant funds or incur additional debt or
obligations, our ability to obtain financing for working capital or other purposes could be adversely affected, and we may be
more vulnerable to economic downturns and competitive pressures. Over the last five years, we made a number of tactical
acquisitions which complemented our existing businesses. We continue to integrate some of those acquisitions. Any inability to
successfully integrate new businesses, including our more recent acquisitions, decreases in customer loyalty or product orders,
failure to retain or develop the acquired workforce, failure to realize anticipated economic, operational and other benefits and
synergies in a timely manner, failure to establish and maintain appropriate controls or unknown or contingent liabilities could
adversely affect our ability to realize the anticipated benefits of any new product or acquisition. The integration of an acquired
business, whether or not successful, requires significant efforts which may result in additional expenses and divert the attention
of our management and technical personnel from other projects. Acquisitions, in particular, are inherently risky, and we cannot
guarantee that any past or future transaction will be successful.
THIRD-PARTY REIMBURSEMENT AND GUIDELINES
Healthcare cost containment legislation and the failure of third-party payors to provide appropriate levels of coverage and
reimbursement for the use of products and treatments facilitated by our products could harm our business and prospects.
Sales and market acceptance of our diagnostics, breast and skeletal health and surgical products and the treatments
facilitated by these products are dependent upon the coverage decisions and reimbursement policies established by government
healthcare programs and private health insurers. These policies affect which products customers purchase and the prices they
are willing to pay. Reimbursement varies by country and can significantly impact the acceptance of new products and
technologies. Even if we develop a promising new product, we may find limited demand for the product unless appropriate
reimbursement approval is obtained from private and governmental third-party payors. Further legislative or administrative
reforms to the reimbursement systems in the U.S. and other countries in a manner that significantly reduces reimbursement for
procedures using our diagnostics, breast and skeletal health and surgical products or denies coverage for those procedures
facilitated by our products, including price regulation, competitive bidding and tendering, coverage and payment policies,
comparative effectiveness of therapies, technology assessments and managed-care arrangements, could have a material adverse
effect on our business, financial condition or results of operations.
Guidelines, recommendations and studies published by various organizations may reduce the use of our products.
Professional societies, government agencies, practice management groups, private health/science foundations, and
organizations involved in healthcare issues may publish guidelines, recommendations or studies to the healthcare and patient
communities. Organizations like these have in the past made recommendations about our products and those of our competitors.
If followed by healthcare providers and insurers, such publications could result in decreased use of our products. For example,
in November 2012, the American Congress of Obstetrics and Gynecologists, known as the ACOG, released updates in which it
recommended less frequent cervical cancer screening similar to guidelines released in March 2012 by the U.S. Preventive
Services Task Force, or the USPSTF, and the American Cancer Society. We believe that these recommendations and guidelines
may have contributed to increased screening intervals for cervical cancer, which we believe has and may continue to adversely
affect our ThinPrep revenues. Our cervical cancer screening revenues, primarily from ThinPrep sales, may also be adversely
affected by the July 2020 American Cancer Society cervical cancer screening guidelines, which recommended the use of a
human papillomavirus (HPV) test for primary screening rather than co-testing (the use of an HPV test with a Pap test) or a
standalone Pap test. In addition, on October 20, 2015, the American Cancer Society issued guidelines recommending that
women start annual mammograms at age 45 instead of 40 and have a mammogram every two years instead of annually. We
believe that this recommendation may have resulted in a decrease in the use of mammography systems.
REGULATORY AND LEGAL
We operate in a highly regulated industry and our business generally is subject to extensive and complex laws and
governmental regulations, and changes in healthcare laws and regulations or our inability to obtain in a timely manner or
at all U.S. or foreign regulatory clearances or approvals for our current and newly developed products and services or
product or service enhancements or any adverse regulatory action could adversely affect our business and prospects.
21
We operate in a highly regulated industry. As a result, governmental actions may adversely affect our business,
operations or financial condition, including:
•
new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to
healthcare availability, method of delivery and payment for healthcare products and services;
•
changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products
and result in lost market opportunity;
•
changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions
on product distribution or use, or other measures after the introduction of our products to market, which could increase
our costs of doing business, adversely affect the future permitted uses of approved products, or otherwise adversely
affect the market for our products; and
•
new laws, regulations and judicial decisions affecting pricing or marketing practices.
Given the high level of regulatory oversight to which our products are subject, the process of obtaining clearances and
approvals can be costly and time consuming. In addition, there is a risk that any approvals or clearances, once obtained, may be
withdrawn. Most medical devices cannot be marketed in the U.S. without 510(k) clearance or pre-market approval by the FDA.
Any modifications to a device that has received a pre-market approval that affect the safety or effectiveness of the device
require a pre-market approval supplement or possibly a separate pre-market approval, either of which is likely to be time
consuming, expensive and uncertain to obtain. If the FDA requires us to seek one or more pre-market approval supplements or
new pre-market approvals for any modification to a previously approved device, we may be required to cease marketing or to
recall the modified device until we obtain approval, and we may be subject to significant criminal and/or civil sanctions,
including, but not limited to, regulatory fines or penalties. States may also regulate the manufacture, sale and use of medical
devices, particularly those that employ x-ray technology. Delays in receipt of, or failure to obtain or maintain, clearances or
approvals for products could also delay or preclude realization of product revenues from new or existing products or result in
substantial additional costs which could decrease our profitability.
Our products are also subject to approval and regulation by foreign regulatory and safety agencies. For example, the EU
has adopted the EU Medical Device Regulation (the “EU MDR”) and the In Vitro Diagnostic Regulation (the “EU IVDR”),
each of which impose stricter requirements for the marketing and sale of medical devices, including in the area of clinical
evaluation requirements, quality systems and post-market surveillance. Implementation of the compliance requirements of these
regulations requires us to incur significant expenditures and utilize resources. Failure to continue to meet these requirements
could adversely impact our business in the EU and other regions that tie their product registrations to the EU requirements.
In addition, maintaining compliance with multiple regulators, and multiple centers within the FDA, adds complexity and
cost to our manufacturing processes. Our manufacturing facilities and those of our contract manufacturers are subject to
periodic regulatory inspections by the FDA and other regulatory agencies, and these facilities are subject to the FDA's Quality
System Regulation and Good Manufacturing Practices. The results of these inspections can include, and have in the past
included, inspectional observations on the FDA’s Form 483, warning letters, or other forms of enforcement. If the FDA were to
conclude that we, or our contractors, are not in compliance with applicable laws or regulations, or that any of our medical
products are ineffective or pose an unreasonable health risk, it may prevent us from selling our products.
We anticipate that governmental authorities will continue to scrutinize the healthcare industry closely and that changes in
laws, regulations or policies by governmental authorities may cause increased uncertainties and compliance costs, exposure to
litigation and other adverse effects to our business and operations. These and other rapidly changing laws, regulations, policies
and related interpretations that our business activities are subject to, may increase the ongoing costs and complexities of
compliance, including by requiring investments in technology or other compliance systems. In addition, the legal, regulatory
and ethical landscape around the use of artificial intelligence and machine learning is rapidly evolving, and our obligations to
comply with the evolving legal and regulatory landscape could entail significant costs or limit our ability to incorporate certain
artificial intelligence capabilities into our products. Additionally, we are party to various other legal proceedings, claims,
governmental and/or regulatory inspections, inquiries and investigations arising out of the ordinary course of its business, which
are difficult to predict and the adverse outcomes of which could harm our business. If we are unable to continue to adapt to the
various changes or comply with all laws, regulations, policies and related interpretations, it could negatively impact our
reputation and our business results.
Some of our activities may subject us to risks under federal and state laws prohibiting “kickbacks” and false or fraudulent
claims.
We are subject to the provisions of a federal law commonly known as the anti-kickback statute, and several similar state
laws, which prohibit payments intended to induce physicians or others either to refer patients or to acquire or arrange for or
recommend the acquisition of healthcare products or services. While the federal law applies only to products or services for
which payment may be made by a federal healthcare program, state laws often apply regardless of whether federal funds may
22
be involved. These laws constrain the sales, marketing and other promotional activities of manufacturers of medical devices by
limiting the kinds of financial arrangements, including sales programs that may be used with hospitals, physicians, laboratories
and other potential purchasers of medical devices. Other federal and state laws generally prohibit individuals or entities from
knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that
are false or fraudulent, or are for items or services that were not provided as claimed. Similarly, the Patient Protection and
Affordable Care Act also includes stringent reporting requirements of financial relationships between device manufacturers and
physicians and teaching hospitals. Specifically, under one provision of the law, which is commonly referred to as the Physician
Payment Sunshine Act, we are required to collect data on and annually report to CMS certain payments or other transfers of
value to physicians and teaching hospitals and annually report certain ownership and investment interests held by physicians or
their immediate family members. Anti-kickback and false claims laws and the Physician Payment Sunshine Act prescribe civil
and criminal penalties (including fines) for noncompliance that can be substantial.
Similarly, our international operations are subject to the provisions of the U.S. Foreign Corrupt Practices Act of 1977, as
amended (“FCPA”), which prohibits U.S. companies and their representatives from offering or making improper payments to
foreign officials for the purpose of obtaining or retaining business. In many countries, the healthcare professionals we regularly
interact with may meet the definition of a foreign official for purposes of the FCPA. Our international operations are also
subject to various other international anti-bribery laws such as the UK Anti-Bribery Act. Despite meaningful measures that we
undertake to facilitate lawful conduct, which include training and compliance programs and internal policies and procedures,
we may not always prevent unauthorized, reckless or criminal acts by our employees or agents, or employees or agents of
businesses or operations we may acquire. Violations of these laws, or allegations of such violations, could disrupt our
operations, involve significant management distraction and have a material adverse effect on our business, financial condition
and results of operations. We also could be subject to adverse publicity, severe penalties, including criminal and civil penalties,
disgorgement, further changes or enhancements to our procedures, policies and controls, personnel changes and other remedial
actions. Moreover, our failure to comply with domestic or foreign laws could result in various adverse consequences, including
possible delay in approval or refusal to approve a product, recalls, seizures, and withdrawal of an approved product from the
market.
We are subject to the risk of product liability claims relating to our products for which we may not have adequate insurance.
Our business involves the risk of product liability and other claims inherent to the medical device business. If even one of
our products is found to have caused or contributed to injuries or deaths, we could be held liable for substantial damages. We
maintain product liability insurance subject to deductibles and exclusions. There is a risk that the insurance coverage will not be
sufficient to protect us from product and other liability claims, or that product liability insurance will not be available to us at a
reasonable cost, if at all. An under-insured or uninsured claim could harm our business and prospects. In addition, claims could
adversely affect the reputation of the related product, which could damage that product’s competitive position in the market.
The sale and use of our diagnostic products could also lead to product liability claims if someone were to allege that one
of our products contained a design or manufacturing defect that resulted in inaccurate test results or the failure to detect a
disorder for which it was being used to screen, or caused injuries to a patient. We are currently the subject of product liability
litigation proceedings described in more detail under Note 16 to our consolidated financial statements entitled “Litigation and
Related Matters”. The outcome of litigation is difficult to assess or quantify. Any product liability claim brought against us,
with or without merit, could result in an increase in our product liability insurance rates or the inability to secure additional
coverage in the future. Also, even a meritless or unsuccessful product liability claim could be time consuming and expensive to
defend. This could result in a diversion of management’s attention from our business and adversely affect the perceived safety
and efficacy of our products, which could harm our business and prospects.
We are subject to environmental, health and safety laws and regulations, including related to our use and recycling of
hazardous materials and the composition of our products.
Our research and development and manufacturing processes involve the controlled use of hazardous materials, such as
toxic and carcinogenic chemicals and various radioactive compounds, and the risk of contamination or injury from these
materials cannot be eliminated. In such event, we could be held liable for any resulting damages, and any such liability could be
extensive. From time to time new regulations are enacted, and it is difficult to anticipate how such regulations will be
implemented and enforced. We continue to evaluate the necessary steps for compliance with regulations as they are enacted.
These regulations include, for example, regulations enacted in the EU such as the Registration, Evaluation, Authorization and
Restriction of Chemical Substances, or REACH, which requires the registration of and regulates use of certain chemicals, the
Restriction on the Use of Certain Hazardous Substances in Electrical and Electronic Equipment Directive, or RoHS, which
regulates the use of certain hazardous substances in certain products we manufacture, and the Waste Electrical and Electronic
Equipment Directive, or WEEE, which requires the collection, reuse and recycling of waste from certain products we
manufacture. These and similar legislation that has been or is in the process of being enacted in Japan, China and various states
23
of the U.S. may require us to re-design our products to ensure compliance with the applicable standards, for example by
requiring the use of different types of materials. These redesigns or the use of alternative materials may detrimentally impact
the performance of our products, add greater testing lead times for product introductions, result in additional costs or have other
similar effects. In addition, changes in environmental laws and regulations, in particular relating to climate change and
greenhouse gas (“GHG”) emissions, could require us, or our contract manufacturers or suppliers, to install additional
equipment, or alter operations to incorporate new technologies or processes, which may result in additional expenses and
adversely affect our operating results.
We are also subject to other substantial regulation relating to environmental, health and safety matters, including
occupational health and safety, environmental protection, hazardous substance control, and waste management and disposal.
The failure to comply with such regulations could subject us to, among other things, fines and criminal liability. We may also
be required to incur significant costs to comply with these and future regulations, which may result in a material adverse effect
upon our business, financial condition and results of operations. Increasingly, regulators, customers, investors, employees and
other stakeholders are focusing on environmental matters and related disclosures. These changing rules, regulations and
stakeholder expectations have resulted in, and are likely to continue to result in, increased general and administrative expenses
and increased management time and attention spent meeting such regulations and expectations and copying with disclosure
requirements. For example, collecting, measuring and reporting environmental data is subject to evolving reporting standards,
including the SEC’s climate-related reporting requirements, if such reporting requirements survive pending judicial review,
California’s disclosure requirements and similar regulations established by other international regulatory bodies, such as the
Corporate Sustainability Reporting Directive in the European Union. In addition, a number of our customers who are payors or
distributors have adopted, or may adopt, procurement policies that include environmental provisions that their suppliers or
manufacturers must comply with. If we do not adapt to or comply with new regulations, or fail to meet evolving investor,
industry or stakeholder expectations and concerns regarding environmental issues, investors may reconsider their investment in
our Company, and customers and suppliers may choose to limit their business with us, which could have a material adverse
effect on our business, operations or reputation.
Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company's operating results.
We are subject to income taxes, as well as taxes that are not income-based, in both the U.S. and jurisdictions outside of
the U.S. Changes in tax laws or regulations in the jurisdictions in which we operate, including the U.S. and as led by the
Organization for Economic Cooperation and Development of a global minimum tax, could negatively impact the Company’s
effective tax rate, results of operations and cash flows. In addition, our future effective tax rate could be unfavorably affected by
numerous other factors including a change in the interpretation of tax rules and regulations in the jurisdictions in which we
operate, a change in our geographic earnings mix, and/or to the jurisdictions in which we operate, or a change in the
measurement of our deferred taxes. We are also subject to ongoing tax audits in various jurisdictions, and tax authorities may
disagree with certain positions we have taken and assess additional taxes.
GLOBAL CHALLENGES, INCLUDING MACROECONOMIC CONDITIONS AND RELATED FINANCIAL RISKS
The continuing worldwide macroeconomic and geopolitical uncertainty may adversely affect our business and prospects,
both domestically and internationally.
Continued concerns about the systemic impact of potential long-term and wide-spread recession and geopolitical issues,
including wars and terrorism, have contributed to increased market volatility and diminished expectations for economic growth
in the world. Our business and results of operations have been and may continue to be adversely impacted by changes in
macroeconomic conditions, including inflation, bank failures, rising interest rates and availability of capital markets.
Uncertainty about global economic conditions, particularly in emerging markets and countries with government-sponsored
healthcare systems, may also cause decreased demand for our products and services and increased competition, which could
result in lower sales volume and downward pressure on the prices for our products, longer sales cycles, and slower adoption of
new technologies. A weakening of macroeconomic conditions may also adversely affect our suppliers, which could result in
interruptions in supply. In addition, continuing social and political concerns and divisions in the U.S. and throughout the world,
could have a material, adverse effect on the economic conditions in markets we serve, and our results of operations, cash flow
and financial position. Elections and political changes in various countries, including the U.S., may further exacerbate
geopolitical and geoeconomic tensions and market instability.
Market acceptance of our medical products in the U.S. and other countries is dependent upon the medical equipment
purchasing and procurement practices of our customers, patient need for our products and procedures and the reimbursement of
patients' medical expenses by government healthcare programs and third-party payors. The continuing uncertainty surrounding
global economic conditions and financial markets may cause the purchasers of medical equipment to decrease their medical
health insurance premiums and procurement activities. Economic uncertainty, an increase in unemployment rates, as well as an
24
increase in health insurance premiums, co-payments and deductibles may result in cost-conscious consumers making fewer
trips to their physicians and specialists, which in turn would adversely affect demand for our products and procedures.
Furthermore, governments and other third-party payors around the world facing tightening budgets could move to further
reduce the reimbursement rates or the scope of coverage offered, which could adversely affect sales of our products.
Our international sales are often denominated in foreign currencies, including the Euro, U.K. Pound and Chinese Yuan.
Changes in currency exchange rates, particularly the increase in the value of the dollar against any such foreign currencies, may
reduce the reported value of our revenues outside the U.S. and associated cash flows and our ability to compete effectively in
foreign markets. In addition, such fluctuations can also result in foreign currency exchange losses. We cannot predict changes
in currency exchange rates, the impact of exchange rate changes, nor the degree to which we will be able to manage the impact
of currency exchange rate changes. We currently have limited hedging arrangements in place to mitigate some of the impact of
negative exchange rates.
Our international operations and foreign acquisitions expose us to additional operational challenges that we might not
otherwise face.
International expansion is a key component of our growth strategy. In fiscal 2024, 25.0% of our revenue came from
outside of the U.S. Our future and existing international operations may subject us to a number of additional risks and expenses,
any of which could harm our operating results. These risks and expenses include:
•
political and economic changes and disruptions, export/import controls and tariff regulations;
•
difficulties in developing staffing and simultaneously managing operations in multiple locations as a result of, among
other things, distance, language and cultural differences;
•
governmental currency controls;
•
multiple, conflicting and changing government laws and regulations (including, among other things, antitrust and tax
requirements);
•
protectionist laws and business practices that favor local companies;
•
difficulties in the collection of trade accounts receivable;
•
difficulties and expenses related to implementing internal controls over financial reporting and disclosure controls and
procedures;
•
expenses associated with customizing products for clients in foreign countries;
•
possible adverse tax consequences;
•
the inability to obtain and maintain required regulatory approvals or favorable third-party reimbursement;
•
operation in parts of the world where strict compliance with anti-bribery laws may conflict with local customs and
practices;
•
the inability to effectively obtain, maintain, protect or enforce intellectual property rights, reduced protection for
intellectual property rights in some countries, and the inability to otherwise protect against clone or “knock off”
products;
•
the lack of ability to enforce non-compete agreements with former owners of acquired businesses competing with us in
China and other foreign countries; and
•
lower margins on a number of our products sold outside of the U.S.
In addition, government policies on international trade and investment such as import quotas, capital controls or tariffs,
whether adopted by individual governments or addressed by regional trade blocks, can affect cost of and the demand for our
products and services, impact the competitive position of our products or prevent us from being able to sell products in, or
otherwise adversely affect our ability to sell products in the affected countries. The implementation of more restrictive trade
policies, such as more detailed inspections, higher tariffs or new barriers to entry, could negatively impact our business, results
of operations and financial condition. For example, a government's adoption of “buy national” policies or retaliation by another
government against such policies could have a negative impact on our results of operations.
Additionally, the regulatory environment in China continues to evolve, and officials in the Chinese government exercise
broad discretion in deciding how to interpret and apply regulations. It is possible that the Chinese government’s current or
future interpretation and application of existing or new regulations will negatively impact our China operations, result in
regulatory investigations or lead to fines or penalties.
CYBERSECURITY AND DATA PRIVACY
Increased cybersecurity requirements, vulnerabilities, threats and more sophisticated and targeted computer crime could
pose a risk to our systems, networks, products, solutions, services and data.
Increased global cybersecurity vulnerabilities, threats, computer viruses, ransomware and phishing attacks and more
sophisticated and targeted cyber-related attacks, as well as cybersecurity and other information technology failures resulting
25
from human error and technological errors, pose a risk to the security of Hologic and its customers, business partners' and
suppliers' products, systems and networks and the confidentiality, availability and integrity of data on these products, systems
and networks. As the perpetrators of such attacks become more capable, as cybercrime becomes commoditized, and as critical
infrastructure is increasingly becoming digitized, the risks in this area continue to grow. While we attempt to mitigate these
risks, we remain potentially vulnerable to additional known or unknown threats, and we cannot assure that the impact from such
threats will not be material. Moreover, certain vulnerabilities are difficult to detect even using our best efforts, which may allow
those vulnerabilities to persist in our systems over long periods of time. In addition to existing risks, flexible work
arrangements, the adoption of new technologies such as artificial intelligence, and acquisitions of new businesses may also
increase our exposure to cybersecurity breaches and failures. Geopolitical tensions or conflicts may further heighten the risk of
cyber-related attacks. It may also be difficult to determine the best way to investigate, mitigate, contain, and remediate the harm
caused by a cyber-related incident. Such efforts may not be successful, and we may make errors or fail to take necessary
actions. It may take considerable time for us to investigate and evaluate the full impact of incidents, particularly for
sophisticated attacks. These factors may inhibit our ability to provide prompt, full, and reliable information about the incident to
our customers, partners, regulators, and the public. Additionally, we have incurred and expect to continue to incur significant
costs implementing additional security measures to protect against existing and emerging cybersecurity threats.
We also have access to sensitive, confidential or personal data or information that is subject to privacy and security laws,
regulations or customer-imposed controls. Despite our implementation of certain controls to protect our systems and sensitive,
confidential or personal data or information, we may be vulnerable to material security breaches, theft, misplaced, lost or
corrupted data, employee errors and/or malfeasance (including misappropriation by departing employees) that could potentially
lead to the compromising of sensitive, confidential or personal data or information, improper use of our systems, software
solutions or networks or those of our customers, business partners or suppliers, unauthorized access, use, disclosure,
modification or destruction of information, defective products, production downtimes and operational disruptions. In addition, a
cyber-related attack could result in other negative consequences, including damage to our reputation or competitiveness,
remediation or increased protection costs, litigation or regulatory action. While we carry cyber liability insurance, such
insurance may not cover us with respect to any or all claims or costs associated with such a breach. Although we have
experienced occasional cybersecurity incidents and/or attempted breaches of our computer systems, to date we do not believe
any of these breaches have had a material effect on our business strategy, results of operations, or financial condition.
Failure to comply with laws relating to the confidentiality of sensitive personal information or standards related to the
transmission of electronic health data, may require us to make significant changes to our products, or incur penalties or
other liabilities.
State, federal and foreign laws, such as the federal Health Insurance Portability and Accountability Act of 1996, or
HIPAA, regulate the confidentiality of sensitive personal information and the circumstances under which such information may
be released. These measures may govern the disclosure and use of personal and patient medical record information and may
require users of such information to implement specified security measures, and to notify individuals in the event of privacy and
security breaches. Evolving laws and regulations in this area could restrict the ability of our customers to obtain, use or
disseminate patient information, or could require us to incur significant additional costs to re-design our products in a timely
manner, either of which could have an adverse impact on our results of operations. Other health information standards, such as
regulations under HIPAA, establish standards regarding electronic health data transmissions and transaction code set rules for
specified electronic transactions, for example transactions involving submission of claims to third-party payors. These standards
also continue to evolve and are often unclear and difficult to apply. We have incurred and expect that we will continue to incur
significant costs implementing additional security measures to protect against new or enhanced data security or privacy threats,
or to comply with current and new federal, state and international laws governing the unauthorized disclosure or exfiltration of
confidential and personal information which are continuously being enacted and proposed. Outside the U.S., we are impacted
by privacy and data security requirements at the international, national and regional level, and on an industry specific basis.
More privacy and security laws and regulations are being adopted, and more are being enforced, with potential for significant
financial penalties. In the EU, increasingly stringent data protection and privacy rules have been enacted. The EU General Data
Protection Regulation (GDPR) applies uniformly across the EU and includes, among other things, a requirement for prompt
notice of data breaches to data subjects and supervisory authorities in certain circumstances. The GDPR also requires
companies processing personal data of individuals residing in the EU to comply with EU privacy and data protection rules.
Failure to maintain the confidentiality of sensitive personal information in accordance with the applicable regulatory
requirements, or to abide by electronic health data transmission standards, could expose us to breach of contract claims, fines
and penalties, costs for remediation and harm to our reputation.
BUSINESS CONTINUITY AND RELIANCE ON THIRD PARTIES
Supply Chain and Manufacturing
26
Supply chain constraints and inflationary pressures have had, and in the future, may have, a material adverse effect on our
ability to procure raw materials and components, including semiconductor chips, and to meet customer demand for, and
increase our costs to manufacture, warehouse, and transport, certain of our products.
Global supply constraints have had an adverse effect on our ability to meet customer demand, and increased our costs to
manufacture, transport and warehouse a certain subset of our products. In particular, our ability to manufacture our Breast
Health capital equipment products, primarily, but not limited to, our 3D Dimensions systems, Trident specimen radiography
systems, Affirm Prone Biopsy systems and Brevera systems, is dependent on the supply of such raw materials and components,
including semiconductor chips. If going forward we are unable to obtain sufficient quantities of raw materials and components
on commercially reasonable terms or in a timely manner, our ability to manufacture our capital equipment products, in
particular, our Breast Health products, on a timely and cost-competitive basis could materially adversely affect our revenues
and results of operations and harm our competitive position and reputation.
Our reliance on one third-party manufacturer for certain of our product lines and a limited number of suppliers for some
key raw materials, components and subassemblies for our products exposes us to increased risks associated with production
delays, delivery schedules, manufacturing capability, quality control, quality assurance and costs.
We have sole source third-party manufacturers for each of our Panther molecular diagnostics instruments and for our
Skeletal Health products. Similarly, we rely on one or a limited number of suppliers for some key components or subassemblies
for our products due to cost, quality, expertise or other considerations. We have no firm long-term volume commitments with
certain of our sole source suppliers, including the manufacturers of our Panther instruments. Similarly, we rely on one or a
limited number of suppliers for some key raw materials for our products due to cost, quality, expertise or other considerations,
and some of these suppliers are competitors. For example, F. Hoffmann-LaRoche Ltd, a direct competitor of our Diagnostics
business, is the parent company of Roche, our current supplier of certain key raw materials for certain of our amplified NAT
diagnostic assays. GE Healthcare Bio-Sciences Corp., an affiliate of GE, supplies us with the membranes used in connection
with our ThinPrep product line. GE is a direct competitor with our Breast Health and Skeletal Health businesses. Moreover, we
use certain components in our products, including semiconductor chips, that have been the subject of global supply chain
shortages and disruptions. If any of our sole source manufacturers or suppliers, or other third-party manufacturers or suppliers,
experiences delays, disruptions, capacity constraints or quality control problems in its development or manufacturing operations
or becomes insolvent or otherwise fails to supply us with goods in sufficient quantities, including as a result of disruptions
caused by epidemics or pandemics, natural disasters, supplier facility shutdowns, or otherwise, then shipments to our customers
could be delayed, which would decrease our revenues and harm our competitive position and reputation. Moreover, the failure
of a supplier to provide sufficient quantities, acceptable quality and timely delivery of goods at an acceptable price, or an
interruption in the delivery of goods from such a supplier could adversely affect our business and results of operations.
Obtaining alternative sources of supply of products, components, subassemblies or raw materials could involve significant
delays and other costs and regulatory challenges and may not be available to us on reasonable terms, if at all.
We may in the future need to find new contract manufacturers or suppliers to replace existing manufacturers or suppliers,
increase our volumes or reduce our costs. We may not be able to find contract manufacturers or suppliers that meet our needs,
including regulatory requirements, and even if we do, the process of qualifying such alternative manufacturers and suppliers is
often expensive and time consuming. As a result, we may lose revenues and our customer relationships may suffer.
Business Continuity
Interruptions, delays, shutdowns or damage at our manufacturing or laboratory facilities, or the facilities of third parties on
which we depend, could harm our business.
In most cases, the manufacturing and warehousing of each of our products is concentrated in one or a few locations. In
addition, we rely on a single laboratory facility to process each of our Biotheranostics gene expression tests for breast cancer.
An interruption in manufacturing, testing capabilities or warehousing at any of these facilities, as a result of equipment failure,
transportation interruptions, disruptions caused by strikes or other labor unrest, epidemics or pandemics, natural disaster,
environmental factors or property damage could reduce, delay or prevent the production and distribution of our products. Our
facilities and those of our contract manufacturers, suppliers, customers or third parties on which we depend are also subject to
the risk of disruption or catastrophic loss due to unanticipated events, such as fires, earthquakes, explosions, floods or weather
conditions, or other events outside of our control. Any such disruptions or other delays and cancellations of elective procedures
and exams may cause reduced demand for our products. Our facilities may experience plant shutdowns, strikes or other labor
disruptions, or periods of reduced production as a result of equipment failures, loss of power, gray outs, delays in deliveries or
extensive damage, which could harm our business and prospects. Some of our manufacturing operations are located outside the
U.S., including in Costa Rica and the United Kingdom. Those manufacturing operations are also subject to additional
challenges and risks associated with international operations described herein.
27
Pandemics or disease outbreaks, such as the COVID-19 pandemic, have created and may in the future create significant
volatility, uncertainty and economic disruption in the markets we sell our products into and operate in, primarily the U.S.,
Europe, and Asia-Pacific and may negatively impact business and healthcare activity globally. The extent to which pandemics,
disease outbreaks or a similar widespread health concern impacts our business will depend on future developments, which are
highly uncertain and cannot be predicted with confidence, such as the speed and extent of geographic spread of the disease, the
duration of the outbreak, travel restrictions, the efficacy of vaccination and treatment; delays and cancellations of elective
procedures and exams; impact on the U.S. and international healthcare systems, the U.S. economy and worldwide economy; the
timing, scope and effectiveness of U.S. and international governmental response; and the impact on the health, well-being and
productivity of our employees. In addition, healthcare professional and staff strikes or other work stoppages may in the future
cause reduced demand for our products.
CUSTOMER CONCENTRATION AND DISTRIBUTORS
Our Diagnostics segment depends on a small number of customers for a significant portion of its product sales, and the loss
of any of these customers or any cancellation or delay of a large purchase by any of these customers could significantly
reduce revenues in our Diagnostics segment.
Although we do not currently have any customers that represent more than 10% of our consolidated revenues, a material
portion of product sales in our Diagnostics segment comes from (and we anticipate will continue to come from) a limited
number of customers, two of which accounted for 12.8% and 10.1% of our Diagnostics segment revenue in fiscal 2024. No
customer represented more than 10% of Diagnostics revenue in fiscal 2023 or 2022. The loss of any of these key customers, or
a significant reduction in sales volume or pricing to these customers, could significantly reduce our Diagnostics segment
revenues or profitability.
We utilize distributors for a portion of our sales, the loss of which could harm our revenues in the territory serviced by these
distributors.
We rely on strategic relationships with a number of key distributors for sales and service of our products. If any of our
strategic relationships terminate without replacement or if our strategic partners fail to perform their contractual obligations, our
revenues and/or ability to service our products in the territories serviced by these distributors could be adversely affected. We
do not control our distributors, and these parties may not be successful in marketing our products. These parties may fail to
commit the necessary resources to market and sell our products to the level of our expectations.
If we elect to distribute new products directly, we will have to invest in additional sales and marketing resources,
including additional field sales personnel, which would significantly increase future selling, general and administrative
expenses. If we fail to successfully market our products, our product sales will decrease. We may also be exposed to risks as a
result of transitioning a territory from a distributor sales model to a direct sales model, such as difficulties maintaining
relationships with specific customers, hiring appropriately trained personnel or ensuring compliance with local product
registration requirements, any of which could result in lower revenues than previously received from the distributor in that
territory.
TALENT AND EMPLOYEE RETENTION
Our success depends on our ability to attract, motivate and retain key personnel and plan for future executive transitions.
The loss of any of our key personnel, particularly executive management or key research and development personnel,
could harm our business and prospects and could impede the achievement of our research and development, operational or
strategic objectives. We also continue to face the challenges of maintaining employee well-being, recognizing that the
continued additional financial, family and health burdens that many employees may be experiencing due to macroeconomic
uncertainties, including inflation, and other factors, may adversely impact job performance and employee retention.
Additionally, in our industry, there is substantial competition for key personnel in the regions in which we operate. We face
intense competition for employees, particularly as employees are increasingly able to work remotely. Also, facilitating seamless
leadership transitions for key positions is a critical factor in sustaining the success of our organization. If our succession
planning efforts are not effective, it could adversely impact our business. We continue to assess the key personnel that we
believe are essential to our long-term success. Future organizational changes could also cause our employee attrition rate to
increase. If we fail to effectively manage any organizational and/or strategic changes, our financial condition, results of
operations, and reputation, as well as our ability to successfully attract, motivate and retain key employees, could be harmed.
INTELLECTUAL PROPERTY
28
Our business is dependent on technologies we license, and if we fail to maintain these licenses or license new technologies
and rights to particular nucleic acid sequences for targeted diseases in the future, we may be limited in our ability to develop
new products.
Our business is dependent on licenses from third parties for some of our key technologies. For example, our patented
TMA technology is based on technology we licensed from Stanford University. We anticipate that we will enter into new
licensing arrangements in the ordinary course of business to expand our product portfolio and access new technologies to
enhance our products and develop new products. Many of these licenses will provide us with exclusive rights to the subject
technology or disease marker. If our license with respect to any of these technologies or markers is terminated for any reason,
we may not be able to sell products that incorporate that technology. Similarly, we may lose competitive advantages if we fail
to maintain exclusivity under an exclusive license.
Our ability to develop additional diagnostic tests for diseases may depend on the ability of third parties to discover
particular sequences or markers and correlate them with disease, as well as the rate at which such discoveries are made. Our
ability to design products that target these diseases may depend on our ability to obtain the necessary rights from the third
parties that make any of these discoveries. In addition, there are a finite number of diseases and conditions for which our NAT
diagnostic assays may be economically viable. If we are unable to access new technologies or the rights to particular sequences
or markers necessary for additional diagnostic products on commercially reasonable terms, we may be limited in our ability to
develop new diagnostic products.
Our products and manufacturing processes may require access to technologies and materials that may be subject to
patents or other intellectual property rights held by third parties. Our business could be adversely affected if we are unable to
obtain the additional intellectual property rights necessary to commercialize our products.
Our business could be harmed if we are unable to protect our proprietary technology.
We have relied primarily on a combination of trade secrets, patents, copyrights, trademarks and confidentiality
procedures to protect our products and technology. Despite these precautions, unauthorized third parties may infringe,
misappropriate or otherwise violate our intellectual property, or copy or reverse engineer portions of our technology. The
pursuit and assertion of a patent right, particularly in areas like nucleic acid diagnostics and biotechnology, involve complex
determinations and, therefore, are characterized by substantial uncertainty. We do not know if current or future patent
applications will be issued with the full scope of the claims sought, if at all, or whether any patents that are issued will be
challenged or invalidated. The patents that we own or license could also be subjected to invalidation proceedings or similar
disputes, and an unfavorable outcome could require us to cease using the related technology or to attempt to license rights to the
technology from the prevailing party. There is also a risk that intellectual property laws outside of the U.S. will not protect our
intellectual property rights to the same extent as intellectual property laws in the U.S. Even if our proprietary information is
protected by patents or otherwise, the initiation of actions to protect our proprietary information could be costly and divert the
efforts and attention of our management and technical personnel, and the outcome of such litigation is often uncertain. As a
result of these uncertainties, we could also elect to forego such litigation or settle such litigation without fully enforcing our
proprietary rights. In the absence of significant patent protection, we may be vulnerable to competitors who attempt to copy our
products, processes or technology. Additionally, rights provided by a patent are finite in time. Over the coming years, certain
patents relating to current products will expire in the U.S. and abroad thus allowing third parties to utilize certain of our
technologies.
Our business could be harmed if we infringe upon the intellectual property rights of others.
There has been substantial litigation regarding patent and other intellectual property rights in medical devices, diagnostic
products and related industries. We are and have been involved in patent litigation and may in the future be subject to further
claims of infringement of intellectual property rights possessed by third parties. In connection with claims of patent
infringement, we may seek to enter into settlement and/or licensing arrangements. There is a risk in these situations that no
license will be available or that a license will not be available on reasonable terms. Alternatively, we may decide to litigate such
claims or to design around the technology. These actions could be costly and would divert the efforts and attention of our
management and technical personnel. As a result, any infringement claims by third parties or claims for indemnification by
customers resulting from infringement claims, whether or not proven to be true, may harm our business and prospects.
INDEBTEDNESS
We have a significant amount of indebtedness outstanding, which limits our operating flexibility, and could adversely affect
our operations and financial results and prevent us from fulfilling our obligations.
29
As of September 28, 2024, we had approximately $2.55 billion aggregate principal of indebtedness outstanding
(exclusive of additional funds that would be available to draw under our revolver), and we may incur additional indebtedness in
the future. We also have other contractual obligations and deferred tax liabilities, which as of September 28, 2024, are described
under “Notes to Consolidated Financial Statements — Income Taxes, and Non-cancelable Purchase Commitments.” This
significant level of indebtedness and our other obligations may:
•
make it more difficult for us to satisfy our obligations with respect to our outstanding indebtedness;
•
increase our vulnerability to general adverse economic and industry conditions, including increases in interest rates;
•
require us to dedicate a substantial portion of our cash flow from operations to interest and principal payments on our
indebtedness, which would reduce the availability of our cash flow to fund working capital, capital expenditures,
expansion efforts, strategic transactions and other general corporate purposes;
•
limit our flexibility in planning for, or reacting to, changes in our business and the markets in which we participate;
•
place us at a competitive disadvantage compared to our competitors that have less debt; and
•
limit our ability to borrow additional funds for working capital, capital expenditures, expansion efforts, strategic
transactions or other general corporate purposes.
In addition, the terms of our financing obligations contain certain covenants that restrict our ability, and that of our
subsidiaries, to engage in certain transactions and may impair our ability to respond to changing business and economic
conditions, including, among other things, limitations on our ability to:
•
incur indebtedness or issue certain preferred equity;
•
pay dividends, repurchase our common stock, or make other distributions or restricted payments;
•
make certain investments;
•
agree to payment restrictions affecting the restricted subsidiaries;
•
sell or otherwise transfer or dispose of assets, including equity interests of our subsidiaries;
•
enter into transactions with our affiliates;
•
create liens;
•
designate our subsidiaries as unrestricted subsidiaries;
•
consolidate, merge or sell substantially all of our assets; and
•
use the proceeds of permitted sales of our assets.
Our credit facilities also require us to satisfy certain financial covenants. Our ability to comply with these provisions may
be affected by general economic conditions, political decisions, industry conditions and other events beyond our control. Our
failure to comply with the covenants contained in our credit facilities, including financial covenants, could result in an event of
default, which could materially and adversely affect our results of operations and financial condition.
If there were an event of default under one of our debt instruments or a change of control, the holders of the defaulted
debt could cause all amounts outstanding with respect to that debt to be due and payable immediately and may be cross-
defaulted to other debt, including our outstanding notes. Our assets or cash flow may not be sufficient to fully repay borrowings
under our outstanding debt instruments if accelerated upon an event of default or a change of control, and there is no guarantee
that we would be able to repay, refinance or restructure the payments on such debt. See “Management’s Discussion and
Analysis of Financial Condition and Results of Operations-Liquidity and Capital Resources.”
We may not be able to generate sufficient cash flow to service all of our indebtedness and other obligations.
Our ability to make payments on and to refinance our indebtedness and to fund planned capital expenditures, strategic
transactions and expansion efforts will depend on our ability to generate cash in the future. This, to a certain extent, is subject to
general economic, financial, competitive, legislative, regulatory and other factors that are beyond our control. Our business may
not be able to generate sufficient cash flow from operations, and we cannot assure that future borrowings will be available to us
in amounts sufficient to enable us to pay our indebtedness as such indebtedness matures and to fund our other liquidity needs. If
this occurs, we will need to refinance all or a portion of our indebtedness on or before maturity, and there can be no assurance
that we will be able to refinance any of our indebtedness on commercially reasonable terms, or at all. We may need to adopt one
or more alternatives, such as reducing or delaying planned expenses and capital expenditures, selling assets, restructuring debt,
or obtaining additional equity or debt financing. These alternative strategies may not be effected on satisfactory terms, if at all.
Our ability to refinance our indebtedness or obtain additional financing, or to do so on commercially reasonable terms, will
depend on, among other things, our financial condition at the time, restrictions in agreements governing our indebtedness, and
other factors, including the condition of the financial markets and the markets in which we compete. If we do not generate
sufficient cash flow from operations, and additional borrowings, refinancings or proceeds from asset sales are not available to
us, we may not have sufficient cash to enable us to meet all of our obligations.
A significant portion of our indebtedness is subject to floating interest rates, which may expose us to higher interest
payments.
30
A significant portion of our indebtedness is subject to floating interest rates, which makes us more vulnerable in the event
of adverse economic conditions, increases in prevailing interest rates, or a downturn in our business. As of September 28, 2024,
approximately $1.2 billion aggregate principal of our indebtedness, which represented the outstanding principal under our credit
facilities, was subject to floating interest rates. We currently have hedging arrangements (interest rate swaps) in place to
partially mitigate the impact of higher interest rates. We have two consecutive interest rate swaps that will provide us with a
continued hedge, in the notional amounts of $500 million, through September 25, 2026.
GENERAL RISK FACTORS
Provisions in our charter, bylaws, and indebtedness may have the effect of discouraging advantageous offers for our
business or common stock and limit the price that investors might be willing to pay in the future for shares of our common
stock.
Our charter, bylaws, and the provisions of the Delaware General Corporation Law include provisions that may have the
effect of discouraging or preventing a change of control. Our indebtedness also contains provisions which either accelerate or
require us to offer to repurchase the indebtedness at a premium upon a change of control. These provisions could limit the price
that our stockholders might receive in the future for shares of our common stock.
Our stock price is volatile.
The market price of our common stock has been, and may continue to be, highly volatile. We believe that a variety of
factors could cause the price of our common stock to fluctuate, perhaps substantially, including:
•
new, or changes in, recommendations, guidelines or studies that could affect the use of our products;
•
announcements and rumors of developments related to our business, including changes in reimbursement rates or
regulatory requirements, proposed and completed acquisitions, or the industry in which we compete;
•
published studies and reports relating to the comparative efficacy of products and markets in which we participate;
•
quarterly fluctuations in our actual or anticipated operating results and order levels;
•
general conditions in the U.S. or worldwide economy;
•
our stock repurchase program;
•
announcements of technological innovations;
•
new products or product enhancements by us or our competitors;
•
developments in patents or other intellectual property rights and litigation;
•
developments in relationships with our customers and suppliers;
•
the implementation of healthcare reform legislation and the adoption of additional reform legislation in the future; and
•
the success or lack of success of integrating our acquisitions.
In addition, the stock market in general and the markets for shares of “high-tech” and life sciences companies, have
historically experienced extreme price fluctuations which have often been unrelated to the operating performance of affected
companies. Any such fluctuations in the future could adversely affect the market price of our common stock, and the market
price of our common stock may decline.
Item 1B. Unresolved Staff Comments
None.
31
Item 1C. Cybersecurity
Risk Management and Strategy
We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures
designed to protect the security, confidentiality, integrity, and availability of our business systems and information. We base our
cybersecurity risk management program upon and measure it against the National Institute of Standards and Technology
(NIST) Cybersecurity Framework 2.0.
Our cybersecurity risk management program includes the following:
•
A dedicated staff of cybersecurity and risk management professionals;
•
Defined security policies and standards;
•
Annual mandatory employee cybersecurity and privacy compliance awareness training;
•
Cybersecurity tooling for detecting and responding to cyber incidents;
•
Cybersecurity incident response and major crisis plans that govern activities such as detection, coordination,
remediation, recovery, and escalation to senior management and, where appropriate, our Audit and Finance Committee
and our Board;
•
Disaster recovery plans;
•
Periodic tabletop exercises to promote awareness and improve internal processes;
•
Periodic penetration testing and vulnerability management processes; and
•
Third-party risk assessments for suppliers and vendors, which may require such third parties to sign data processing
agreements, comply with particular security controls, or complete an additional security and privacy assessment.
Our program also utilizes third-party security providers for specialized areas, including penetration testing, staff
augmentation, consulting and other on-demand cybersecurity services. We also leverage a managed security service provider to
augment our cybersecurity organization and to provide additional monitoring and response capabilities.
We have integrated cybersecurity related risks into our enterprise risk management program, which is designed to
identify, prioritize, assess, monitor and mitigate the various risks confronting our Company, including both external and internal
cybersecurity risks. When identified, risks are reported to relevant business and governance leaders within the Company for
appropriate action. When potential improvements are identified, we weigh the costs and benefits of such improvements
(including against other potential improvements) and, if selected, the improvements are added to a roadmap for possible
implementation.
As a global company, we manage a variety of cybersecurity threats and cannot wholly eliminate the risk of adverse
impacts from such incidents. Further, the scope and impact of any future incident cannot be predicted. However, as of the date
of this Form 10-K, we are not aware of cybersecurity threats, including as a result of any previous cybersecurity incidents, that
have materially affected or are reasonably likely to materially affect us, including our business strategy, results of our
operations or financial condition. For additional information on the risks from cybersecurity threats that we face, please refer to
the “Risk Factors” in Part I, Item 1A. of this Form 10-K.
Governance
Our cybersecurity risk management program is led by our Chief Information Security Officer (CISO), who oversees a
dedicated cybersecurity and risk management team, which works in partnership across the Company, under the direction of our
Chief Information Officer (CIO). Our CISO has over 20 years of experience working in defense and cybersecurity and has
served in various cybersecurity leadership roles within Fortune 500 companies. He and our cybersecurity team have extensive
experience in leading and addressing IT risk management, security architecture and engineering, security operations, data
security, and identity and access management. Our CISO also works closely with our legal team to oversee compliance with
legal, regulatory and contractual security requirements.
As part of management’s oversight of our cybersecurity program, we also maintain an executive-level cybersecurity
steering committee, comprised of Hologic’s Chief Financial Officer, General Counsel, Head of Internal Audit, Chief
Information Officer, Head of Human Resources, Head of Global Supply Chain, and Division President of Breast and Skeletal
Health, to help address cybersecurity risks at an enterprise level. The cybersecurity steering committee is a decision-making
body that coordinates and communicates the direction, current state, and oversight of our cybersecurity and risk management
programs.
While our Board oversees our overall risk management process, as part of its oversight, the Board has delegated primary
responsibility for the oversight of cybersecurity risks, including management’s steps to monitor and control such risks, to our
Audit and Finance Committee. On a quarterly basis, our CIO and CISO provide updates to the Audit and Finance Committee on
32
the cybersecurity and related risk management programs, including recent developments and current risk assessments. Our CIO
and CISO typically also meet in person with the Audit and Finance Committee twice annually for a more detailed discussion of
significant threats, risk mitigation strategies, any security program assessments and identified improvements. Additionally, our
CIO and CISO meet at least annually with the full Board and report on the Company’s Information Technology program and
more specifically, cybersecurity matters.
Item 2. Properties
We own and lease real estate property to support our business, including manufacturing, marketing, research and
development, logistical support and administration. The following lists those properties that we own or lease that we believe are
material to our business. We believe that we have adequate space for our anticipated needs and that suitable additional space
will be available at commercially reasonable prices as needed.
Material Properties Owned:
Primary Use
Newark, DE
Breast Health DirectRay digital detector research and
development and plate manufacturing operations
Manchester, UK
Administrative and supply chain operations
Londonderry, NH
Diagnostics manufacturing operations
San Diego, CA
Diagnostics headquarters, including administrative and
manufacturing operations
San Diego, CA
Diagnostics research and development, administrative and
manufacturing operations
Material Properties
Leased:
Primary Use
Lease
Expiration
(fiscal year)
Renewals
Marlborough, MA
Headquarters, including research
and development, manufacturing
and distribution operations
2034
1, five-year period
Marlborough, MA
Manufacturing operations
2029
None
Alajuela, Costa Rica
Administrative and Surgical and
Breast Health manufacturing
facility
2028
2, five-year periods
Manchester, UK
Diagnostics manufacturing
operations
2035
None
We also lease various administrative and customer support centers throughout the world including in Brussels, Belgium,
Berlin, Germany, Madrid, Spain, United Kingdom and Shanghai and Beijing, China. In addition, we also lease space for
smaller, specialized research and development and manufacturing operations at various additional locations, including Ougrée,
Belgium.
Item 3. Legal Proceedings
For a discussion of legal matters as of September 28, 2024, please see Note 16 to our consolidated financial statements
entitled “Litigation and Related Matters,” which is incorporated by reference into this item.
Item 4. Mine Safety Disclosures
Not Applicable.
33
PART II
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities
Market Information. Our common stock is traded on the Nasdaq Global Select Market under the symbol “HOLX.”
Number of Holders. As of November 21, 2024, there were approximately 703 holders of record of our common stock,
including multiple beneficial holders at depositories, banks and brokers listed as a single holder in the street name of each
respective depository, bank or broker.
Dividend Policy. We have never declared or paid cash dividends on our capital stock, and we currently have no plans to
do so. Our current policy is to retain all of our earnings to finance future growth (including acquisitions), pay down our existing
indebtedness and repurchase our common stock. The existing covenants under certain of our credit facilities also place limits on
our ability to issue dividends and repurchase stock.
Recent Sales of Unregistered Securities. We did not sell unregistered securities during the fourth quarter of fiscal 2024.
Issuer's Purchases of Equity Securities
Period of Repurchase
Total Number
of Shares
Purchased (#)
(2)
Average Price
Paid Per Share
($) (2)
Total Number of
Shares Purchased
As Part of
Publicly
Announced Plans
or
Programs
(#) (2)
Maximum
Number (or
Approximate
Dollar Value) of
Shares That May
Yet Be Purchased
Under Our
Programs
(in millions)
($) (1)(2)
June 30, 2024 – July 27, 2024
4,010 $
72.94
4,010 $
248.3
July 28, 2024 – August 24, 2024
190,607
80.00
190,607
233.1
August 25, 2024 – September 28, 2024
534,228
79.96
534,228
1,690.3
Total
728,845 $
79.93
728,845 $
1,690.3
___________________________________
(1) On September 12, 2024, the Board of Directors authorized a stock repurchase program, with a five-year term, to repurchase
up to $1.5 billion of the Company’s outstanding stock. This new stock repurchase authorization is in addition to the
Company’s prior stock repurchase authorization. As of September 28, 2024, $1.5 billion remained unused under this
program.
(2) On September 22, 2022, the Board of Directors authorized a stock repurchase program, with a five-year term, to repurchase
up to $1.0 billion of the Company’s outstanding common stock, effective as of the close of trading on September 23, 2022.
As of September 28, 2024, $190.3 million remained unused under this program.
These programs do not obligate the Company to acquire a minimum number of shares. Under these programs, shares may
be repurchased in privately negotiated and/or open market transactions, including under plans complying with Rule 10b5-1 under
the Exchange Act. For additional information regarding the Company’s repurchase programs, please see “Management's Discussion
and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources – Stock Repurchase Program.”
34
Stock Performance Graph
The following information shall not be deemed to be “filed” with the SEC nor shall the information be incorporated by
reference into any filings under the Securities Act, except to the extent that we specifically incorporate it by reference into a
document filed under the Securities Act or the Exchange Act.
The following graph compares cumulative total shareholder return on our common stock since September 28, 2019 with
the cumulative total return of the Standard & Poor’s 500 Index and the S&P Health Care Supplies Index. This graph assumes
the investment of $100 on September 28, 2019 in our common stock. Measurement points are the last trading day of each
respective fiscal year.
Item 6. Reserved
Not applicable.
35
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements, the
information described under the caption “Risk Factors” in Part I, Item 1A of this Annual Report and our Special Note
Regarding Forward-Looking Statements at the outset of this Annual Report.
OVERVIEW
We are a developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical
products focused on women's health and well-being through early detection and treatment. We sell and service our products
through a combination of direct sales and service personnel and a network of independent distributors and sales representatives.
We operate in four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health.
Through our Diagnostics segment, we offer a wide range of diagnostic products, which are used primarily to aid in the
screening and diagnosis of human diseases. Our primary Diagnostics products include our molecular diagnostic assays, which
run on our advanced instrumentation systems (Panther and Panther Fusion), our ThinPrep cytology system, including our
Genius Digital Diagnostics System, and the Rapid Fetal Fibronectin Test. Our Aptima family of molecular diagnostic assays is
used to detect, among other things, the infectious microorganisms that cause common sexually transmitted diseases, or STDs,
such as chlamydia and gonorrhea, or CT/NG; certain high-risk strains of human papillomavirus, or HPV; Trichomonas
vaginalis, the parasite that causes trichomoniasis; Mycoplasma genitalium; and Herpes Simplex viruses 1 and 2. We also offer
viral load tests for the quantitation of Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, or HIV-1, and
human cytomegalovirus, or CMV, for use on our Panther instrument system. In addition, we offer bacterial vaginosis and
candida vaginitis assays for the diagnosis of vaginitis, a common and complex ailment affecting millions of women a year. Our
assay portfolio also includes diagnostic tests for a range of acute respiratory infections, including SARS-CoV-2, various strains
of influenza and parainfluenza, and respiratory syncytial virus, as well as a test for the detection of Group B Streptococcus, or
GBS, that are run on the Panther Fusion system, a field upgradeable instrument addition to the base Panther system. In response
to the COVID-19 pandemic, we developed and launched the Aptima SARS-CoV-2 assay and the Aptima SARS-CoV-2/Flu
assay (each of which runs on our standard Panther system) and the Panther Fusion SARS-CoV-2 assay and the Panther Fusion
SARS-CoV-2/Flu A/B/RSV assay (which run on our Panther Fusion system). In May 2022, we obtained CE-marking for two
new molecular assays, Panther Fusion EBV Quant assay for quantitation of Epstein-Barr virus, and the Panther Fusion BKV
Quant assay for quantitation of the BK virus. These two assays are the first quantitative real-time PCR assays on the Panther
Fusion system, and, together with the Aptima CMV Quant assay, expand our menu of transplant monitoring assays. The
ThinPrep System is primarily used in cytology applications, such as cervical cancer screening, and the Rapid Fetal Fibronectin
Test assists physicians in assessing the risk of pre-term birth. We also generate service revenues from our CLIA-certified
laboratory for testing related to breast cancer and all metastatic cancers.
Our Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology.
These solutions include 3D digital mammography systems, image analysis software utilizing artificial intelligence, reading
workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen
radiology systems. Our most advanced breast imaging platforms, Selenia 3D Dimensions and 3Dimensions systems, utilize
tomosynthesis to produce 3D images that show multiple contiguous slice images of the breast.
Our GYN Surgical products include our MyoSure hysteroscopic tissue removal system, our NovaSure endometrial
ablation system, our Fluent fluid management system, our Acessa ProVu laparoscopic radiofrequency ablation system, as well
as our CoolSeal vessel sealing portfolio and our JustRight surgical stapler. The MyoSure suite of devices offers four options to
provide incision-less removal of fibroids, polyps, and other pathology within the uterus. The NovaSure portfolio is comprised
of the NovaSure ADVANCED device and the NovaSure V5 device for the treatment of abnormal uterine bleeding. The Fluent
and Fluent Pro fluid management system provides liquid distention during diagnostic and operative hysteroscopic procedures.
The Acessa ProVu system is a fully integrated system that uses laparoscopic ultrasound, guidance mapping and radiofrequency
ablation to treat nearly all types of fibroids. The CoolSeal portfolio includes the CoolSeal Trinity, CoolSeal Reveal, and
CoolSeal Mini advanced bipolar vessel sealing devices. The JustRight 5 mm stapler features a smaller instrument profile and is
used for laparoscopic general and pediatric surgery.
Our Skeletal Health segment's products include the Horizon DXA, a dual energy x-ray system, which evaluates bone
density and performs body composition assessments, and the Fluoroscan Insight FD mini C-arm, which assists in performing
minimally invasive orthopedic surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot, and ankle.
Unless the context otherwise requires, references to we, us, Hologic or our company refer to Hologic, Inc. and its
consolidated subsidiaries.
36
Acquisitions and Dispositions
The following sets forth a description of certain of our acquisitions and dispositions we have completed in our last two
fiscal years:
Endomag
On July 25, 2024, we completed the acquisition of Endomagnetics Ltd (“Endomag”) for a purchase price of $313.9
million. Endomag, located in the U.K., develops and sells breast surgery localization and lymphatic tracing technologies. Based
on our preliminary valuation, we allocated $197.8 million of the purchase price to the value of intangible assets and $138.9
million to goodwill. The allocation of the purchase price is preliminary as we continue to gather information supporting the
acquired assets and liabilities. Endomag’s results of operations are reported in our Breast Health segment.
SuperSonic Imagine Ultrasound Imaging
On September 28, 2023, we entered into a definitive agreement to sell our SSI ultrasound imaging business to SSH
Holdings Limited for a sales price of $1.9 million in cash. The sale was completed on October 3, 2023. We also agreed to
provide certain transition services for up to one year, depending on the nature of the service. The SSI ultrasound imaging asset
group met the criteria to be classified as assets held-for-sale in the fourth quarter of fiscal 2023. As a result, we recorded a
charge of $51.7 million in the fourth quarter of fiscal 2023 to record the asset group at its fair value less costs to sell pursuant to
ASC 360, Property, Plant and Equipment—Impairment or Disposal of Long-Lived Assets.
37
RESULTS OF OPERATIONS
Fiscal Year Ended September 28, 2024 Compared to Fiscal Year Ended September 30, 2023
Product Revenues
Fiscal Years Ended
September 28, 2024
September 30, 2023
Change
Amount
% of Total
Revenue
Amount
% of Total
Revenue
Amount
%
Product Revenues
Diagnostics
$
1,658.3
41.1 % $
1,764.4
43.8 % $
(106.1)
(6.0) %
Breast Health
912.9
22.7 %
836.6
20.8 %
76.3
9.1 %
GYN Surgical
635.0
15.8 %
600.0
14.9 %
35.0
5.8 %
Skeletal Health
48.9
1.2 %
78.9
2.0 %
(30.0)
(38.0) %
$
3,255.1
80.8 % $
3,279.9
81.4 % $
(24.8)
(0.8) %
We had a decrease in product revenues of 0.8% in fiscal 2024 compared to fiscal 2023. This decrease was primarily due to
a decrease in Diagnostics revenue as a result of lower COVID-19 assay sales and to a lesser extent a decrease in Skeletal
revenue. In addition, the prior year period included an extra week based on our fiscal calendar. Partially offsetting this decrease
was an increase in Breast Health revenue as supply chain constraints continued to have a significant impact in the first quarter
of the prior year and to a lesser extent an increase in our GYN Surgical business.
Diagnostics product revenues decreased 6.0% in fiscal 2024 compared to fiscal 2023 primarily due to a decrease in
Molecular Diagnostics of $100.8 million. The decrease was primarily driven by a decrease of $169.6 million in sales from our
two SARS-CoV-2 assays due to lower volumes, which we primarily attribute to lower demand from an improvement in the
COVID-19 pandemic and greater use of rapid tests compared to the prior year. We expect sales of our two SARS-CoV-2 assays
to continue to decline in fiscal 2025 compared to fiscal 2024. In addition, we had a reduction in CT/GC revenue, primarily from
slightly lower average selling prices, and a reduction in legacy Mobidiag products. These decreases were partially offset by an
increase in volumes of our BV/CV assays, Fusion respiratory products and to a lesser extent an increase in Cytology
instruments and related products in our international markets.
Breast Health product revenues increased 9.1% in fiscal 2024 compared to fiscal 2023 primarily due to an increase in
volumes of our digital mammography systems, primarily 3Dimensions systems and related workstation and workflow products
including software, and to a lesser extent an increase in Trident systems unit sales. The increase in volume was primarily driven
by the improvement in supply chain constraints related to electronic components which have substantially abated. In addition,
we had an increase in sales of our interventional breast solutions products of $21.6 million in the current fiscal year compared
to the prior fiscal year primarily driven by higher volumes of Brevera disposables and Somatex Tumark markers. To a lesser
extent there was an increase in average selling prices of ATEC disposable products. In addition, the Endomag acquisition
contributed an incremental $6.6 million in product revenue. These increases were partially offset by a decrease in sales of SSI
ultrasound imaging products of $14.6 million in the current fiscal year compared to the prior fiscal year as a result of the sale of
this business in the beginning of the first quarter of fiscal 2024, and a reduction in volumes of our Localizer consumables.
GYN Surgical product revenues increased 5.8% in fiscal 2024 compared to fiscal 2023, primarily due to increases in the
sales volume of our MyoSure devices and Fluent fluid management products, partially offset by lower volumes and average
selling prices of our NovaSure devices in the U.S. The reduction of U.S. NovaSure devices was partially offset by an increase
in volumes internationally, primarily in Western Europe.
Skeletal Health product revenues decreased 38.0% in fiscal 2024 compared to fiscal 2023 primarily due to a decrease in
sales volume of our Horizon DXA systems as a temporary stop-ship was implemented during the third quarter of fiscal 2024
due to a non-conformance matter pertaining to electromagnetic compatibility requirements. We are working to resolve this issue
with our suppliers and expect to resume shipments during the first quarter of fiscal 2025. To a lesser extent, we had a decrease
in sales volumes of our Insight FD systems from competitive pressures.
At the end of any of our fiscal quarters and years, there remain open orders, primarily related to consumable products, that
are not fulfilled until the beginning of the subsequent quarter or year, depending on a number of factors, including but not
limited to management discretion to defer shipping orders based on achieving certain financial targets, customer ordering
patterns, and various operational and logistical issues. The estimated annual effect of this over the last three fiscal years has
been less than 0.5% of consolidated revenues.
38
Product revenues by geography as a percentage of total revenues were as follows:
Years Ended
September 28,
2024
September 30,
2023
United States
73.0 %
74.0 %
Europe
14.2 %
13.9 %
Asia-Pacific
6.8 %
6.6 %
Rest of World
6.0 %
5.5 %
100.0 %
100.0 %
The percentage of product revenue derived from the U.S. decreased, which we primarily attribute to the decrease in sales
from our two SARS-CoV-2 assays and a decrease in sales volumes of our Horizon DXA systems. This decrease was partially
offset by an increase in sales of our 3D Dimensions systems and related workflow products, and an increase in GYN Surgical
sales in the U.S. The increase in Europe was primarily due to an increase in sales of our GYN Surgical products, specifically
our MyoSure and NovaSure devices. The increase in Asia-Pacific was primarily due to an increase in sales of our 3D
Dimensions systems and to a lesser extent 2D Dimensions systems, and ThinPrep Pap tests in China. We primarily attribute the
increase in Rest of World due to an increase in sales of our MyoSure devices, BV/CV assays, Trident HD and Pathvision
systems in Canada and an increase in sales of our 3D Dimensions systems in Latin America.
Service and Other Revenues
Years Ended
September 28, 2024
September 30, 2023
Change
Amount
% of Total
Revenue
Amount
% of Total
Revenue
Amount
%
Service and Other Revenues
$
775.2
19.2 % $
750.5
18.6 % $
24.7
3.3 %
Service and other revenues are primarily comprised of revenue generated from our field service organization to provide
ongoing service, installation and repair of our products. Service and other revenues increased 3.3% in fiscal 2024 compared to
fiscal 2023 primarily due to an increase in Breast Health service contract revenue from our expanded installed base, partially
offset by a reduction in spare parts sales. In addition, we had higher lab testing volumes from our Biotheranostics business,
which we primarily attribute to greater adoption of our Breast Cancer Index test. These increases were partially offset by one
less week of service contract revenue as the prior fiscal year included an extra week of activity of approximately $7.9 million.
Cost of Product Revenues
Years Ended
September 28, 2024
September 30, 2023
Change
Amount
% of Product
Sales
Amount
% of Product
Sales
Amount
%
Cost of Product Revenues
$
1,206.2
37.1 % $
1,184.3
36.1 % $
21.9
1.8 %
Amortization of Acquired Intangible
Assets
180.5
5.5 %
205.7
6.3 %
(25.2)
(12.3) %
Impairment of Acquired Intangible
Assets and Equipment
39.2
1.2 %
179.5
5.5 %
(140.3)
**
$
1,425.9
43.8 % $
1,569.5
47.9 % $
(143.6)
(9.1) %
** Percentage not meaningful
Product gross margin was 56.2% in fiscal 2024 compared to 52.1% in fiscal 2023.
Cost of Product Revenues. The cost of product revenues as a percentage of product revenues was 37.1% in the current
year compared to 36.1% in the prior year. Cost of product revenues as a percentage of revenue increased in fiscal 2024
primarily due to a decrease in sales of our SARS-CoV-2 assays, which have higher gross margins compared to our other
Diagnostic products and comprised 2.4% and 7.6% of total product revenue in fiscal 2024 and fiscal 2023, respectively.
39
Diagnostics' product costs as a percentage of revenue increased in fiscal 2024 compared to fiscal 2023 primarily due to
lower sales of our SARS-CoV-2 assays, an increase in inventory reserves and higher field service costs for our expanded
instrument installed base. Partially offsetting these increases was an increase in volumes of our Women’s Health Aptima and
Fusion respiratory assays and the shutdown of our Mobidiag manufacturing facility in early fiscal 2024 resulting in lower
period costs in fiscal 2024.
Breast Health’s product costs as a percentage of revenue decreased in fiscal 2024 compared to fiscal 2023 primarily due to
higher sales volumes of our higher margin products, primarily 3D Dimensions and related software products and a slight
increase in average selling prices of our biopsy disposables as well as an increase in prices across multiple products in Europe.
Also contributing to the decrease in product costs as a percentage of revenue was a decrease in inventory excess and
obsolescence charges and freight costs partially offset by an increase in unfavorable manufacturing variances.
GYN Surgical’s product costs as a percentage of revenue increased slightly in fiscal 2024 compared to fiscal 2023
primarily due to product mix of higher volumes of lower margin products, mostly attributable to sales of our Fluent fluid
management systems, and lower volumes and average selling prices of our NovaSure devices, partially offset by an increase in
MyoSure volumes.
Skeletal Health’s product costs as a percentage of revenue increased in fiscal 2024 compared to fiscal 2023 primarily due
to a $6.5 million charge recorded in the current year to repair certain Horizon DXA units in the field due to a non-conformance
matter pertaining to electromagnetic compatibility requirements and to a lesser extent a decrease in volume of Horizon DXA
systems due to the temporary stop-ship implemented during the third quarter of fiscal 2024.
Amortization of Acquired Intangible Assets. Amortization of intangible assets included in cost of product revenues
relates to acquired developed technology, which is generally amortized over its estimated useful life of between 5 and 15 years
using a straight-line method or, if reliably determinable, based on the pattern in which the economic benefits of the assets are
expected to be consumed. Amortization expense decreased in fiscal 2024 compared to fiscal 2023 primarily due to lower
amortization as a result of an impairment in the prior year related to the Mobidiag acquisition, the disposition of the SSI
ultrasound business as of the beginning of the first quarter of fiscal 2024 and the BioZorb impairments recorded in the second
and third quarters of fiscal 2024.
Impairment of Intangible Assets and Equipment. During the second quarter of fiscal 2024, in connection with
commencing our company-wide annual strategic planning process, we identified indicators of impairment in our BioZorb
product line, which was part of the Focal acquisition and included in our Breast Health reportable segment. As a result, we
performed an undiscounted cash flow analysis to determine if the cash flows expected to be generated by the BioZorb product
line over the remaining estimated useful life of the primary asset were sufficient to recover the carrying value of the asset
group. Based on this analysis the undiscounted cash flows were not sufficient to recover the carrying value of the long-lived
assets. Therefore, we were required to perform Step 3 of the impairment test and determine the fair value of the asset group. To
estimate the fair value of the asset group, we utilized the income approach, which is based on a discounted cash flow (DCF)
analysis and calculated the fair value by estimating the after-tax cash flows attributable to the asset group and then discounting
the after-tax cash flows to present value using a risk-adjusted discount rate. Based on this analysis, the fair value of the BioZorb
asset group was below its carrying value and we recorded an aggregate impairment charge of $26.8 million. The impairment
charge was allocated to the BioZorb long-lived assets, of which $25.9 million was allocated to developed technology. During
the third quarter of fiscal 2024, the Federal Drug Administration classified a prior safety notice for the BioZorb Marker as a
Class I recall. This was a technical classification of a prior safety notice only, not a product removal. Following this, we
lowered our forecast for this product line, which is an indicator of impairment. Accordingly, we performed an undiscounted
cash flow analysis and determined the cash flows were not sufficient to recover the carrying value of the asset group. We
performed a fair value analysis and determined that the fair value of the asset group was immaterial. As a result, we recorded an
impairment charge of $13.3 million to developed technology to fully write-off the asset.
40
During the third quarter of fiscal 2023, in connection with our company-wide annual budgeting and strategic planning
process as well as evaluating the current operating performance of our Mobidiag business (included in the Diagnostics
reportable segment), including product design and manufacturing requirements, we reassessed the short-term and long-term
commercial plans for this business. We made certain operational and strategic decisions to invest and focus more on the long-
term success of this business, which resulted in the significant reduction of forecasted revenues and operating results. As a
result, we determined indicators of impairment existed and performed an undiscounted cash flow analysis to determine if the
cash flows expected to be generated by the Mobidiag business over the estimated remaining useful life of its primary asset were
sufficient to recover the carrying value of the asset group. Based on this analysis the undiscounted cash flows were not
sufficient to recover the carrying value of the long-lived assets. As a result, we were required to perform Step 3 of the
impairment test and determine the fair value of the asset group. To estimate the fair value of the asset group, we utilized the
income approach, which is based on a DCF. Assumptions used in the DCF require significant judgment, including judgment
about appropriate discount rates, growth rates, and the amount and timing of expected future cash flows. The forecasted cash
flows were based on our most recent strategic plan at the time and for periods beyond the strategic plan, our estimates were
based on assumed growth rates expected as of the measurement date. We believed the assumptions were consistent with the
plans and estimates that a market participant would use to manage the business. The discount rate used was intended to reflect
the risks inherent in future cash flow projections and was based on an estimate of the weighted average cost of capital (WACC)
of market participants relative to the asset group. We used a discount rate of 17.0%. As a result of this analysis, the fair value of
the Mobidiag asset group was below its carrying value. To record the asset group to fair value, the Company recorded an
impairment charge of $186.9 million during the third quarter of fiscal 2023. The impairment charge was allocated to the long-
lived assets on a pro-rata basis and $153.7 million of developed technology assets and $9.1 million of equipment was written
off to cost of product revenues. We believed our assumptions used to determine the fair value of the asset group were
reasonable. Actual operating results and the related cash flows of the asset group could differ from the estimated operating
results and related cash flows. In the event the asset group does not meet its forecasted projections, additional impairment
charges could be recorded in the future.
In addition to the impairment charges discussed above, during the third quarter of fiscal 2023, we also identified
indicators of impairment related to our SSI ultrasound imaging business (included in the Breast Health reportable segment). We
determined that the fair value of this asset group was approximately zero and the carrying value of the long-lived assets was
fully impaired. As a result, we recorded an impairment charge of $26.4 million. The impairment charge was allocated to the
long-lived assets and $16.7 million of developed technology assets were written off to cost of product revenues.
Cost of Service and Other Revenues
Years Ended
September 28, 2024
September 30, 2023
Change
Amount
% of Service
and Other
Revenues
Amount
% of Service
and Other
Revenues
Amount
%
Cost of Service and Other Revenues
$
376.6
48.6 % $
389.4
51.9 % $
(12.8)
(3.3) %
Service and other revenues gross margin was 51.4% in fiscal 2024 compared to 48.1% in fiscal 2023. The increase in
gross margin was primarily due to an increase in lab testing revenue from our Biotheranostics business, which has higher
margins than our legacy service business. Additionally, there was a decrease in service department costs related to the extra
week in the prior fiscal year and to a lesser extent a decrease in spare parts sales in Breast Health, which have lower gross
margins.
41
Operating Expenses
Years Ended
September 28, 2024
September 30, 2023
Change
Amount
% of Total
Revenue
Amount
% of Total
Revenue
Amount
%
Operating Expenses
Research and development
$
272.8
6.8 % $
294.3
7.3 % $
(21.5)
(7.3) %
Selling and marketing
585.4
14.5 %
595.2
14.8 %
(9.8)
(1.6) %
General and administrative
409.4
10.2 %
392.4
9.7 %
17.0
4.3 %
Amortization of acquired
intangible assets
29.2
0.7 %
28.1
0.7 %
1.1
3.9 %
Impairment of intangible assets
and equipment
5.6
0.1 %
44.3
1.1 %
(38.7)
**
Contingent consideration fair
value adjustments
1.7
— %
(14.9)
(0.4) %
16.6
(111.4) %
Loss on assets held-for-sale
—
— %
51.7
1.3 %
(51.7)
**
Restructuring charges
41.1
1.0 %
12.0
0.3 %
29.1
242.5 %
$
1,345.2
33.3 % $
1,403.1
34.8 % $
(57.9)
(4.1) %
** Percentage not meaningful
Research and Development Expenses. Research and development expenses decreased 7.3% in fiscal 2024 compared to
fiscal 2023 primarily due to a decrease in compensation and benefits from lower headcount, primarily in Breast Health and
Diagnostics, a decrease in project spend, and the elimination of expenses from our SSI ultrasound business of $11.3 million as a
result of its divestiture. To a lesser extent, in the current fiscal year, expenses were lower as the prior year period included an
extra week of expenses. These decreases were partially offset by a $10.0 million charge related to the purchase of intellectual
property to be used in a development project in Diagnostics that has no future alternative use and a decrease in credits of $7.1
million for funds received from the Biomedical Advanced Research and Development Authority (BARDA) grant to obtain
FDA approval of our SARS-CoV-2 in the current fiscal year compared to the prior fiscal year. At any point in time, we have a
number of different research projects and clinical trials being conducted and the timing of these projects and related costs can
vary from period to period.
Selling and Marketing Expenses. Selling and marketing expenses decreased 1.6% in fiscal 2024 compared to fiscal 2023
primarily due to lower spending on advertising and marketing initiatives, primarily from our sponsorship of the Women’s
Tennis Association, the elimination of expenses from our SSI ultrasound business of $6.4 million and lower travel expenses
partially offset by an increase in compensation from higher headcount internationally as well as incremental expense of $3.0
million from the Endomag acquisition. In addition, the current fiscal year expenses were lower as the prior fiscal year included
an extra week of activity.
General and Administrative Expenses. General and administrative expenses increased 4.3% in fiscal 2024 compared to
fiscal 2023 primarily due to an increase in compensation and benefits from higher expense from our deferred compensation
plan driven by stock market gains, higher salaries from an increase in headcount, an increase in acquisition transaction costs,
and an increase in legal expenses related to the BioZorb litigation and other projects as well as the prior fiscal year included a
benefit of $7.4 million from a settlement awarded in the Minerva litigation. These increases were partially offset by a decrease
of $10.0 million in charitable contributions, an $8.9 million charge recorded in the prior fiscal year for a dispute in connection
with terminating the Mobidiag joint venture agreement in China, the elimination of expenses from our SSI ultrasound business
of $4.3 million, and lower expenses from one less week of activity.
Amortization of Acquired Intangible Assets. Amortization of acquired intangible assets primarily results from customer
relationships and trade names related to our acquisitions. These intangible assets are generally amortized over their estimated
useful lives of between 5 and 30 years using a straight-line method or, if reliably determinable, based on the pattern in which
the economic benefits of the assets are expected to be consumed utilizing expected undiscounted future cash flows.
Amortization expense increased 3.9% in fiscal 2024 compared to fiscal 2023 primarily due to accelerated amortization of
customer relationship and trade name intangible assets acquired in the Mobidiag acquisition.
Impairment of Intangible Assets and Equipment. During the second quarter of fiscal 2024, as discussed above, we
recorded an impairment charge of $26.8 million related to our BioZorb product line of which $0.9 million was allocated to trade
42
names. During the third quarter of fiscal 2024, as discussed above, we recorded an additional impairment charge related to our
BioZorb product line of $13.7 million of which $0.4 million was allocated to trade names. During the first quarter of fiscal
2024, as discussed in Note 2 to the consolidated financial statements, we recorded an impairment charge of $4.3 million to
record our only IPR&D asset from the Mobidiag acquisition to fair value. The reduction in fair value was primarily due to a
reduction in forecasted revenues and an extension in the timing of completing the project.
During the third quarter of fiscal 2023, as discussed above, we recorded an aggregate impairment charge of $197.4
million related to our Mobidiag acquisition and $26.4 million related to our SSI ultrasound imaging assets. The impairment
charges were allocated to the long-lived assets and written off to operating expenses as follows: Mobidiag - $10.5 million to
IPR&D, $10.4 million to customer relationships, $10.7 million to trade names, and $3.0 million to equipment; Ultrasound
Imaging - $2.4 million to customer relationships, $1.7 million to trade names, and $5.6 million to equipment.
Contingent Consideration Fair Value Adjustments. In connection with the acquisition of Acessa Health Inc., or Acessa,
we were obligated to make contingent earn-out payments based on achieving incremental revenue growth over a three-year
period ending annually in December of each of 2021, 2022, and 2023. As of the acquisition date, we recorded a contingent
consideration liability for the estimated fair value of the amount we expected to pay to the former shareholders of the acquired
business. In the current year, the third and final measurement period was completed, and we recorded a loss of $1.7 million to
increase the contingent consideration liability to fair value based on actual revenue results in the final earn-out period. In fiscal
2023, we recorded a gain of $14.9 million to record the liability at its fair value. This reduction in fair value was primarily due
to a decrease in forecasted revenues over the remaining measurement period at that time.
Loss on Assets Held-For-Sale. In the prior fiscal year, we recorded a charge of $51.7 million related to our SSI
ultrasound imaging assets to record the asset group to fair value less the costs to sell. For additional information, please refer to
Note 7 to our consolidated financial statements.
Restructuring Charges. We have implemented various cost reduction initiatives to align our cost structure with our
operations and related integration activities. These actions have primarily resulted in the termination of employees and the
shutdown of certain facilities. During the first quarter of fiscal 2024, we further refined our strategy for the Mobidiag business
and decided to discontinue the manufacture and sale of certain products. This decision resulted in the closure of facilities in
Finland and France and moving the development activities and operations to our San Diego, California location. As a result, we
recorded impairment charges, accelerated depreciation and severance benefits totaling $31.6 million in fiscal 2024. For
additional information, please refer to Note 8 to our consolidated financial statements.
Interest Income
Years Ended
September 28, 2024
September 30, 2023
Change
Amount
Amount
Amount
%
Interest Income
$
108.7 $
120.5 $
(11.8)
(9.8) %
Interest income in fiscal 2024 decreased compared to fiscal 2023 due to lower average cash and investment balances in
the current year compared to the prior year, partially offset by higher interest rates in the current year as the U.S. Federal
Reserve raised the Federal Funds Rate throughout the majority of our fiscal 2023.
Interest Expense
Years Ended
September 28, 2024
September 30, 2023
Change
Amount
Amount
Amount
%
Interest Expense
$
(122.1) $
(111.1) $
(11.0)
9.9 %
Interest expense in fiscal 2024 and 2023 primarily consisted of the cash interest costs and the related amortization of the
debt discount and deferred issuance costs on our outstanding debt. Interest expense increased in fiscal 2024 compared to fiscal
2023 primarily due to the increase in the variable interest rate under our 2021 Credit Agreement and a decrease in amounts
received under our interest rate swap agreements primarily due to a decrease in our overall hedged principal amount from $1.0
billion to $500 million and an increase in the fixed rate under those agreements. These decreases were partially offset by a
lower principal balance outstanding under our 2021 Credit Agreement as we voluntarily prepaid $250.0 million during the first
quarter of fiscal 2024.
43
Other Income (Expense), net
Years Ended
September 28, 2024
September 30, 2023
Change
Amount
Amount
Amount
%
Other Income (Expense), net
$
(4.1) $
(1.7) $
(2.4)
141.2 %
In fiscal 2024, this account primarily consisted of net foreign currency exchange losses of $21.0 million, primarily from
the mark-to-market of foreign currency contracts used to hedge operating results and to a lesser extent losses of $3.6 million
from our Maverix strategic investment that is accounted for under the equity method, partially offset by a gain of $14.9 million
from the change in cash surrender value of life insurance contracts related to our deferred compensation plan driven by stock
market gains and a gain of $6.3 million from a change in control provision related to a license agreement.
In fiscal 2023, this account primarily consisted of net foreign currency exchange losses of $7.9 million, primarily from
the mark-to-market of foreign currency contracts used to hedge operating results, partially offset by a gain of $5.6 million from
the change in cash surrender value of life insurance contracts related to our deferred compensation plan driven by stock market
gains.
Provision for Income Taxes
Years Ended
September 28, 2024
September 30, 2023
Change
Amount
Amount
Amount
%
Provision for Income Taxes
$
75.6 $
220.1 $
(144.5)
(65.7) %
Our effective tax rate for fiscal 2024 was a provision of 8.7%. The effective tax rate for fiscal 2024 was lower than the
U.S. statutory tax rate primarily due to a one-time tax benefit of $107.2 million related to a worthless stock deduction on an
investment in one of our international subsidiaries recorded in the first quarter of fiscal 2024, the U.S. deduction for foreign
derived intangible income, the geographic mix of income earned by the Company’s international subsidiaries, and federal and
state tax credits.
Our effective tax rate for fiscal 2023 was a provision of 32.6%. The effective tax rate was higher than the U.S. statutory
tax rate primarily due to the tax effect of the SSI ultrasound imaging assets-held-for-sale charge, income tax reserves, the global
intangible low-taxed income inclusion, and state income taxes, partially offset by the impact of the U.S. deduction for foreign
derived intangible income, and the geographic mix of income earned by our international subsidiaries.
Segment Results of Operations
We operate in four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The accounting policies of
the segments are the same as those described in the footnotes to the accompanying consolidated financial statements contained
in Item 15 of this Annual Report. We measure segment performance based on total revenues and operating income (loss).
Revenues from product sales of each of these segments are described in further detail above. The discussion that follows is a
summary analysis of total revenues and the primary changes in operating income or loss by segment.
Diagnostics
Years Ended
September 28, 2024
September 30, 2023
Change
Amount
Amount
Amount
%
Total Revenues
$
1,782.0
$
1,880.1
$
(98.1)
(5.2) %
Operating Income
$
303.1
$
193.9
$
109.2
56.3 %
Operating Income as a % of Segment Revenue
17.0 %
10.3 %
Diagnostics revenues decreased in fiscal 2024 compared to fiscal 2023 primarily due to the decrease in product revenues
discussed above, partially offset by higher lab testing revenue from our Biotheranostics business.
44
Operating income for this business segment increased in fiscal 2024 compared to fiscal 2023 primarily due to an increase
in gross profit and a decrease in operating expenses. Gross margin was 52.7% in the current year compared to 44.7% in the
prior year. The increase in gross margin was primarily due to the prior year period included an impairment charge of $162.8
million related to Mobidiag, lower intangible asset amortization expense, lower manufacturing costs from the shut-down of the
Mobidiag Finland facility, an increase in sales volume of Women’s Health Aptima and Fusion assays and an increase in
Biotheranostics lab testing revenue, which has higher gross margins. These increases were partially offset by lower sales
volumes of our SARS-CoV-2 assays, which have a higher gross margin than our core products.
Operating expenses decreased in fiscal 2024 compared to fiscal 2023 as the prior year period included impairment
charges of $34.6 million related to Mobidiag and a charge of $8.9 million related to the termination of the Mobidiag joint
venture in China as well as an additional week of expenses. In addition, in the current year, we had lower marketing initiatives,
R&D project spend, and allocated charitable contributions partially offset by a decrease in BARDA credits of $7.1 million and
an increase in restructuring charges of $31.2 million primarily related to Mobidiag.
Breast Health
Years Ended
September 28, 2024
September 30, 2023
Change
Amount
Amount
Amount
%
Total Revenues
$
1,522.9
$
1,432.7
$
90.2
6.3 %
Operating Income
$
394.5
$
273.0
$
121.5
44.5 %
Operating Income as a % of Segment Revenue
25.9 %
19.1 %
Breast Health revenues increased in fiscal 2024 compared to fiscal 2023 primarily due to an increase in product and
service revenue discussed above.
Operating income for this business segment increased in fiscal 2024 compared to fiscal 2023 primarily due to an increase
in gross profit from both an increase in product sales and services and a decrease in operating expenses. Gross margin remained
flat at 54.8% in the current year compared to the prior year. Product margin increased primarily due to an increase in sales of
3D Dimensions systems, which have a higher gross margin, lower intangible asset amortization, a slight increase in average
selling prices of our biopsy disposables, as well as an increase in prices across multiple products in Europe. Service margin
increased from the continued conversion of digital mammography systems to service contracts. Offsetting these improvements
to margin was an increase in impairment charges of $22.5 million, as charges related to our BioZorb asset group of $39.2
million that were included in cost of revenues exceeded impairment charges recorded in fiscal 2023 related to the SSI
ultrasound imaging business.
Operating expenses decreased in fiscal 2024 compared to fiscal 2023 primarily due to the prior year period included
charges related to the SSI ultrasound imaging business comprised of a loss on assets-held-for-sale of $51.7 million and
intangible asset impairment charges of $9.7 million as well as lower operating expenses of $22.1 million from the SSI
divestiture. Partially offsetting these decreases was incremental operating expenses of $5.9 million from Endomag, and an
increase in acquisition expenses, litigation, and commissions from higher sales, partially offset by lower compensation from
headcount reductions in R&D, and a reduction in marketing initiatives, research and development project spend, and allocated
charitable contributions.
GYN Surgical
Years Ended
September 28, 2024
September 30, 2023
Change
Amount
Amount
Amount
%
Total Revenues
$
641.3
$
604.2
$
37.1
6.1 %
Operating Income
$
185.5
$
188.9
$
(3.4)
(1.8) %
Operating Income as a % of Segment Revenue
28.9 %
31.3 %
GYN Surgical revenues increased in fiscal 2024 compared to fiscal 2023 due to the increase in product revenues
discussed above.
Operating income for this business segment decreased in fiscal 2024 compared to fiscal 2023 primarily due to an increase
in operating expenses partially offset by an increase in gross profit. Gross margin was 67.3% in the current year, compared to
67.7% in the prior year. The decrease in gross margin was primarily due to product mix of higher volumes of lower margin
45
products, mostly attributable to sales of our Fluent fluid management systems, lower volumes of our NovaSure devices and
unfavorable manufacturing variances partially offset by an increase in volume of our MyoSure devices.
Operating expenses increased in fiscal 2024 compared to fiscal 2023 primarily due to the prior year period included a
gain of $14.9 million to decrease the Acessa contingent consideration liability to fair value and a $7.4 million settlement
awarded to us in the Minerva litigation. Partially offsetting these increases was a decrease in commissions expense and research
and development project spend.
Skeletal Health
Years Ended
September 28, 2024
September 30, 2023
Change
Amount
Amount
Amount
%
Total Revenues
$
84.1
$
113.4
$
(29.3)
(25.8) %
Operating Income (Loss)
$
(0.5)
$
12.6
$
(13.1)
104.0 %
Operating Income (Loss) as a % of Segment
Revenue
(0.6) %
11.1 %
Skeletal Health revenues decreased in fiscal 2024 compared to fiscal 2023 primarily due to the decrease in product
revenues discussed above.
Operating income decreased in fiscal 2024 compared to fiscal 2023 primarily due to a decrease in gross profit. Gross
margin was 28.0% in the current year compared to 32.2% in the prior year. The decrease in gross margin was primarily due to a
$6.5 million charge recorded in the current fiscal year to repair certain Horizon DXA units in the field due to a non-
conformance matter pertaining to electromagnetic compatibility requirements and to a lesser extent a decrease in volume of
Horizon DXA systems due to the temporary stop-ship implemented during the third quarter of fiscal 2024.
Operating expenses were consistent in fiscal 2024 compared to fiscal 2023.
Fiscal Year Ended September 30, 2023 Compared to Fiscal Year Ended September 24, 2022
Discussions of year-to-year comparisons between fiscal 2023 and 2022 that are not included in this Form 10-K can be
found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of the
Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023.
LIQUIDITY AND CAPITAL RESOURCES
At September 28, 2024, we had working capital of $2,786.1 million, and our cash and cash equivalents totaled $2,160.2
million. Our cash and cash equivalents balance decreased by $595.5 million during fiscal 2024 principally due to cash used in
investing and financing activities primarily related to repurchases of our common stock, debt payments, purchases of available-
for-sale securities and a payment made to acquire Endomag, partially offset by cash generated from operating activities.
In fiscal 2024, our operating activities provided cash of $1,285.2 million, primarily due to net income of $789.5 million,
non-cash charges for depreciation and amortization aggregating $309.0 million, stock-based compensation expense of $82.3
million, intangible asset impairment charges of $44.8 million, and other adjustments and non-cash items of $45.9 million. These
adjustments to net income were partially offset by a decrease in net deferred taxes of $72.1 million primarily due to the
amortization of intangible assets and to a lesser extent the capitalization of research expenditures under the tax rules. Cash
provided by operations included a net cash inflow of $84.1 million from changes in our operating assets and liabilities. The net
cash inflow was primarily driven by a decrease in accounts receivable of $41.0 million primarily related to strong cash
collections as we experienced an improvement in days sales outstanding by five days in the fourth quarter of fiscal 2024
compared to the prior year period, an increase in accrued expenses of $73.4 million primarily due to an increase in deferred
compensation, employee commissions and benefits, an increase in accounts payable of $22.2 million primarily due to the
timing of payments and an increase in deferred revenue of $9.3 million primarily due to billings for annual service contracts
under our expanded installed base of digital mammography systems. These cash inflows were partially offset by an increase in
prepaid income taxes of $21.7 million primarily due to the timing of tax payments relative to the provision for income taxes and
an increase in inventory of $47.4 million to meet expected demand across our primary product lines, the build of Breast Health
capital equipment prior to the transfer of manufacturing to Newark, and an increase in Skeletal Health Horizon systems and
components as a result of the current stop-ship for nonconformance issues.
46
In fiscal 2024, our investing activities used cash of $781.0 million primarily due to a payment of $297.3 million to
acquire Endomag in the fourth quarter of fiscal 2024, purchases of available-for-sale securities of $267.7 million, capital
expenditures of $130.2 million, which primarily consisted of the placement of equipment under customer usage agreements and
purchase of manufacturing equipment and building improvements at our Newark and San Diego facilities, $42.5 million for
strategic investments and a net payment of $31.1 million related to the sale of our SSI ultrasound imaging business.
In fiscal 2024, our financing activities used cash of $1,108.6 million, primarily due to $835.1 million for repurchases of
our common stock, including a $500 million accelerated share repurchase program, $287.5 million for debt principal payments
under our 2021 Credit Agreement, including a $250.0 million voluntary prepayment, and $17.4 million for the payment of
employee taxes withheld for the net share settlement of vested restricted stock units. Partially offsetting these uses of cash was
$37.8 million from our equity plans from the exercise of stock options and issuance of shares under our employee stock
purchase plan.
Debt
We had total recorded debt outstanding of $2.53 billion at September 28, 2024, which was comprised of amounts
outstanding under our 2021 Credit Agreement of $1.20 billion (principal of $1.20 billion), 2029 Senior Notes of $940.8 million
(principal of $950.0 million), and 2028 Senior Notes of $397.6 million (principal of $400.0 million).
2021 Credit Agreement
On September 27, 2021, we refinanced our existing term loan and revolving credit facility with Bank of America, N.A. in
its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders from time to time party
thereto (the “2018 Credit Agreement”) by entering into Refinancing Amendment (the “2021 Credit Agreement”). Borrowings
under the 2021 Credit Agreement are secured by first-priority liens on, and a first priority security interest in, substantially all of
our and our Subsidiary Guarantors’ U.S. assets. The credit facilities (the “2021 Credit Facilities”) under the 2021 Credit
Agreement consist of:
•
A $1.5 billion secured term loan (“2021 Term Loan”) with a stated maturity date of September 25, 2026; and
•
A secured revolving credit facility (the “2021 Revolver”) under which the Borrowers may borrow up to $2.0 billion,
subject to certain sublimits, with a stated maturity date of September 25, 2026.
As of September 28, 2024, there were no borrowings under the 2021 Revolver.
Borrowings under the 2021 Credit Agreement, other than Swing Line Loans, bear interest, at our option, at the Base Rate,
at the Term SOFR Rate, at the Alternative Currency Daily Rate, or at the Daily SOFR Rate, in each case plus the Applicable
Rate.
The Applicable Rate in regard to the Base Rate, the Term SOFR Rate, the Alternative Currency Daily Rate, the
Alternative Currency Term Rate and the Daily SOFR Rate is subject to change depending on the Total Net Leverage Ratio (as
defined in the 2021 Credit Agreement). As of September 28, 2024, the interest rate under the 2021 Term Loan was 5.96% per
annum.
We are required to make scheduled principal payments under the 2021 Term Loan in increasing amounts, which currently
range from $9.375 million per three-month period to $18.75 million per three-month period commencing with the three-month
period ending on December 26, 2025. The remaining scheduled balance of $1.085 billion (or such lesser aggregate principal
amount of the Term Loans then outstanding) on the 2021 Term Loan and any amounts outstanding under the 2021 Revolver are
due at their respective maturities. In addition, subject to the terms and conditions set forth in the 2021 Credit Agreement, we
may be required to make certain mandatory prepayments from the net proceeds of specified types of asset sales (subject to
certain reinvestment rights), debt issuances (excluding permitted debt) and insurance recoveries (subject to certain reinvestment
rights). Certain of the mandatory prepayments are subject to reduction or elimination if certain financial covenants are met.
Subject to certain limitations, we may voluntarily prepay any of the 2021 Credit Facilities without premium or penalty. As of
September 28, 2024, the outstanding principal balance of the 2021 Term Loan was $1.2 billion.
The 2021 Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit
facilities including the requirement we maintain two financial covenants (a total net leverage ratio and an interest coverage
ratio) measured as of the last day of each quarter for the previous twelve-month period. As of September 28, 2024, we were in
compliance with these covenants.
47
2028 Senior Notes
The total aggregate principal balance of the 2028 Senior Notes is $400.0 million. The 2028 Senior Notes are general
senior unsecured obligations and are guaranteed on a senior unsecured basis by certain of our domestic subsidiaries. The 2028
Senior Notes mature on February 1, 2028 and bear interest at the rate of 4.625% per year, payable semi-annually on February 1
and August 1 of each year. We have the option to redeem the 2028 Senior Notes on or after: February 1, 2024 through February
1, 2025 at 101.541% of par; February 1, 2025 through February 1, 2026 at 100.770% of par; and February 1, 2026 and
thereafter at 100% of par. In addition, if there is a change of control coupled with a decline in ratings, as provided in the
indenture, we will be required to make an offer to purchase each holder’s 2028 Senior Notes at a price equal to 101% of their
principal amount, plus accrued and unpaid interest, if any, to the repurchase date.
2029 Senior Notes
The total aggregate principal balance of the 2029 Senior Notes is $950.0 million. The 2029 Senior Notes are general
senior unsecured obligations and are guaranteed on a senior unsecured basis by certain domestic subsidiaries. The 2029 Senior
Notes mature on February 15, 2029 and bear interest at the rate of 3.250% per year, payable semi-annually on February 15 and
August 15 of each year. We have the option to redeem the 2029 Senior Notes on or after: September 28, 2024 through
September 27, 2025 at 100.813% of par; and September 28, 2025 and thereafter at 100% of par. In addition, if there is a change
of control coupled with a decline in ratings, as provided in the indenture, we will be required to make an offer to purchase each
holder’s 2029 Senior Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to the
repurchase date.
Acquisition
On October 11, 2024, we entered into a definitive agreement to acquire Gynesonics, Inc. (“Gynesonics”) for a purchase
price of approximately $350.0 million, subject to working capital and other customary adjustments. Gynesonics, located in
Redwood, California, develops a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain
symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. Completion of the acquisition is
subject to customary closing conditions, including receipt of required regulatory approvals. Gynesonics will be included in the
GYN Surgical reportable segment.
Stock Repurchase Program
On September 22, 2022, our Board of Directors authorized a stock repurchase program, with a five-year term, to
repurchase up to $1.0 billion of our outstanding common stock. As of September 28, 2024, $190.3 million remained authorized
for repurchase. Subsequent to September 28, 2024, we repurchased 2.7 million shares of our common stock for total
consideration of $217.2 million.
On September 12, 2024, our Board of Directors authorized a new stock repurchase program, with a five-year term, to
repurchase up to $1.5 billion of our outstanding stock. This new stock repurchase authorization is in addition to the Company’s
prior stock repurchase authorization. As of September 28, 2024, the entire authorization remained unused.
On November 19, 2024, we executed an accelerated share repurchase (ASR) agreement with JPMorgan Chase & Co.,
(“JP Morgan”) pursuant to which we agreed to repurchase $250 million of our common stock. In connection with the launch of
the ASR, on November 20, 2024, we paid JP Morgan an aggregate of $250 million and received approximately 2.5 million
shares of our common stock, representing 80% of the transaction value based on our closing share price on November 18, 2024.
The final number of shares to be received under the ASR agreement will be determined upon completion of the transaction and
will be based on the total transaction value and the volume-weighted average share price of our common stock during the term
of the transaction. Final settlement of the transaction is expected to be completed in the second quarter of fiscal 2025.
The timing of any future share repurchases will be based upon our continuing analysis of market, financial, and other
factors. Repurchases under the authorized share repurchase program may be made using a variety of methods, which may
include, but are not limited to, open market purchases, privately negotiated transactions, accelerated share repurchase
agreements, or purchases pursuant to a Rule 10b5-1 plan under the Exchange Act. The authorized share repurchase program
may be suspended, delayed or discontinued at any time.
Future Liquidity Considerations
We expect to continue to review and evaluate potential strategic transactions that we believe will complement our current
or future business. Subject to the “Risk Factors” set forth in Part I, Item 1A of this Annual Report and the general disclaimers
set forth in our Special Note Regarding Forward-Looking Statements at the outset of this Annual Report, we believe that our
48
cash and cash equivalents, short and long-term investments, cash flows from operations, and the cash available under our 2021
Revolver will provide us with sufficient funds in order to fund our existing commitments and our expected normal operations
and debt payments over the next twelve months. Our longer-term liquidity is contingent upon future operating performance. We
may also require additional capital in the future to fund capital expenditures, repayment of debt, acquisitions, strategic
transactions or other investments. As described above, we have significant indebtedness outstanding under our 2021 Credit
Agreement, 2028 Senior Notes, and 2029 Senior Notes. These capital requirements could be substantial. Our operating
performance may also be affected by matters discussed under the above-referenced Risk Factors set forth elsewhere in this
report. These risks, trends and uncertainties may also adversely affect our long-term liquidity.
Legal Contingencies
We are currently involved in certain legal proceedings and claims. In connection with these legal proceedings and claims,
management periodically reviews estimates of potential costs to be incurred by us in connection with the adjudication or
settlement, if any, of these proceedings. These estimates are developed, as applicable in consultation with outside counsel, and
are based on an analysis of potential litigation outcomes and settlement strategies. In accordance with ASC 450, Contingencies,
loss contingencies are accrued if, in the opinion of management, an adverse outcome is probable and such financial outcome
can be reasonably estimated. It is possible that future results for any particular quarter or annual period may be materially
affected by changes in our assumptions or the effectiveness of our strategies relating to these proceedings.
Guarantees and Other Off-Balance Sheet Arrangements
We do not have guarantees or other off-balance sheet financing arrangements, including variable interest entities, of a
magnitude that we believe could have a material impact on our financial condition or liquidity.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial
statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of
these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate
our estimates, including those related to revenue recognition for multiple element arrangements, allowance for doubtful
accounts, reserves for excess and obsolete inventories, valuations, purchase price allocations and contingent consideration
related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other
assumptions used to evaluate the recoverability of long-lived assets and goodwill, estimated fair values of intangible assets and
goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, restructuring and other related
charges, stock-based compensation, contingent liabilities, tax reserves and the recoverability of our net deferred tax assets and
related valuation allowances. We base our estimates on historical experience and various other assumptions that are believed to
be reasonable under the circumstances. Actual results could differ from these estimates if past experience or other assumptions
do not turn out to be substantially accurate. Any differences may have a material impact on our financial condition and results
of operations.
The following is a discussion of what we believe to be the more significant critical accounting policies and estimates used
in the preparation of our consolidated financial statements.
Inventory
Our inventories include material, labor and overhead, and are stated at the lower of cost (first-in, first-out) or net
realizable value. As a developer and manufacturer of high technology medical equipment, diagnostic test kits, and disposable
surgical devices, we may be exposed to a number of economic and industry factors that could result in portions of our inventory
becoming either obsolete or in excess of anticipated usage. Our policy is to establish inventory reserves when conditions exist
that suggest that our inventory may be in excess of anticipated demand or is obsolete based upon our assumptions about future
demand for our products and market conditions. Although considerable effort is made to ensure the accuracy of our forecasts of
future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative
impact on the value of our inventory and our operating results.
Business Combinations
We record tangible and intangible assets acquired and liabilities assumed in business combinations under the purchase
method of accounting. Amounts paid for each acquisition are allocated to the assets acquired and liabilities assumed based on
their fair values at the dates of acquisition. Contingent consideration, which is not deemed to be linked to continuing
employment, is recorded at fair value measured on the date of acquisition using an appropriate valuation model, such as the
49
Monte Carlo simulation model. The value recorded is based on estimates of future financial projections under various potential
scenarios, in which the model runs many simulations based on comparable companies’ growth rates and their implied volatility.
These cash flow projections are discounted with a risk adjusted rate. Each quarter until such contingent amounts are earned, the
fair value of the liability is remeasured at each reporting period and adjusted as a component of operating expenses based on
changes to the underlying assumptions. The estimates used to determine the fair value of the contingent consideration liability
are subject to significant judgment, specifically projected revenues, and given the inherent uncertainties in making these
estimates, actual results are likely to differ from the amounts originally recorded and could be materially different.
The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions
provided by management, which consider management’s best estimate of inputs and assumptions that a market participant
would use. We allocate any excess purchase price over the fair value of the net tangible and intangible assets acquired and
liabilities assumed to goodwill.
We generally use the income approach in which cash flow projections on an after-tax basis are discounted using a risk
adjusted rate to determine the estimated fair value of certain identifiable intangible assets including developed technology, in-
process research and development projects, customer relationships, and trade names. The significant assumptions used to
estimate the fair value of intangible assets include discount rates and certain assumptions that form the basis of the forecasted
results, specifically revenue growth rates. These significant assumptions are forward looking and could be affected by future
economic and market conditions.
Goodwill
We test goodwill at the reporting unit level for impairment on an annual basis and between annual tests if events and
circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that
could indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and
market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate,
operational performance of the business or key personnel, and an adverse action or assessment by a regulator. Our annual
impairment test date is the first day of our fiscal fourth quarter.
In performing the test, we either use the qualitative assessment permitted by ASC 350, Intangibles—Goodwill and Other,
or the single step quantitative approach prescribed under ASC 350 including amendments under ASU 2017-04. Under the
qualitative approach we consider a number of factors, including the amount by which the previous quantitative test's fair value
exceeded the carrying value of the reporting units, the forecasts in our then-current strategic plan compared to the forecasts in
the previous quantitative test, an evaluation of discount rates, long-term growth rates including the terminal year rate, if tax
rates would have significantly changed, an evaluation of current economic factors for both the worldwide economy and
specifically the medical device industry, and any significant changes in customer and supplier relationships. We weigh these
factors to determine if it is more likely than not that the fair value of the reporting unit exceeds its carrying value. If after
performing a qualitative assessment, indicators are present, or we identify factors that cause us to believe it is appropriate to
perform a more precise calculation of fair value, we would move beyond the qualitative assessment and perform a quantitative
impairment test.
Under the quantitative impairment test, we perform a comparison of the reporting unit’s carrying value to its fair value.
We consider a number of factors to determine the fair value of a reporting unit, including an independent valuation to conduct
this test. The valuation is based upon expected future discounted operating cash flows of the reporting unit as well as analysis of
recent sales and ratio comparisons of similar companies. We base the discount rate on the weighted average cost of capital, or
WACC, of market participants. If the carrying value of a reporting unit exceeds its estimated fair value, we apply the single step
approach under ASU 2017-04. As a result of this simplified approach the goodwill impairment is calculated as the amount by
which the carrying value of the reporting unit exceeds its fair value to the extent of the goodwill balance.
We conducted our fiscal 2024 annual impairment test on the first day of the fourth quarter and utilized the quantitative
approach. We used discounted cash flow analyses, or DCF, and market approaches to estimate the fair value of our reporting
units as of June 30, 2024 and ultimately used the fair value determined by the DCF in making our impairment test conclusions.
We believe we used reasonable estimates and assumptions about future revenue, cost projections, cash flows, discount rates and
market multiple as of the measurement date. As a result of completing this analysis, all of our reporting units had fair values
exceeding their carrying values.
At September 28, 2024, we believe that our reporting units, with goodwill aggregating $3.4 billion, were not at risk of
failing the goodwill impairment test based on our current forecasts and qualitative assessment.
Since the fair value of our reporting units was determined by use of the DCF, and the key assumptions that drive the fair
value in this model are the WACC, terminal values, growth rates, and the amount and timing of expected future cash flows,
50
significant judgment is applied in determining fair value. If the current economic environment were to deteriorate, this would
likely result in a higher WACC because market participants would require a higher rate of return. In the DCF as the WACC
increases, the fair value decreases. The other significant factor in the DCF is our projected financial information (i.e., amount
and timing of expected future cash flows and growth rates) and if these assumptions were to be adversely impacted, this could
result in a reduction of the fair value of a reporting unit.
Intangible Assets
Intangible assets are initially recorded at fair value and stated net of accumulated amortization and impairments. We
amortize intangible assets that have finite lives using either the straight-line method, or if reliably determinable, based on the
pattern in which the economic benefit of the asset is expected to be utilized. We evaluate the recoverability of our definite lived
intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these
assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying
value of an asset or asset group exceeds its undiscounted cash flows, we estimate the fair value of the assets, generally utilizing
a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a
risk-adjusted discount rate. To estimate the fair value of the assets, the Company uses market participant assumptions pursuant
to ASC 820, Fair Value Measurements.
Indefinite lived intangible assets, such as IPR&D assets, are initially recorded at fair value and are required to be tested
for impairment annually, or more frequently if indicators of impairment are present. The Company’s annual impairment test
date is as of the first day of its fourth quarter. We estimate the fair value of IPR&D assets utilizing a DCF and key assumptions
are revenue growth rates, timing of completion of the project, costs to complete the project and discount rates. These estimates
require significant judgment and adverse changes in assumptions could result in a lower fair value.
Revenue Recognition
We generate revenue from the sale of our products, primarily medical imaging systems and diagnostic and surgical
disposable products, and related services, which are primarily support and maintenance services on our medical imaging
systems. See Note 3 for further discussion of revenue recognition.
We consider revenue to be earned when all of the following criteria are met: we have a contract with a customer that
creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount that
we expect to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in
an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and we have transferred
control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or
service to the customer and is the unit of account in the contract. The transaction price for the contract is measured as the
amount of consideration we expect to receive in exchange for the goods and services expected to be transferred. A contract's
transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the
distinct good or service is transferred. Transfer of control for our products is generally at shipment or delivery, depending on
contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the
customer obtains the use of and substantially all of the remaining benefit of the product. As such, the performance obligation
related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts and extended warranties
are recognized over time based on the contract term, which represents a faithful depiction of the transfer of goods and services
given the stand-ready nature of the performance obligations. Service revenue related to professional services for installation,
training and repairs is recognized as the services are performed based on the specific nature of the service.
We recognize receivables when we have an unconditional right to payment, which represents the amount we expect to
collect in a transaction and is most often equal to the transaction price in the contract. Payment terms are typically 30 days in
the U.S. but may be longer in international markets. We treat shipping and handling costs performed after a customer obtains
control of the good as a fulfillment cost and record these costs within costs of product revenue when the corresponding revenue
is recognized.
Generally the contracts for capital equipment include multiple performance obligations. For contracts with multiple
performance obligations, we are required to allocate the transaction price to each performance obligation using our best
estimate of the standalone selling price of each distinct good or service in the contract. We determine the best estimate of
standalone selling price using average selling prices over 3- to 12-month periods of data depending on the products or nature of
the services coupled with current market considerations. If the product or service does not have a history of sales or if sales
volume is not sufficient, we rely on prices set by our pricing committees or applicable marketing department adjusted for
expected discounts.
51
We exercise judgement in estimating variable consideration, which includes volume discounts, sales rebates, product
returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. We
base our estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a
predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, we apply
judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. We
evaluate constraints based on our historical and projected experience with similar customer contracts. Our contracts for the sale
of capital equipment and related components, and assays and tests typically do not provide the right to return product, however,
our contracts for the sale of our interventional breast and surgical handpieces provide for a right of return for a limited period of
time. In general, estimates of variable consideration and constraints are not material to our financial statements.
We also place instruments (or equipment) at customer sites but retain title to the instrument (for example, the ThinPrep
Processor, ThinPrep Imaging System, and the Panther and Panther Fusion systems). The customer has the right to use the
instrument for a period of time, and then we recover the cost of providing the instrument through the sales of disposables,
namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded
operating lease for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. We
recognize a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the
agreement.
Income Taxes
We use the asset and liability method for accounting for income taxes in accordance with ASC 740, Income Taxes. Under
this method, we recognize deferred income tax assets and liabilities for the future tax consequences of differences between the
financial statement carrying amount of existing assets and liabilities and their respective tax bases, and also for operating loss
and tax credit carryforwards at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates and
laws applicable to the period and jurisdiction in which we expect the differences to affect taxable income. We evaluate both the
positive and negative evidence that affects the realizability of net deferred tax assets and assess the need for a valuation
allowance. The future benefit to be derived from our deferred tax assets is dependent upon our ability to generate sufficient
future taxable income in each jurisdiction of the right type to realize the assets. We establish a valuation allowance when
necessary to reduce deferred tax assets to the amounts expected to be realized. To the extent we establish or release a valuation
allowance, a tax charge or benefit will be recorded as a component of the income tax provision on the statement of operations in
the reporting period that such determination is made.
Accounting for income taxes requires a two-step approach to recognize and measure uncertain tax positions. The first
step is to evaluate the tax position for recognition by determining if, based on the technical merits, it is more likely than not that
the position will be sustained upon audit, including resolutions of related appeals or litigation processes, if any. The second step
is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. We
evaluate these uncertain tax positions on a quarterly basis. This evaluation is based on factors including, but not limited to,
changes in facts or circumstances, changes in tax law, effectively settled issues under audit and new audit activity. Any change
in these factors could result in the recognition of a tax benefit or an additional charge to the tax provision.
In the ordinary course of business, there are many transactions and calculations where the ultimate tax outcome is
uncertain. Judgment is required in determining our worldwide income tax provision. In our opinion, we have made adequate
provisions for income taxes for all years subject to audit. While we consider our estimates reasonable, no assurance can be
given that the final tax outcome will not be different than amounts reflected in our historical income tax provisions and
accruals. If our assumptions are incorrect, the differences could have a material impact on our income tax provision and
operating results in the period in which such determination is made.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Financial Instruments, Other Financial Instruments, and Derivative Commodity Instruments. Financial instruments
consist of cash and cash equivalents, available-for-sale debt securities, accounts receivable, equity investments, foreign
currency derivative contracts, interest rate swap agreements, insurance contracts, accounts payable and debt obligations. Except
for our outstanding 2028 and 2029 Senior Notes, the fair value of these financial instruments approximate their carrying
amount. The fair value of our 2028 and 2029 Senior Notes was approximately $393.1 million and $882.2 million, respectively,
as of September 28, 2024. Amounts outstanding under our 2021 Credit Agreement of $1.2 billion aggregate principal as of
September 28, 2024 are subject to variable rates of interest based on current market rates, and as such, we believe the carrying
amount of these obligations approximates fair value.
Primary Market Risk Exposures. Our primary market risk exposure is in the areas of interest rate risk and foreign
currency exchange rate risk. We incur interest expense on borrowings outstanding under our 2028 and 2029 Senior Notes, and
52
2021 Credit Agreement. The 2028 and 2029 Senior Notes have fixed interest rates. Effective September 25, 2022 (the first day
of fiscal 2023), borrowings under our 2021 Credit Agreement bear interest at the SOFR Rate plus SOFR Adjustment of 0.10%
plus the applicable margin of 1.00% per annum.
As of September 28, 2024, there was $1.20 billion of aggregate principal outstanding under the 2021 Credit Agreement.
Since this debt obligation is a variable rate instrument, our interest expense associated with the instrument is subject to change.
A hypothetical 10% adverse movement (increase in the SOFR rate) would increase annual interest expense by approximately
$3.4 million, which is net of the impact of our interest rate swap hedge. We previously entered into interest rate swap
agreements to help mitigate the interest rate volatility associated with the variable rate interest on the amounts outstanding
under our credit facilities. The critical terms of the interest rate swaps were designed to mirror the terms of our SOFR-based
borrowings under the 2021 Credit Agreement, and therefore the interest rate swap is highly effective at offsetting the cash flows
being hedged. We designated these derivative instruments as a cash flow hedge of the variability of the Term SOFR-based
interest payments on $500 million of principal.
The return from cash and cash equivalents, and our short and long-term investments, which are available-for-sale debt
securities, will vary as short-term interest rates change. A hypothetical 100 basis point change in market rates would change
annual interest income by approximately $10.4 million based on our current cash and investment balances.
Foreign Currency Exchange Risk. Our international business is subject to risks, including, but not limited to: unique
economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign
exchange rate volatility. Accordingly, our future results could be materially adversely impacted by changes in these or other
factors.
We conduct business worldwide and maintain sales and service offices outside the U.S. as well as manufacturing
facilities in Costa Rica and the United Kingdom. Our international sales are denominated in a number of currencies, primarily
the Euro, U.S. dollar, U.K. Pound, Australian dollar, Canadian dollar, Chinese Yuan and Japanese Yen. The majority of our
foreign subsidiaries functional currency is the local currency, although certain foreign subsidiaries functional currency is the
U.S. dollar based on the nature of their operations or functions. Our revenues denominated in foreign currencies are positively
affected when the U.S. dollar weakens against them and adversely affected when the U.S. dollar strengthens. Fluctuations in
foreign currency rates could affect our sales, cost of goods and operating margins and could result in exchange losses. In
addition, currency devaluations can result in a loss if we hold deposits of that currency. We have executed forward foreign
currency contracts and foreign currency collars (principally the Japanese yen) to hedge a portion of results denominated in the
Euro, U.K. Pound, Australian dollar, Japanese Yen, Canadian dollar and Chinese Yuan. These contracts do not qualify for
hedge accounting. As a result, we may experience volatility in our Consolidated Statements of Income due to (i) the impact of
unrealized gains and losses reported in other income, net on the mark-to-market of outstanding contracts and (ii) realized gains
and losses recognized in other income, net, whereas the offsetting economic gains and losses are reported in the line item of the
underlying cash flow, for example, revenue.
We believe that the operating expenses of our international subsidiaries that are incurred in local currencies will not have
a material adverse effect on our business, results of operations or financial condition. Our operating results and certain assets
and liabilities that are denominated in foreign currencies are affected by changes in the relative strength of the U.S. dollar
against those currencies. Our expenses, denominated in foreign currencies, are positively affected when the U.S. dollar
strengthens against those currencies and adversely affected when the U.S. dollar weakens. However, we believe that the foreign
currency exchange risk is not significant. We believe a hypothetical 10% increase or decrease in foreign currencies that we
transact in would not have a material adverse impact on our financial condition or results of operations. During fiscal 2024, we
incurred net foreign exchange losses of $21.0 million, net foreign exchange losses of $7.9 million in fiscal 2023 and net foreign
exchange gains of $48.5 million in fiscal 2022.
Item 8. Financial Statements and Supplementary Data
Our Consolidated Financial Statements and Supplementary Data are set forth under Part IV, Item 15, which is
incorporated herein by reference.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
53
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in
our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules
and forms, and that such information is accumulated and communicated to our management, including our Chief Executive
Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and
evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how
well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are
designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of
possible controls and procedures.
As of September 28, 2024, we carried out an evaluation, under the supervision and with the participation of our
management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and
operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act.
Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and
procedures are effective.
54
Report of Management on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting.
Internal control over financial reporting is defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act, as amended, as a
process designed by, or under the supervision of our principal executive and principal financial officers and effected by our
board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted
accounting principles and includes those policies and procedures that:
•
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and
disposition of our assets;
•
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in
accordance with authorization of our management and directors; and
•
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of
our assets that could have a material effect on the financial statements.
Our internal control system was designed to provide reasonable assurance to our management and board of directors
regarding the preparation and fair presentation of published financial statements. Because of its inherent limitations, internal
control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future
periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.
Management has assessed the effectiveness of our internal control over financial reporting as of September 28, 2024. In
making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway
Commission (2013 framework) (COSO) in Internal Control-Integrated Framework.
Management has excluded from our assessment of and conclusion on the effectiveness of internal control over financial
reporting the internal controls of Endomagnetics Ltd acquired on July 25, 2024, which is included in the consolidated financial
statements of Hologic, Inc. as of and for the year ended September 28, 2024 and constituted 4.2% and 6.2% of assets and net
assets, respectively, as of September 28, 2024 and less than 1% of revenues and pre-tax income for the year then ended.
Subject to the foregoing, based on management’s assessment, we determined that, as of September 28, 2024, our internal
control over financial reporting is effective at a reasonable assurance level based on these criteria.
Ernst & Young LLP, an independent registered public accounting firm, has issued an attestation report on the
effectiveness of our internal control over financial reporting. This report in which they expressed an unqualified opinion is
included below.
55
Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors of Hologic, Inc.
Opinion on Internal Control Over Financial Reporting
We have audited Hologic, Inc.’s internal control over financial reporting as of September 28, 2024, based on criteria
established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission (2013 framework) (the COSO criteria). In our opinion, Hologic, Inc. (the Company) maintained, in all material
respects, effective internal control over financial reporting as of September 28, 2024, based on the COSO criteria.
As indicated in the accompanying Report of Management on Internal Control over Financial Reporting, management’s
assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal
controls of Endomagnetics Ltd, which is included in the 2024 consolidated financial statements of the Company and constituted
4.2% and 6.2% of total and net assets, respectively, as of September 28, 2024 and less than 1% of revenues and net income, for
the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of
the internal control over financial reporting of Endomagnetics Ltd.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United
States) (PCAOB), the 2024 consolidated financial statements of the Company and our report dated November 27, 2024
expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial reporting included in the accompanying Report of
Management on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s
internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was
maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a
material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed
risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides
a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures
that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and directors of the
company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Boston, Massachusetts
November 27, 2024
56
Changes in Internal Control Over Financial Reporting
During the quarter ended September 28, 2024, there have been no changes in our internal control over financial reporting
that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item 9B. Other Information
Rule 10b5-1 Trading Plans
During the fourth quarter of fiscal 2024, none of our directors or executive officers adopted or terminated any Rule
10b5-1 trading plans or non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
57
PART III
Item 10. Directors, Executive Officers and Corporate Governance
Pursuant to Section 406 of the Sarbanes-Oxley Act of 2002, we have adopted a Code of Ethics for Senior Financial
Officers that applies to our principal executive officer, principal financial officer, and principal accounting officer and
controller, and other persons performing similar functions. Our Code of Ethics for Senior Financial Officers is publicly
available on our website at investors.hologic.com as Appendix A to our Code of Conduct. We intend to satisfy the disclosure
requirement under Item 5.05 of Current Report on Form 8-K regarding an amendment to, or waiver from, a provision of this
code by posting such information on our website, at the address specified above. Additionally, we intend to disclose future
amendments to certain provisions of the Code of Conduct, and waivers of the Code of Conduct granted to executive officers
and directors, on our website, at the address specified above.
The additional information required by this item is incorporated by reference to our Definitive Proxy Statement for our
annual meeting of stockholders to be filed with the SEC within 120 days after the close of our fiscal year.
Item 11. Executive Compensation
The information required by this item is incorporated by reference to our Definitive Proxy Statement for our annual
meeting of stockholders to be filed with the SEC within 120 days after the close of our fiscal year.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
We maintain a number of equity compensation plans for employees, officers, directors and others whose efforts
contribute to our success. The table below sets forth certain information as of the end of our fiscal year ended September 28,
2024 regarding the shares of our common stock available for grant or granted under stock option plans and equity incentives
that (i) were approved by our stockholders, and (ii) were not approved by our stockholders.
Equity Compensation Plan Information
Plan Category
Number of
securities to be
issued upon
exercise of
outstanding
options, warrants
and rights
(a)
Weighted-average
exercise price of
outstanding
options,
warrants and rights
(b) (2)
Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding
securities reflected in
column (a))
(c)
Equity compensation plans approved by security
holders (1)
7,115,264 $
55.32
7,472,695
Equity compensation plans not approved by security
holders
—
—
—
Total
7,115,264 $
55.32
7,472,695
___________
(1) Includes 2,848,339 shares that are issuable upon restricted stock units (RSUs), performance stock units (PSUs) and market
stock units (MSUs) vesting. The remaining balance consists of outstanding stock option grants.
(2) The weighted average exercise price does not take into account the shares issuable upon vesting of outstanding RSUs,
PSUs and MSUs, which have no exercise price.
The additional information required by this item is incorporated by reference to our Definitive Proxy Statement for our
annual meeting of stockholders to be filed with the SEC within 120 days after the close of our fiscal year.
Item 13. Certain Relationships and Related Transactions and Director Independence
The information required by this item is incorporated by reference to our Definitive Proxy Statement for our annual
meeting of stockholders to be filed with the SEC within 120 days after the close of our fiscal year.
58
Item 14. Principal Accounting Fees and Services
The information required by this item is incorporated by reference to our Definitive Proxy Statement for our annual
meeting of stockholders to be filed with the SEC within 120 days after the close of our fiscal year. Our independent public
accounting firm is Ernst & Young LLP, New York, NY, PCAOB Auditor ID [PCAOB ID: 42].
59
PART IV
Item 15. Exhibits and Financial Statement Schedules
(a) The following documents are filed as part of this report:
(1) Financial Statements
Report of Independent Registered Public Accounting Firm on Consolidated Financial Statements
Consolidated Statements of Income for the years ended September 28, 2024, September 30, 2023 and
September 24, 2022
Consolidated Statements of Comprehensive Income for the years ended September 28, 2024, September 30,
2023 and September 24, 2022
Consolidated Balance Sheets as of September 28, 2024 and September 30, 2023
Consolidated Statements of Stockholders’ Equity for the years ended September 28, 2024, September 30,
2023 and September 24, 2022
Consolidated Statements of Cash Flows for the years ended September 28, 2024, September 30, 2023 and
September 24, 2022
Notes to Consolidated Financial Statements
(2) Financial Statement Schedules
All schedules have been omitted because they are not required or because the required information is given
in the Consolidated Financial Statements or Notes thereto.
(b) Listing of Exhibits
2.1 Share Purchase Agreement, dated as of April 8, 2021, by and among Hologic,
Inc. and certain sellers listed therein (1)
8-K
04/08/2021
3.1
Certificate of Incorporation of Hologic, with amendments
10-K
09/30/2017
3.2
Seventh Amended and Restated Bylaws of Hologic, Inc.
8-K
06/25/2019
4.1 Indenture, dated September 28, 2020, by and among Hologic, Inc., the
guarantors party thereto and Wells Fargo Bank, National Association, as Trustee
8-K
09/28/2020
4.2 First Supplemental Indenture dated as of May 18, 2021 among Hologic, Inc.,
The Subsidiary Guarantor Party Hereto and Wells Fargo Bank, National
Association, as Trustee
10-K
09/25/2021
4.3 Form of 3.250% Senior Note due 2029 (included in Exhibit 4.2)
8-K
09/28/2020
4.4 Indenture dated January 19, 2018, by and among Hologic, the Guarantors party
thereto and Wells Fargo Bank, National Association, as Trustee
8-K
01/19/2018
4.5 First Supplemental Indenture dated January 19, 2018, by and among Hologic,
the Guarantors party thereto and Wells Fargo Bank, National Association, as
Trustee
8-K
01/19/2018
4.6 Second Supplemental Indenture dated July 25, 2024, by and among Hologic,
Inc., The Subsidiary Guarantors Party Hereto and Computershare Trust
Company, National Association, as Trustee
Filed
herewith
4.7 Form of 4.625% Senior Note due 2028 (included in Exhibit 4.5)
8-K
01/19/2018
Incorporated by
Reference
Exhibit
Number
Exhibit Description
Form
Filing Date/
Period End
Date
60
4.8 Second Supplemental Indenture dated as of November 9, 2018 among Hologic,
Inc., The Subsidiary Guarantor Parties Hereto and Wells Fargo Bank, National
Association, as Trustee
10-K
09/25/2021
4.9 Third Supplemental Indenture dated as of January 8, 2019 among Hologic, Inc.,
the Subsidiary Guarantors Party Hereto and Wells Fargo Bank, National
Association, as Trustee
10-K
09/25/2021
4.10 Fourth Supplemental Indenture dated as of March 14, 2019 among Hologic, Inc.,
The Subsidiary Guarantor Party Hereto and Wells Fargo Bank, National
Association, as Trustee
10-K
09/25/2021
4.11 Fifth Supplemental Indenture dated as of May 18, 2021 among Hologic, Inc., the
Subsidiary Guarantor Party Hereto and Wells Fargo Bank, National Association,
as Trustee
10-K
09/25/2021
4.12 Sixth Supplemental Indenture dated as of July 25, 2024 among Hologic, Inc.,
The Subsidiary Guarantor Party Hereto and Computershare Trust Company,
N.A., as Trustee
Filed
herewith
4.13 Description of Securities
10-K
09/28/2019
10.1* Hologic Amended and Restated 2008 Equity Incentive Plan
8-K
03/10/2023
10.2* Form of Stock Option Award Agreement Under 2008 Equity Incentive Plan
(adopted fiscal 2016)
8-K
10/14/2015
10.3* Form of Stock Option Award Agreement Under 2008 Equity Incentive Plan
(adopted fiscal 2017)
8-K
11/09/2016
10.4*
Form of Independent Director Stock Option Award Agreement Under 2008
Equity Incentive Plan
10-K
11/21/2023
10.5*
Form of Stock Option Award Agreement Under 2008 Equity Incentive Plan
(Outside US) (adopted fiscal 2017)
10-K
11/15/2022
10.6*
Form of Stock Option Award Agreement Under 2008 Equity Incentive Plan
(adopted fiscal 2024)
8-K
11/13/2023
10.7*
Form of Independent Director Restricted Stock Unit Award Agreement Under
2008 Equity Incentive Plan
10-K
11/21/2023
10.8*
Form of Restricted Stock Unit Award Agreement Under 2008 Equity Incentive
Plan (adopted fiscal 2017)
8-K
11/09/2016
10.9*
Form of Restricted Stock Unit Award Agreement Under 2008 Equity Incentive
Plan (Outside US) (adopted fiscal 2017)
10-K
11/15/2022
10.10*
Form of Restricted Stock Unit Award Agreement Under 2008 Equity Incentive
Plan (adopted fiscal 2024)
8-K
11/13/2023
10.11*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (relative TSR) (adopted fiscal 2021)
8-K
11/06/2020
10.12*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (ROIC) (adopted fiscal 2021)
8-K
11/06/2020
10.13*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (Free Cash Flow) (adopted fiscal 2021)
8-K
11/06/2020
10.14*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (ROIC – Outside US) (adopted fiscal 2021)
8-K
11/06/2020
10.15*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (relative TSR – Outside US) (adopted fiscal 2021)
8-K
11/06/2020
Incorporated by
Reference
Exhibit
Number
Exhibit Description
Form
Filing Date/
Period End
Date
61
10.16*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (Free Cash Flow – Outside US) (adopted fiscal 2021)
8-K
11/06/2020
10.17*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (relative TSR) (adopted fiscal 2022)
8-K
11/04/2021
10.18*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (ROIC) (adopted fiscal 2022)
8-K
11/04/2021
10.19*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (Free Cash Flow) (adopted fiscal 2022)
8-K
11/04/2021
10.20*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (ROIC – Outside US) (adopted fiscal 2022)
8-K
11/04/2021
10.21*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (relative TSR – Outside US) (adopted fiscal 2022)
8-K
11/04/2021
10.22*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (Free Cash Flow – Outside US) (adopted fiscal 2022)
8-K
11/04/2021
10.23*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (relative TSR) (adopted fiscal 2023)
8-K
11/04/2022
10.24*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (ROIC) (adopted fiscal 2023)
8-K
11/04/2022
10.25*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (Free Cash Flow) (adopted fiscal 2023)
8-K
11/04/2022
10.26*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (ROIC – Outside US) (adopted fiscal 2023)
8-K
11/04/2022
10.27*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (relative TSR – Outside US) (adopted fiscal 2023)
8-K
11/04/2022
10.28*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (Free Cash Flow – Outside US) (adopted fiscal 2023)
8-K
11/04/2022
10.29*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (ROIC) (adopted fiscal 2024)
8-K
11/13/2023
10.30*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (relative TSR) (adopted fiscal 2024)
8-K
11/13/2023
10.31*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (Free Cash Flow) (adopted fiscal 2024)
8-K
11/13/2023
10.32*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (Free Cash Flow) (adopted fiscal 2025)
8-K
11/08/2024
10.33*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (ROIC) (adopted fiscal 2025)
8-K
11/08/2024
10.34*
Form of Performance Stock Unit Award Agreement Under 2008 Equity
Incentive Plan (relative TSR) (adopted fiscal 2025)
8-K
11/08/2024
10.35*
Hologic, Inc. Amended and Restated 2012 Employee Stock Purchase Plan, as
amended
8-K
03/10/2023
10.36*
Hologic Short-Term Incentive Plan, as amended and restated
8-K
11/07/2018
10.37*
Hologic Amended and Restated Deferred Equity Plan
8-K
12/16/2015
10.38*
Hologic, Inc. Amended and Restated Deferred Compensation Program and
Amendment No. 1 thereto
10-Q
08/01/2023
10.39*
Rabbi Trust Agreement
10-K
09/28/2013
Incorporated by
Reference
Exhibit
Number
Exhibit Description
Form
Filing Date/
Period End
Date
62
10.40*
Form of Indemnification Agreement (as executed with each director of Hologic)
8-K
03/06/2009
10.41*
Employment Agreement dated December 6, 2013 by and between Stephen P.
MacMillan and Hologic
8-K
12/09/2013
10.42*
Amended and Restated Employment Agreement by and between the Company
and Stephen P. MacMillan, dated September 18, 2015
8-K
09/21/2015
10.43*
Amendment No. 1 to Amended and Restated Employment Agreement by and
between the Company and Stephen P. MacMillan, dated September 24, 2016
10-K
09/24/2016
10.44*
Amendment No. 2 to Amended and Restated Employment Agreement by and
between the Company and Stephen P. MacMillan, dated October 5, 2020
8-K
10/06/2020
10.45*
Change of Control Agreement dated December 6, 2013 by and between Stephen
P. MacMillan and Hologic
8-K
12/09/2013
10.46*
Severance and Change of Control Agreement dated July 31, 2018 by and
between Karleen M. Oberton and Hologic, Inc.
8-K
07/31/2018
10.47*
Severance and Change of Control Agreement dated February 2, 2015 by and
between John M. Griffin and Hologic
10-Q
03/28/2015
10.48*
Amended and Restated Employment Agreement between Jan Verstreken and
Hologic dated June 14, 2023
10-Q
08/01/2023
10.49*
Transition Agreement dated December 31, 2023 by and between Hologic, Inc.
and Elisabeth (Lisa) Hellmann
10-Q
05/03/2024
10.50*
Severance and Change of Control Agreement dated July 20, 2023 by and
between Erik S. Anderson and Hologic, Inc.
10-Q
08/01/2023
10.51*
Severance and Change of Control Agreement dated July 20, 2023 by and
between Essex D. Mitchell and Hologic, Inc.
10-Q
08/01/2023
10.52*
Severance and Change of Control Agreement dated July 20, 2023 by and
between Jennifer Schneiders and Hologic, Inc.
10-Q
08/01/2023
10.53*
Severance and Change of Control Agreement dated September 19, 2024 by and
between Diana De Walt and Hologic, Inc.
Filed
herewith
10.54*
Severance and Change of Control Agreement dated January 18, 2024 by and
between Hologic, Inc. and Brandon Schnittker
10-Q
05/03/2024
10.55*
Form of RSU Grant Agreement
Filed
herewith
10.56
Office Lease dated December 31, 2003 between Cytyc and Marlborough
Campus Limited Partnership
Cytyc
Corporation
10-K
12/31/2003
10.57 First Amendment to that Office Lease dated December 31, 2003 between Cytyc
and Marlborough Campus Limited Partnership, entered into August 23, 2017, by
and between Hines Global REIT Marlborough Campus LLC and Hologic, Inc.
(2)
10-K
09/30/2017
10.58 Second Amendment to Lease dated October 30, 2023 by and between BH GRP
TCAM Owner LLC and Hologic, Inc. (3)
Filed
herewith
10.59 Third Amendment to Lease dated May 15, 2024 by and between BH GRP
TCAM Owner LLC and Hologic, Inc. (3)
Filed
herewith
Incorporated by
Reference
Exhibit
Number
Exhibit Description
Form
Filing Date/
Period End
Date
63
10.60
Lease Agreement by and between Zona Franca Coyol S.A. and Cytyc Surgical
Products Costa Rica S.A. dated April 23, 2007
10-K
09/29/2007
10.61 Addendum 1 to Lease Agreement by and between Zona Franca Coyol S.A. and
Cytyc Surgical Products Costa Rica S.A. dated July 22, 2007 (1) (3)
10-K
09/28/2019
10.62 Addendum 2 to Lease Agreement by and between Zona Franca Coyol S.A. and
Cytyc Surgical Products Costa Rica S.A. dated September 22, 2008 (1) (3)
10-K
09/28/2019
10.63 Addendum No. 3 to Current Lease by and Between BCR Fondo de Inversion
Inmobiliario and Hologic Surgical Products Costa Rica S.R.L. (2)
10-Q
12/30/2017
10.64
Lease Agreement by and between 445 Simarano Drive, Marlborough LLC and
Cytyc dated July 11, 2006
10-K
09/29/2007
10.65
First Amendment to Lease by and between 445 Simarano Drive Marlborough
LLC and Hologic, Inc. dated July 14, 2016 (3)
10-K
09/28/2019
10.66 Lease of land situated at Crewe Road, Wythenshawe in the City of Manchester
between the Council of the City of Manchester and V.G. Instruments Group
Limited dated February 8, 1988 (3)
10-K
09/25/2021
10.67
Amended and Restated Credit and Guaranty Agreement, originally dated May
29, 2015, and amended and restated as of October 3, 2017 among Hologic,
Hologic GGO 4 Ltd, each Designated Borrower from time to time party thereto,
the Guarantors from time to time party thereto, each Lender from time to time
party thereto and Bank of America, N.A., as Administrative Agent, Swing Line
Lender and L/C Issuer
8-K
10/04/2017
10.68 Refinancing Amendment No. 1 dated as of December 17, 2018 to the Amended
and Restated Credit and Guaranty Agreement dated as of October 3, 2017
8-K
12/18/2018
10.69 Refinancing Amendment No. 2, dated as of September 27, 2021, to the
Amended and Restated Credit and Guaranty Agreement dated as of October 3,
2017, as amended
8-K
09/27/2021
10.70 Refinancing Amendment No. 3, dated as of August 22, 2022, to the Amended
and Restated Credit and Guaranty Agreement dated as of October 3, 2017, as
amended
10-K
11/15/2023
10.71
Supply Agreement for Panther Instrument System effective November 22, 2006
between Gen-Probe Incorporated and STRATEC Biomedical Systems AG (2)
Gen-Probe
10-Q
09/30/2007
10.72 Amendment No. 1 dated June 1, 2011 to Supply Agreement for Panther
Instrument System. (2)
10-K
09/24/2016
10.73 Amendment No. 2 dated February 28, 2013 to Supply Agreement for Panther
Instrument System (2)
10-K
09/24/2016
19.0
Hologic, Inc. Insider Trading Policy (as amended June 13, 2024)
Filed
herewith
21.1
Subsidiaries of Hologic
Filed
herewith
23.1
Consent of Independent Registered Public Accounting Firm
Filed
herewith
31.1
Certification of Hologic’s CEO pursuant to Item 601(b)(31) of Regulation S-K,
as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Filed
herewith
31.2
Certification of Hologic’s CFO pursuant to Item 601(b)(31) of Regulation S-K,
as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Filed
herewith
Incorporated by
Reference
Exhibit
Number
Exhibit Description
Form
Filing Date/
Period End
Date
64
32.1
Certification of Hologic’s CEO pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Furnished
herewith
32.2
Certification of Hologic’s CFO pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Furnished
herewith
97.1 Hologic, Inc. Amended and Restated Policy on Recoupment (Claw-back) of
Incentive-based Compensation
10-K
11/21/2023
101.INS
Inline XBRL Instance Document - the instance document does not appear in the
Interactive Data File because its XBRL tags are embedded within the Inline
XBRL document.
Filed
herewith
101.SCH
Inline XBRL Taxonomy Extension Schema Document.
Filed
herewith
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
Filed
herewith
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document.
Filed
herewith
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document.
Filed
herewith
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
Filed
herewith
104 Cover Page Interactive Data File (formatted as inline XBRL and contained in
Exhibit 101)
Filed
herewith
Incorporated by
Reference
Exhibit
Number
Exhibit Description
Form
Filing Date/
Period End
Date
______________
*
Indicates management contract or compensatory plan, contract or arrangement.
(1)
Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K.
(2)
Confidential treatment has been granted with respect to certain portions of this exhibit. A complete version of this
exhibit has been filed separately with the SEC.
(3)
Certain portions of this exhibit are considered confidential and have been omitted as permitted under SEC rules and
regulations.
65
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
HOLOGIC, INC.
By:
/S/ STEPHEN P. MACMILLAN
Stephen P. MacMillan
Chairman, President and Chief Executive Officer
Date: November 27, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature
Title
Date
/S/ STEPHEN P. MACMILLAN
Chairman, President and Chief
Executive Officer (Principal Executive
Officer)
November 27, 2024
STEPHEN P. MACMILLAN
/S/ KARLEEN M. OBERTON
Chief Financial Officer (Principal
Financial Officer)
November 27, 2024
KARLEEN M. OBERTON
/S/ BENJAMIN J. COHN
Vice President, Corporate Controller
(Principal Accounting Officer)
November 27, 2024
BENJAMIN J. COHN
/S/ AMY M. WENDELL
Lead Independent Director
November 27, 2024
AMY M. WENDELL
/S/ SALLY W. CRAWFORD
Director
November 27, 2024
SALLY W. CRAWFORD
/S/ CHARLES DOCKENDORFF
Director
November 27, 2024
CHARLES DOCKENDORFF
/S/ SCOTT T. GARRETT
Director
November 27, 2024
SCOTT T. GARRETT
/S/ LUDWIG N. HANTSON
Director
November 27, 2024
LUDWIG N. HANTSON
/S/ NANAZ MOHTASHAMI
Director
November 27, 2024
NANAZ MOHTASHAMI
/S/ CHRISTIANA STAMOULIS
Director
November 27, 2024
CHRISTIANA STAMOULIS
/S/ STACEY D. STEWART
Director
November 27, 2024
STACEY D. STEWART
66
Hologic, Inc.
Consolidated Financial Statements
Years ended September 28, 2024, September 30, 2023 and September 24, 2022
Contents
Report of Independent Registered Public Accounting Firm
F-2
Consolidated Financial Statements
Consolidated Statements of Income
F-5
Consolidated Statements of Comprehensive Income
F-6
Consolidated Balance Sheets
F-7
Consolidated Statements of Stockholders’ Equity
F-8
Consolidated Statements of Cash Flows
F-9
Notes to Consolidated Financial Statements
F-11
F-1
Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors of Hologic, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Hologic, Inc. (the Company) as of September 28,
2024 and September 30, 2023, the related consolidated statements of income, comprehensive income, stockholders’ equity and
cash flows for each of the three years in the period ended September 28, 2024, and the related notes (collectively referred to as
the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material
respects, the financial position of the Company at September 28, 2024 and September 30, 2023, and the results of its operations
and its cash flows for each of the three years in the period ended September 28, 2024, in conformity with U.S. generally
accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United
States) (PCAOB), the Company’s internal control over financial reporting as of September 28, 2024, based on criteria
established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission (2013 framework) and our report dated November 27, 2024 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an
opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the
PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement,
whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the
financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the
overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial
statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or
disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex
judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial
statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on
the critical audit matters or on the accounts or disclosures to which they relate.
F-2
Capital Equipment Revenue Recognition
Description of
the Matter
As discussed in Note 3 to the consolidated financial statements, the Company generates capital equipment
revenue from the sale of medical imaging systems. The Company’s contracts for capital equipment sales
generally have multiple performance obligations.
Auditing the revenue recognition for capital equipment sales required auditor judgment because it
involves management judgment and estimation associated with the identification of performance
obligations within the contracts and the estimation of the standalone selling price of each performance
obligation that is based primarily on historical average selling prices.
How We
Addressed the
Matter in Our
Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of controls
over the Company’s processes to account for capital equipment revenue recognition, including
management’s controls over the identification of performance obligations in revenue contracts and the
estimation of the standalone selling price for each performance obligation.
To test capital equipment revenue, we performed procedures which included, among others, analytical
procedures and the evaluation of whether management’s revenue recognition policies with respect to
identification of performance obligations and estimation of standalone selling price associated with such
performance obligations are in accordance with ASC 606, Revenue from Contracts with Customers. We
tested management’s identification of the performance obligations by performing an independent test of a
sample of customer contracts. We tested management’s estimated standalone selling prices for its
identified performance obligations primarily based on performing a sensitivity analysis and verifying a
sample of historical prices charged for certain products and services included within capital equipment
revenue contracts.
Valuation of Intangible Assets acquired in Business Combination
Description of
the Matter
As disclosed in Note 5 to the consolidated financial statements the Company completed the acquisition of
Endomagnetics Ltd for a total purchase price of $313.9 million in 2024. The transaction was accounted
for as a business combination.
Auditing the Company’s accounting for the business combination was complex due to the significant
judgment required to estimate the fair value of identified finite-lived intangible assets, which totaled
$180.9 million and principally consisted of developed technology related to currently marketed products.
The Company used an income approach to determine the fair value of the developed technology
intangible assets acquired, which was sensitive to changes in significant assumptions related to estimated
discount rates and revenue growth rates. These significant assumptions are forward looking and could be
affected by future economic and market conditions.
How We
Addressed the
Matter in Our
Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of the controls
over the Company’s accounting for the business combination. For example, we tested controls over the
identification and valuation of the developed technology intangible assets, including the completeness and
accuracy of data within the underlying assumptions used to develop such estimates.
To test the estimated fair value of the developed technology intangibles assets, we performed audit
procedures that included, among others, testing the significant assumptions used in the valuation, as
described above. We evaluated the completeness and accuracy of the underlying data used in the analysis.
For example, we compared the significant assumptions, as described above, to the historical results of the
acquired business and to other guideline companies within the same industry. We also performed a
sensitivity analysis over the significant assumptions by comparing them to current industry, market and
economic trends and to the assumptions used by management to value similar assets in other acquisitions.
We involved our valuation professionals to assist with our evaluation of the methodology used by the
Company and test significant assumptions, including the discount rate, used in the fair value estimates.
F-3
We have served as the Company’s auditor since 2002.
/s/ Ernst & Young LLP
Boston, Massachusetts
November 27, 2024
F-4
Hologic, Inc.
Consolidated Statements of Income
(In millions, except number of shares, which are reflected in thousands, and per share data)
Years Ended
September 28,
2024
September 30,
2023
September 24,
2022
Revenues:
Product
$
3,255.1 $
3,279.9 $
4,191.2
Service and other
775.2
750.5
671.6
4,030.3
4,030.4
4,862.8
Costs of revenues:
Product
1,206.2
1,184.3
1,166.1
Amortization of acquired intangible assets
180.5
205.7
295.7
Impairment of intangible assets and equipment
39.2
179.5
17.4
Service and other
376.6
389.4
386.2
Gross profit
2,227.8
2,071.5
2,997.4
Operating expenses:
Research and development
272.8
294.3
283.4
Selling and marketing
585.4
595.2
630.3
General and administrative
409.4
392.4
407.7
Amortization of acquired intangible assets
29.2
28.1
45.2
Impairment of intangible assets and equipment
5.6
44.3
27.7
Contingent consideration fair value adjustments
1.7
(14.9)
(39.5)
Loss on assets held-for-sale
—
51.7
—
Restructuring charges
41.1
12.0
2.4
1,345.2
1,403.1
1,357.2
Income from operations
882.6
668.4
1,640.2
Interest income
108.7
120.5
12.9
Interest expense
(122.1)
(111.1)
(95.1)
Debt extinguishment loss
—
—
(0.7)
Other income (expense), net
(4.1)
(1.7)
30.9
Income before income taxes
865.1
676.1
1,588.2
Provision for income taxes
75.6
220.1
286.2
Net income
$
789.5 $
456.0 $
1,302.0
Net income per common share:
Basic
$
3.35 $
1.85 $
5.18
Diluted
$
3.32 $
1.83 $
5.13
Weighted average number of shares outstanding:
Basic
235,723
246,772
251,527
Diluted
237,553
248,831
253,845
See accompanying notes.
F-5
Hologic, Inc.
Consolidated Statements of Comprehensive Income
(In millions)
Years Ended
September 28,
2024
September 30,
2023
September 24,
2022
Net income
$
789.5 $
456.0 $
1,302.0
Changes in foreign currency translation adjustment
53.1
99.2
(224.1)
Changes in unrealized holding gains and losses on available-
for-sale securities, net of taxes
Gain recognized, net of taxes
1.6
—
—
Changes in pension plans, net of taxes
(0.3)
0.6
1.0
Gain (loss) recognized, net of tax of $(5.7) in 2024, $(2.9) in
2023, and $13.7 in 2022, for interest rate swaps
(18.3)
(9.2)
44.0
Other comprehensive income (loss)
36.1
90.6
(179.1)
Comprehensive income
$
825.6 $
546.6 $
1,122.9
See accompanying notes.
F-6
Hologic, Inc.
Consolidated Balance Sheets
(In millions, except number of shares, which are reflected in thousands, and par value)
September 28,
2024
September 30,
2023
ASSETS
Current assets:
Cash and cash equivalents
$
2,160.2 $
2,722.5
Short-term investments
173.4
—
Accounts receivable, less reserves
600.4
625.6
Inventory
679.8
617.6
Prepaid expenses and other current assets
156.2
175.3
Prepaid income taxes
53.3
31.6
Assets held-for-sale - current assets
—
11.9
Total current assets
3,823.3
4,184.5
Property, plant and equipment, net
537.8
517.0
Intangible assets, net
844.6
888.6
Goodwill
3,443.1
3,281.3
Long-term investments
96.4
—
Other assets
410.8
267.9
Total assets
$
9,156.0 $
9,139.3
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt
$
37.5 $
287.0
Accounts payable
203.8
175.2
Accrued expenses
579.7
534.6
Deferred revenue
212.9
199.2
Finance lease obligations
3.3
3.1
Assets held-for-sale - current liabilities
—
8.2
Total current liabilities
1,037.2
1,207.3
Long-term debt, net of current portion
2,497.1
2,531.2
Finance lease obligations, net of current portion
12.2
15.3
Deferred income tax liabilities
59.4
20.2
Deferred revenue, net of current portion
13.8
13.8
Other long-term liabilities
406.3
334.6
Commitments and contingencies (Note 15 and 16)
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued
—
—
Common stock, $0.01 par value – 750,000 shares authorized; 301,185 and
299,940 shares issued, respectively
3.0
3.0
Additional paid-in-capital
6,244.2
6,141.2
Retained earnings
2,845.8
2,056.3
Treasury stock, at cost – 69,460 and 58,231 shares, respectively
(3,851.5)
(3,036.0)
Accumulated other comprehensive loss
(111.5)
(147.6)
Total stockholders’ equity
5,130.0
5,016.9
Total liabilities and stockholders’ equity
$
9,156.0 $
9,139.3
See accompanying notes.
F-7
Hologic, Inc.
Consolidated Statements of Stockholders' Equity
(In millions, except number of shares, which are reflected in thousands)
Common Stock
Additional
Paid-in-
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Treasury Stock
Total
Stockholders’
Equity
Number of
Shares
Par
Value
Number of
Shares
Amount
Balance at September 25, 2021
297,306
$ 3.0
$ 5,965.8
$
298.3
$
(59.1)
43,653
$ (1,989.4) $
4,218.6
Exercise of stock options
336
—
13.8
—
—
—
—
13.8
Vesting of restricted stock units, net of
shares withheld for employee taxes
561
—
(22.9)
—
—
—
—
(22.9)
Common stock issued under the
employee stock purchase plan
330
—
19.2
—
—
—
—
19.2
Stock-based compensation expense
—
—
66.7
—
—
—
—
66.7
Net income
—
—
—
1,302.0
—
—
—
1,302.0
Foreign currency translation
adjustment
—
—
—
—
(224.1)
—
—
(224.1)
Adjustment to minimum pension
liability, net
—
—
—
—
1.0
—
—
1.0
Repurchase of common stock
—
—
—
—
—
7,748
(542.1)
(542.1)
Unrealized gain on interest rate swap
—
—
—
—
44.0
—
—
44.0
Balance at September 24, 2022
298,533
$ 3.0
$ 6,042.6
$
1,600.3
$
(238.2)
51,401
$ (2,531.5) $
4,876.2
Exercise of stock options
504
—
21.5
—
—
—
—
21.5
Vesting of restricted stock units, net of
shares withheld for employee taxes
555
—
(24.0)
—
—
—
—
(24.0)
Common stock issued under the
employee stock purchase plan
348
—
21.5
—
—
—
—
21.5
Stock-based compensation expense
—
—
79.6
—
—
—
—
79.6
Net income
—
—
—
456.0
—
—
—
456.0
Foreign currency translation
adjustment
—
—
—
—
99.2
—
—
99.2
Adjustment to minimum pension
liability, net
—
—
—
—
0.6
—
—
0.6
Unrealized loss on interest rate swap
—
—
—
—
(9.2)
—
—
(9.2)
Repurchase of common stock
—
—
—
—
—
6,830
(504.5)
(504.5)
Balance at September 30, 2023
299,940
$ 3.0
$ 6,141.2
$
2,056.3
$
(147.6)
58,231
$ (3,036.0) $
5,016.9
Exercise of stock options
423
—
16.9
—
—
—
—
16.9
Vesting of restricted stock units, net of
shares withheld for employee taxes
473
—
(17.4)
—
—
—
—
(17.4)
Common stock issued under the
employee stock purchase plan
349
—
21.2
—
—
—
—
21.2
Stock-based compensation expense
—
—
82.3
—
—
—
—
82.3
Net income
—
—
—
789.5
—
—
—
789.5
Foreign currency translation
adjustment
—
—
—
—
53.1
—
—
53.1
Adjustment to minimum pension
liability, net
—
—
—
—
(0.3)
—
—
(0.3)
Unrealized gain on available-for-sale
securities
—
—
—
—
1.6
—
—
1.6
Unrealized loss on interest rate swap
—
—
—
—
(18.3)
—
—
(18.3)
Accelerated share repurchase
agreement
—
—
—
—
—
6,988
(500.0)
(500.0)
Repurchase of common stock(1)
—
—
—
—
—
4,241
(315.5)
(315.5)
Balance at September 28, 2024
301,185
$ 3.0
$ 6,244.2
$
2,845.8
$
(111.5)
69,460
$ (3,851.5) $
5,130.0
(1) Includes excise tax on share repurchases.
See accompanying notes.
F-8
Hologic, Inc.
Consolidated Statements of Cash Flows
(In millions)
Years Ended
September 28,
2024
September 30,
2023
September 24,
2022
OPERATING ACTIVITIES
Net income
$
789.5
$
456.0
$
1,302.0
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation
99.3
89.6
89.2
Amortization of acquired intangible assets
209.7
233.8
340.9
Stock-based compensation expense
82.3
79.6
66.7
Deferred income taxes and other non-cash taxes
(72.1)
(109.1)
(166.2)
Intangible assets and equipment impairment charges
44.8
223.8
45.1
Loss on assets held-for-sale
—
51.7
—
Contingent consideration fair value adjustments
1.7
(14.9)
(39.5)
Debt extinguishment loss
—
—
0.7
Other adjustments and non-cash items
45.9
28.9
32.6
Changes in operating assets and liabilities, excluding the effect of
acquisitions:
Accounts receivable
41.0
(1.5)
272.3
Inventory
(47.4)
(4.9)
(136.6)
Prepaid income taxes
(21.7)
17.4
(23.3)
Prepaid expenses and other assets
7.3
23.6
384.3
Accounts payable
22.2
(23.0)
(14.4)
Accrued expenses and other liabilities
73.4
(14.2)
(15.8)
Deferred revenue
9.3
14.4
(12.3)
Net cash provided by operating activities
1,285.2
1,051.2
2,125.7
INVESTING ACTIVITIES
Acquisition of businesses, net of cash acquired
(297.3)
(5.0)
(158.6)
Sale of business, net of cash disposed
(31.3)
—
—
Purchases of available-for-sale securities
(267.7)
—
—
Capital expenditures
(72.4)
(91.8)
(70.6)
Proceeds from the Department of Defense
—
20.5
75.0
Increase in equipment under customer usage agreements
(57.8)
(58.4)
(56.6)
Strategic investments
(42.5)
(10.0)
—
Purchase of intellectual property
(10.0)
—
—
Other activity
(2.0)
(7.4)
4.5
Net cash used in investing activities
(781.0)
(152.1)
(206.3)
FINANCING ACTIVITIES
Proceeds from long-term debt, net of issuance costs
—
—
1,491.2
Repayment of long-term debt
(287.5)
(15.0)
(1,387.5)
Repayments under accounts receivable securitization agreement
—
—
(248.5)
Repayment of acquired long-term debt
—
—
(63.7)
Payment of contingent consideration
(2.6)
(7.6)
(12.2)
Payment of deferred acquisition consideration
—
(0.8)
—
Repurchases of common stock
(835.1)
(474.8)
(542.1)
Net proceeds from issuance of common stock under employee stock plans
37.8
43.0
33.5
Payment of minimum tax withholdings on net share settlements of equity
awards
(17.4)
(24.0)
(22.9)
F-9
Payments under finance lease obligations
(3.8)
(4.0)
(3.8)
Net cash used in financing activities
(1,108.6)
(483.2)
(756.0)
Effect of exchange rate changes on cash and cash equivalents
8.9
0.3
5.8
Net (decrease) increase in cash and cash equivalents
(595.5)
416.2
1,169.2
Cash and cash equivalents, beginning of period*
2,755.7
2,339.5
1,170.3
Cash and cash equivalents, end of period*
$
2,160.2
$
2,755.7
$
2,339.5
*Includes $33.2 million of cash recorded in assets held-for-sale - current assets as of September 30, 2023.
See accompanying notes.
F-10
Hologic, Inc.
Notes to Consolidated Financial Statements
(all tabular amounts in millions, except number of shares which are reflected in thousands)
1. Operations
Hologic, Inc. (the “Company” or “Hologic”) develops, manufactures and supplies premium diagnostics products, medical
imaging systems, and surgical products with an emphasis on women's health and well-being through early detection and
treatment. The Company operates in four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health.
2. Summary of Significant Accounting Policies
Principles of Consolidation
The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All
intercompany transactions and balances have been eliminated in consolidation. The Company assesses the terms of its strategic
investments to determine if they meet the definition of a variable interest entity (VIE) and if so, whether the Company has a
controlling financial interest. A controlling financial interest occurs if the Company has both the power to direct activities of the
VIE that most significantly impact the VIE’s economic performance and an obligation to absorb the losses of or the right to
receive the benefits from the VIE that could potentially be significant to the VIE. The Company’s strategic investments did not
meet the controlling financial interest criteria, and therefore the Company did not consolidate any VIEs during fiscal 2024,
2023 or 2022. The Company’s fiscal year ends on the last Saturday in September. Fiscal 2024, 2023 and 2022 ended on
September 28, 2024, September 30, 2023 and September 24, 2022, respectively. Fiscal 2023 was a 53-week year and fiscal
2024 and 2022 were 52-week years.
Subsequent Events Consideration
The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the
financial statements to provide additional evidence for certain estimates or to identify matters that may require additional
disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent
events recorded in the consolidated financial statements as of and for the year ended September 28, 2024, except as noted
below.
On October 11, 2024, the Company entered into a definitive agreement to acquire Gynesonics, Inc. (“Gynesonics”) for a
purchase price of approximately $350.0 million, subject to working capital and other customary adjustments. Gynesonics,
located in Redwood, California, develops a technology intended for diagnostic intrauterine imaging and transcervical treatment
of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. Completion of the
acquisition is subject to customary closing conditions, including receipt of required regulatory approvals. Gynesonics will be
included in the GYN Surgical reportable segment.
On November 19, 2024, the Company executed an accelerated share repurchase agreement (ASR) with JPMorgan Chase
& Co., (“JP Morgan”) pursuant to which the Company agreed to repurchase $250 million of the Company’s common stock.
Refer to Note 12 for further discussion.
Management’s Estimates and Uncertainties
The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”)
requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting periods. Significant estimates and assumptions by management affect the Company’s revenue
recognition for multiple performance obligation arrangements, valuations, purchase price allocations and contingent
consideration related to business combinations, expected future cash flows including growth rates, discount rates, terminal
values and other assumptions and estimates used to evaluate the recoverability of long-lived assets and goodwill, estimated fair
values of intangible assets and goodwill, amortization methods and periods, accounts receivable reserves, inventory excess and
obsolescence reserves, warranty reserves, certain accrued expenses, restructuring and other related charges, contingent
liabilities, tax reserves, deferred tax rates and the recoverability of the Company’s net deferred tax assets and related valuation
allowances, and stock-based compensation.
F-11
Although the Company regularly assesses these estimates, actual results could differ materially from these estimates.
Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical
experience and various other assumptions that it believes to be reasonable under the circumstances.
The Company is subject to a number of risks similar to those of other companies of similar size in its industry, including
dependence on third-party reimbursements to support the markets of the Company’s products, early stage of development of
certain products, rapid technological changes, recoverability of long-lived assets (including intangible assets and goodwill),
competition, stability of world financial markets, ability to obtain regulatory approvals, changes in the regulatory environment,
limited number of suppliers, customer concentration, integration of acquisitions, substantial indebtedness, government
regulations, management of international activities, protection of proprietary rights, patent and other litigation, dependence on
contract manufacturers, supply chain constraints, inflation and interest rates, and dependence on key individuals.
Cash Equivalents
The Company classifies all highly liquid investments with stated maturities of three months or less from the date of
purchase as cash equivalents. Cash equivalents are highly liquid investments with insignificant interest rate risk and maturities
of three months or less at the time of acquisition.
Investments
Investments in debt securities are classified as available-for-sale and are reported at estimated fair value with unrealized
gains and losses recorded as a component of accumulated other comprehensive income. The Company determines the
appropriate classification of its investment in debt securities at the time of purchase and re-evaluates such determination at each
balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through
earnings, as required.
Strategic Investments
The majority of the Company’s strategic investments are in non-marketable equity securities, which are measured at cost,
less any impairment, adjusted to fair value for any observable price changes in orderly transactions for identical or similar
investments of the same issuer. Investments in entities for which the Company has the ability to exercise significant influence
are accounted for under the equity method if the Company holds less than 50 percent of the voting stock and the entity is not a
VIE in which the Company is the primary beneficiary in accordance with Accounting Standards Codification (“ASC”) Topic
323, Investments - Equity Method and Joint Ventures. The Company records these investments initially at cost and adjusts the
carrying amount to reflect its proportional share of the earnings or losses of the investee. Refer to Note 6 for additional details
on strategic investment balances.
Concentrations of Credit Risk
Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, available-
for-sale debt securities, equity investments and trade accounts receivable. The Company invests its cash, cash equivalents and
available-for-sale debt securities with high credit quality financial institutions.
The Company’s customers are principally located in the U.S., Europe and Asia. The Company performs ongoing credit
evaluations of the financial condition of its customers and generally does not require collateral. Although the Company is
directly affected by the overall financial condition of the healthcare industry, as well as global economic conditions,
management does not believe significant credit risk exists as of September 28, 2024. The Company generally has not
experienced any material losses related to receivables from individual customers or groups of customers in the healthcare
industry. The Company maintains an allowance for doubtful accounts based on accounts past due and historical collection
experience.
There were no customers with a balance greater than 10% of accounts receivable as of September 28, 2024 and
September 30, 2023. There were no customers that represented greater than 10% of consolidated revenues for fiscal years 2024,
2023 and 2022.
Concentration of Suppliers
The Company purchases certain components of its products from a single or small number of suppliers. A change in or
loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect
results of operations.
Supplemental Cash Flow Statement Information
F-12
Years Ended
September 28, 2024
September 30, 2023
September 24, 2022
Cash paid during the period for income taxes
$
137.9 $
296.1 $
36.2
Cash paid during the period for interest
$
117.1 $
105.4 $
99.7
Non-Cash Financing Activities:
Fair value of contingent consideration at acquisition
$
— $
1.1 $
—
Cash paid for income taxes presented above is net of tax refunds of $19.6 million, $39.3 million and $430.4 million for
fiscal years 2024, 2023 and 2022, respectively. The fiscal 2024 and 2023 refunds received primarily related to tax filings and
over-payments made in the ordinary course of business, while the fiscal 2022 refunds were primarily related to federal and state
loss carryback claims.
Inventories
Inventories are valued at the lower of cost or net realizable value on a first-in, first-out basis. Work-in-process and
finished goods inventories consist of materials, labor and manufacturing overhead. The valuation of inventory requires
management to estimate excess and obsolete inventory. The Company employs a variety of methodologies to determine the net
realizable value of its inventory. Provisions for excess and obsolete inventory are primarily based on management’s estimates
of forecasted sales, usage levels and expiration dates, as applicable for certain disposable products. A significant change in the
timing or level of demand for the Company’s products compared to forecasted amounts may result in recording additional
charges for excess and obsolete inventory in the future. The Company records charges for excess and obsolete inventory within
cost of product revenues.
Inventories consisted of the following:
September 28, 2024
September 30, 2023
Raw materials
$
251.4 $
238.6
Work-in-process
62.0
66.3
Finished goods
366.4
312.7
$
679.8 $
617.6
Property, Plant and Equipment
Property, plant and equipment is recorded at cost less accumulated depreciation and impairments. The straight-line
method of depreciation is used for all property and equipment.
Property, plant and equipment consisted of the following:
Estimated Useful Life
September 28, 2024
September 30, 2023
Equipment
3–10 years
$
378.1 $
380.0
Equipment under customer usage agreements
3–8 years
523.1
508.1
Buildings and improvements
20–35 years
247.1
230.0
Leasehold improvements
Shorter of the Original Lease
Term
or Estimated Useful Life
44.0
44.4
Land
40.8
41.1
Furniture and fixtures
5–7 years
24.6
19.2
Finance lease right-of-use asset
8.8
8.2
1,266.5
1,231.0
Less - accumulated depreciation and
amortization
(728.7)
(714.0)
$
537.8 $
517.0
F-13
Equipment under customer usage agreements primarily consists of diagnostic instruments located at customer sites but
owned by the Company. Generally, the customer has the right to use the equipment for a period of time provided they meet
certain agreed to conditions. The Company recovers the cost of providing the equipment from the sale of disposables, primarily
assays, tests and handpieces. The depreciation costs associated with equipment under customer usage agreements are charged to
cost of product revenues over the estimated useful life of the equipment. The costs to maintain the equipment in the field are
charged to cost of product revenue as incurred.
In September 2020 and October 2020, the Company was awarded grants of $7.6 million and $119.3 million, respectively,
from the Department of Defense Joint Acquisition Task Force (“DOD”) to expand production capacity for the Company's two
SARS-CoV-2 assays. These grants were specifically to fund capital equipment and labor investments to increase manufacturing
capacity to enable the Company to provide a certain amount of COVID-19 tests per month for the U.S. market. The Company
accounted for the funds received under these grants as a reimbursement of the purchased capital equipment. The Company
procured and paid for the capital equipment and necessary resources to build out its facility and construct the manufacturing
lines to meet the requirements specified in the grant agreement. Subsequent to the Company paying for the capital equipment,
the DOD reimbursed the Company upon it meeting certain requirements. However, the DOD retained title to the assets
purchased under the agreement, and title was transferred to the Company upon meeting certain milestones of the manufacturing
efforts and obtaining approval from the DOD that the respective milestone had been met. As of the end of fiscal 2022, the
Company had completed all milestones under the agreement and was awaiting approval by the DOD. During the second quarter
of fiscal 2023, the Company received the final DOD approvals and the final payment from the DOD of $20.5 million, which
was recorded as a reduction of the cost basis of the purchased equipment. As of September 30, 2023, no amounts were awaiting
approval and all defined milestones were completed. In fiscal 2022, the Company received $75.0 million from the DOD for
reimbursement of capital equipment, which was recorded as a reduction of the cost basis of the purchased equipment. In
addition, a portion of the DOD grant funded expenditures in connection with the project that did not qualify for capitalization
and was recorded as a reduction to expenses, which was $7.6 million in fiscal 2022.
During the third quarter of fiscal 2023, the Company identified indicators of impairment related to the long-lived assets of
its Mobidiag business and based on the fair value of the asset group recorded an impairment charge of $12.1 million related to
property, plant and equipment. In addition, during the third quarter of fiscal 2023, the Company identified indicators of
impairment related to the long-lived assets of its SSI ultrasound imaging business and recorded an impairment charge of
$5.8 million related to property, plant and equipment.
Long-Lived Assets
The Company reviews its long-lived assets, which includes property, plant and equipment and identifiable intangible
assets (see below for discussion of intangible assets), for impairment whenever events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable in accordance with ASC 360-10-35-15, Property, Plant and Equipment
—Impairment or Disposal of Long-Lived Assets (ASC 360). Recoverability of these assets is evaluated by comparing the
carrying value of the assets to the undiscounted cash flows estimated to be generated by those assets over their remaining
economic life. If the undiscounted cash flows are not sufficient to recover the carrying value of the assets, the assets are
considered impaired. The impairment loss is measured by comparing the fair value of the assets to their carrying value. Fair
value is determined by either a quoted market price, if any, or a value determined by a discounted cash flow technique.
Business Combinations and Acquisition of Intangible Assets
The Company accounts for the acquisition of a business in accordance with ASC 805, Business Combinations (ASC 805).
Amounts paid to acquire a business are allocated to the assets acquired and liabilities assumed based on their fair values at the
date of acquisition. Contingent consideration not deemed to be linked to continuing employment is recorded at fair value on the
date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios
using a Monte Carlo simulation. These cash flow projections are discounted with an appropriate risk adjusted rate. Each quarter
until such contingent amounts are earned, the fair value of the liability is remeasured and adjusted as a component of operating
expenses based on changes to the underlying assumptions. The estimates used to determine the fair value of the contingent
consideration liability are subject to significant judgment and actual results are likely to differ from the amounts originally
recorded. The Company determines the fair value of acquired intangible assets based on detailed valuations that use certain
information and assumptions provided by management. The Company allocates any excess purchase price over the fair value of
the net tangible and intangible assets acquired to goodwill.
The Company uses the income approach to determine the fair value of developed technology and in-process research and
development (“IPR&D”) acquired in a business combination. This approach determines fair value by estimating the after-tax
cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a
present value. The Company bases its revenue assumptions on estimates of relevant market sizes, expected market growth rates,
F-14
expected trends in technology and expected product introductions by competitors. Developed technology represents patented
and unpatented technology and know-how. The value of the in-process projects is based on the project's stage of completion,
the complexity of the work completed as of the acquisition date, the projected costs to complete, the contribution of core
technologies and other acquired assets, the expected introduction date, the estimated cash flows to be generated upon
commercial release and the estimated useful life of the technology. The Company believes that the estimated developed
technology and IPR&D amounts represent the fair value at the date of acquisition and do not exceed the amount a third-party
would pay for the assets. The significant assumptions used to estimate the fair value of intangible assets include discount rates
and certain assumptions that form the basis of the forecasted results, specifically revenue growth rates. These significant
assumptions are forward looking and could be affected by future economic and market conditions.
The Company also uses the income approach, as described above, to determine the estimated fair value of certain other
identifiable intangible assets including customer relationships and trade names. Customer relationships represent established
relationships with customers, which provide a ready channel for the sale of additional products and services. Trade names
represent acquired company and product names.
Intangible Assets and Goodwill
Intangible Assets
Intangible assets are initially recorded at fair value and stated net of accumulated amortization and impairments. The
Company amortizes its intangible assets that have finite lives using either the straight-line method, or if reliably determinable,
based on the pattern in which the economic benefit of the asset is expected to be utilized. Amortization is recorded over the
estimated useful lives ranging from 5 to 30 years. The Company evaluates the recoverability of its definite lived intangible
assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may
not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an
asset or asset group exceeds its undiscounted cash flows, the Company estimates the fair value of the assets, generally utilizing
a discounted cash flow analysis based on the present value of after-tax cash flows to be generated by the assets using a risk-
adjusted discount rate. To estimate the fair value of the assets, the Company uses market participant assumptions pursuant to
ASC 820, Fair Value Measurements.
Indefinite lived intangible assets, such as IPR&D assets, are initially recorded at fair value and are required to be tested
for impairment annually, or more frequently if indicators of impairment are present. The Company’s annual impairment test
date is as of the first day of its fourth quarter.
Intangible assets consisted of the following:
September 28, 2024
September 30, 2023
Description
Gross
Carrying
Value
Accumulated
Amortization
Gross
Carrying
Value
Accumulated
Amortization
Acquired intangible assets:
Developed technology
$
4,567.0 $
3,834.0 $
4,411.0 $
3,649.5
In-process research and development
25.1
—
25.7
—
Customer relationships
609.7
569.8
600.0
550.6
Trade names
260.3
224.5
253.6
212.8
Total acquired intangible assets
$
5,462.1 $
4,628.3 $
5,290.3 $
4,412.9
Internal-use software
25.7
20.5
24.0
17.8
Capitalized software embedded in products
30.2
24.6
27.7
22.7
Total intangible assets
$
5,518.0 $
4,673.4 $
5,342.0 $
4,453.4
During the second quarter of fiscal 2024, in connection with commencing its company-wide annual strategic planning
process, the Company identified indicators of impairment in its BioZorb product line, which was part of the Focal acquisition.
As a result, the Company performed an undiscounted cash flow analysis pursuant to ASC 360 to determine if the cash flows
expected to be generated by the BioZorb product line over the remaining estimated useful life of the primary asset were
sufficient to recover the carrying value of the asset group. Based on this analysis, the undiscounted cash flows were not
sufficient to recover the carrying value of the long-lived assets. Therefore, the Company was required to perform Step 3 of the
impairment test and determine the fair value of the asset group. To estimate the fair value of the asset group, the Company
utilized the income approach, which is based on a discounted cash flow (DCF) analysis and calculated the fair value by
F-15
estimating the after-tax cash flows attributable to the asset group and then discounting the after-tax cash flows to present value
using a risk-adjusted discount rate. Based on this analysis, the fair value of the BioZorb asset group was below its carrying
value and the Company recorded an impairment charge of $26.8 million during the second quarter of fiscal 2024. The
impairment charge was allocated to the long-lived assets on a pro-rata basis as follows: $25.9 million to developed technology
and $0.9 million to trade names, which reduced the carrying value of the assets to $13.9 million and $0.5 million respectively.
During the third quarter of fiscal 2024, the Federal Drug Administration classified a prior safety notice for the BioZorb
Marker as a Class I recall. This was the technical classification of a prior safety notice only, not a product removal. Following
this, the Company lowered its forecasts for this product line, which is an indicator of impairment. Accordingly, the Company
performed an undiscounted cash flow analysis, and the cash flows were not sufficient to recover the carrying value of the asset
group. The Company performed a fair value analysis and determined that the fair value of the asset group was de minimus. As a
result, the Company recorded an impairment charge of $13.3 million and $0.4 million to developed technology and trade
names, respectively, to fully write-off the assets.
During the first quarter of fiscal 2024, the Company assessed its only in-process research and development intangible
asset from its Mobidiag acquisition for impairment. The Company determined the fair value of this indefinite-lived asset
utilizing the DCF model and recorded a $4.3 million impairment charge, reducing the fair value of this asset to $22.4 million.
The reduction in the fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of
completing the project. In addition, the Company determined that the useful life of the customer relationship and trade name
intangible assets from its Mobidiag acquisition should be shortened and recorded accelerated amortization expense of
$7.3 million to bring the net carrying values to zero.
During the third quarter of fiscal 2023, in connection with its company-wide annual budgeting and strategic planning
process as well as evaluating the current operating performance of its Mobidiag business, including product design and
manufacturing requirements, the Company reassessed its short-term and long-term commercial plans for this business. The
Company made certain operational and strategic decisions to invest and focus more on the long-term success of this business,
which resulted in the Company significantly reducing its forecasted revenues and operating results.
As a result, the Company identified indicators of impairment and performed an undiscounted cash flow analysis pursuant
to ASC 360 to determine if the cash flows expected to be generated by the Mobidiag business over the estimated remaining
useful life of its primary assets were sufficient to recover the carrying value of the asset group. Based on this analysis the
undiscounted cash flows were not sufficient to recover the carrying value of the long-lived assets. As a result, the Company was
required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value of
the asset group, the Company utilized the income approach, which was based on a DCF analysis. Assumptions used in the DCF
require significant judgment, including judgment about appropriate discount rates, growth rates, and the amount and timing of
expected future cash flows. The forecasted cash flows were based on the Company's most recent strategic plan at that time and
for periods beyond the strategic plan, the Company's estimates were based on assumed growth rates expected as of the
measurement date. The Company believed its assumptions were consistent with the plans and estimates that a market
participant would use to manage the business. The discount rate used was intended to reflect the risks inherent in future cash
flow projections and was based on an estimate of the weighted average cost of capital (WACC) of market participants relative
to the asset group. The Company used a discount rate of 17.0%. Based on this analysis, the fair value of the Mobidiag asset
group was below its carrying value. Prior to calculating and allocating the impairment charge, the Company assessed the only
in-process research and development intangible asset in this asset group for impairment. The Company determined the fair
value of this indefinite-lived asset utilizing the DCF model and recorded a $10.5 million impairment charge, reducing the fair
value of this asset to $26.5 million. The reduction in fair value of this asset was primarily due to a reduction in forecasted
revenues and a delay in the timing of completing the project to focus on other projects.
To record the asset group to fair value, the Company recorded an impairment charge of $186.9 million during the third
quarter of fiscal 2023. The impairment charge was allocated to the long-lived assets on a pro-rata basis as follows:
$153.7 million to developed technology, $10.4 million to customer relationships, $10.7 million to trade names, and
$12.1 million to equipment. The Company believed its assumptions used to determine the fair value of the asset group were
reasonable. The Company also re-evaluated the remaining useful lives of the intangible assets and concluded no changes were
necessary at that time.
During the third quarter of fiscal 2023, the Company also identified indicators of impairment associated with its SSI
ultrasound imaging asset group. The Company determined that the fair value of this asset group was approximately zero and the
carrying value of the long-lived assets was fully impaired. As a result, the Company recorded an impairment charge of
$26.4 million, of which $20.6 million was allocated to intangible assets, primarily developed technology, and $5.8 million was
allocated to equipment.
F-16
During the fourth quarter of fiscal 2022, the Company performed its annual impairment test of its Mobidiag IPR&D
intangible asset. The Company determined the fair value of the asset utilizing a DCF model and recorded a $27.7 million
impairment charge. The reduction in fair value was due to an increase in the discount rate from higher interest rates, a reduction
in forecasted revenues and timing of completing the project. During the fourth quarter of fiscal 2022, the Company identified a
certain product line associated with the Focal Therapeutics, Inc. acquisition that would no longer be commercially sold. As a
result, the Company recorded an impairment charge to write-off a developed technology asset of $8.2 million. During the third
quarter of fiscal 2022, the Company identified certain product lines associated with the Faxitron Bioptics, LLC acquisition that
would no longer be commercially sold. As a result, the Company recorded an impairment charge to write-off the developed
technology assets of $9.2 million.
Amortization expense related to developed technology is classified as cost of product revenues—amortization of
intangible assets. Amortization expense related to customer relationships and trade names is classified as a component of
amortization of intangible assets within operating expenses.
The estimated amortization expense at September 28, 2024 for each of the five succeeding fiscal years was as follows:
Fiscal 2025
$
199.3
Fiscal 2026
$
169.2
Fiscal 2027
$
82.1
Fiscal 2028
$
79.0
Fiscal 2029
$
72.9
Goodwill
In accordance with ASC 350, Intangibles—Goodwill and Other (ASC 350), the Company tests goodwill for impairment
annually at the reporting unit level and between annual tests if events and circumstances indicate it is more likely than not that
the fair value of a reporting unit is less than its carrying value. Events that could indicate impairment and trigger an interim
impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market
capitalization, a significant adverse change in legal factors, business climate, operational performance of the business or key
personnel, and an adverse action or assessment by a regulator.
In performing the impairment test, the Company utilizes the single-step approach prescribed under Accounting Standards
Update No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (ASU
2017-04). This approach requires a comparison of the carrying value of each reporting unit to its estimated fair value and to the
extent the carrying value exceeds the fair value a charge is recorded up to the amount of goodwill in the reporting unit. To
estimate the fair value of its reporting units, the Company primarily utilizes the income approach. The income approach is
based on a DCF analysis and calculates the fair value by estimating the after-tax cash flows attributable to a reporting unit and
then discounting the after-tax cash flows to present value using a risk-adjusted discount rate. Assumptions used in the DCF
require significant judgment, including judgment about appropriate discount rates and terminal values, growth rates, and the
amount and timing of expected future cash flows. The forecasted cash flows are based on the Company’s most recent budget
and strategic plan and for years beyond this period, the Company’s estimates are based on assumed growth rates expected as of
the measurement date. The Company believes its assumptions are consistent with the plans and estimates used to manage the
underlying businesses. The discount rates used are intended to reflect the risks inherent in future cash flow projections and are
based on estimates of the weighted-average cost of capital (“WACC”) of market participants. The market approach considers
comparable market data based on multiples of revenue or earnings before interest, taxes, depreciation and amortization
(“EBITDA”) and is primarily used as a corroborative analysis to the results of the DCF analysis. The Company believes its
assumptions used to determine the fair value of its reporting units are reasonable. If different assumptions were used,
particularly with respect to forecasted cash flows, terminal values, WACCs, or market multiples, different estimates of fair
value may result and there could be the potential that an impairment charge could result. Actual operating results and the related
cash flows of the reporting units could differ from the estimated operating results and related cash flows.
The Company conducted its fiscal 2024 impairment test for its reporting units on the first day of the fourth quarter, and as
noted above used DCF and market approaches to estimate the fair value of its reporting units as of June 30, 2024, and
ultimately used the fair value determined by the DCF approach in making its impairment test conclusions. As a result of
completing this analysis, all of the Company's reporting units had fair values exceeding their carrying values.
At September 28, 2024, the Company believes that its reporting units, with goodwill aggregating $3.4 billion, were not at
risk of failing the goodwill impairment test based on its current forecasts and qualitative assessment.
F-17
The Company conducted its fiscal 2023 and 2022 impairment tests for its reporting units on the first day of the fourth
quarter of its respective fiscal year, and as noted above used DCF and market approaches to estimate the fair value of its
reporting units as of the measurement date, and ultimately used the fair value determined by the DCF approach in making its
impairment test conclusions. As a result of completing these analyses, all of the Company's reporting units had fair values
exceeding their carrying values.
A rollforward of goodwill activity by reportable segment from September 30, 2023 to September 28, 2024 is as follows:
Diagnostics
Breast Health
GYN Surgical
Skeletal Health
Total
Balance at September 30, 2023
$
1,351.6 $
787.8 $
1,133.9 $
8.0 $
3,281.3
Endomag acquisition
—
138.9
—
—
138.9
Foreign currency and other adjustments
14.2
7.9
0.8
—
22.9
Balance at September 28, 2024
$
1,365.8 $
934.6 $
1,134.7 $
8.0 $
3,443.1
Other Assets
Other assets consisted of the following:
September 28, 2024
September 30, 2023
Other Assets
Tax receivable
$
37.5 $
33.0
Operating lease right of use assets
92.2
62.7
Life insurance contracts
71.0
56.1
Deferred tax assets
128.8
56.6
Strategic investments
54.3
15.5
Other
27.0
44.0
$
410.8 $
267.9
Life insurance contracts were purchased in connection with the Company’s Nonqualified Deferred Compensation Plan
(“DCP”) and are recorded at their cash surrender value (see Note 14 for further discussion).
Research and Software Development Costs
Costs incurred for the research and development of the Company’s products are expensed as incurred. Nonrefundable
advance payments for goods or services to be received in the future by the Company for use in research and development
activities are deferred. The deferred costs are expensed as the related goods are delivered or the services are performed.
The Company accounts for the development costs of software embedded in the Company’s products in accordance with
ASC 985, Software. Costs incurred in the research, design and development of software embedded in products to be sold to
customers are charged to expense until technological feasibility of the ultimate product to be sold is established. The
Company’s policy is that technological feasibility is achieved when a working model, with the key features and functions of the
product, is available for customer testing. Software development costs incurred after the establishment of technological
feasibility and until the product is available for general release are capitalized, provided recoverability is reasonably assured.
Capitalized software development costs are amortized over their estimated useful life and recorded within cost of revenues -
product.
Foreign Currency Translation
The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, Foreign
Currency Matters. The reporting currency for the Company is the U.S. dollar. The functional currency of the Company’s
foreign subsidiaries is determined based on the guidance in ASC 830. The majority of the Company's foreign subsidiaries'
functional currency is the applicable local currency, although certain of the Company's foreign subsidiaries' functional currency
is the U.S. dollar based on the nature of their operations or functions. Assets and liabilities of subsidiaries whose functional
currency is the local currency are translated at the exchange rate in effect at each balance sheet date. Before translation, the
Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and
payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in other income
(expense), net, in the Consolidated Statements of Income. Revenues and expenses are translated using average exchange rates
F-18
during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive
income (loss), which is a separate component of stockholders’ equity. Gains and losses arising from transactions denominated
in foreign currencies are included in other income (expense), net, in the Consolidated Statements of Income. During fiscal years
2024, 2023 and 2022, the Company recorded net foreign exchange (losses) gains of $(21.0) million, $(7.9) million, and
$48.5 million, respectively.
Accumulated Other Comprehensive Income (Loss)
Other comprehensive income (loss) includes certain transactions that have generally been reported in the statement of
stockholders’ equity. The following tables summarize the components and changes in accumulated balances of other
comprehensive loss for the periods presented:
Year Ended September 28, 2024
Year Ended September 30, 2023
Foreign
Currency
Translation
Pension
Plan
Available-
for-sale
debt
securities
Hedged
Interest
Rate
Swaps
Total
Foreign
Currency
Translation
Pension
Plan
Hedged
Interest
Rate
Swaps
Total
Beginning Balance
$
(168.0) $
0.3
$
—
$
20.1
$
(147.6) $
(267.2) $
(0.3) $
29.3
$
(238.2)
Other comprehensive income
(loss) before reclassifications
53.1
(0.3)
1.6
(18.3)
36.1
99.2
0.6
(9.2)
90.6
Ending Balance
$
(114.9) $
—
$
1.6
$
1.8
$
(111.5) $
(168.0) $
0.3
$
20.1
$
(147.6)
Derivatives
Interest Rate Risk - Cash Flow Hedge
The Company is exposed to certain risks arising from both its business operations and economic conditions. The
Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative
financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a
cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income
(“AOCI”) to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item
affects earnings.
In fiscal 2019, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a
termination date of December 17, 2023 to hedge a portion of its variable rate debt. On August 25, 2022, the interest rate swap
agreement was restructured (consistent with the 2021 Credit Agreement; see Note 9) to convert the benchmark interest rate
from LIBOR to the SOFR rate effective September 23, 2022 with a termination date of December 17, 2023. The Company
applied the practical and optional expedients in ASC 848, Reference Rate Reform, in evaluating the impact of modifying the
contract, which resulted in no change to the accounting for this derivative contract. The notional amount of this swap was $1.0
billion. The restructured interest rate swap fixed the SOFR component of the variable interest rate on $1.0 billion of the notional
amount under the 2021 Credit Agreement at 1.23%. The critical terms of the restructured interest rate swap were designed to
mirror the terms of the Company’s SOFR-based borrowings under the 2021 Credit Agreement and therefore were highly
effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the
variability of the SOFR-based interest payments on $1.0 billion of principal. Therefore, changes in the fair value of the swap
were recorded in AOCI. The contract expired during the first quarter of fiscal 2024.
On March 23, 2023, the Company entered into two consecutive interest rate swap contracts with the first contract having
an effective date of December 17, 2023 and terminating on December 27, 2024, and the second contract having an effective
date of December 27, 2024 and terminating on September 25, 2026. The notional amount of these swaps is $500 million, and
the first interest rate swap fixes the SOFR component of the variable interest rate at 3.46%, and the second interest rate swap
fixes the SOFR component of the variable interest rate at 2.98%. The critical terms of the interest rate swaps are designed to
mirror the terms of the Company’s SOFR-based borrowings under the 2021 Credit Agreement and therefore are highly
effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the
variability of the SOFR-based interest payments on $500 million of principal.
The changes in the fair value of the swaps are recorded in AOCI and net of taxes were a loss of $18.3 million, a loss of
$9.2 million and a gain of $44.0 million, respectively, for fiscal years 2024, 2023, and 2022, respectively. The fair value of
these derivative instruments was in an asset position of $2.9 million as of September 28, 2024.
Forward Foreign Currency Contracts, Foreign Currency Option Contracts
The Company enters into forward foreign currency exchange contracts and foreign currency option contracts (including
collars) to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such
F-19
exposures result from the portion of the Company's cash and operations that are denominated in currencies other than the U.S.
dollar, primarily the Euro, the U.K. Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen.
These foreign currency exchange contracts are entered into to support transactions made in the ordinary course of business and
are not speculative in nature. The Company uses collars and forward contracts as part of its foreign currency hedging strategy to
manage the risk associated with fluctuations in foreign currency exchange rates. Collars, which are a combination of a put and
call option, limit the range of possible positive or negative returns on an underlying exposure to a specific range. The contracts
are generally for periods of one year or less. The Company did not elect hedge accounting for these contracts. The change in the
fair value of these contracts is recognized directly in earnings as a component of other income (expense), net.
Realized and unrealized gains and losses from these contracts, which were the only derivative contracts not designated
for hedge accounting, for the years ended September 28, 2024, September 30, 2023, and September 24, 2022 were as follows:
Years Ended
September 28, 2024
September 30, 2023
September 24, 2022
Amount of realized gain (loss) recognized in income
Forward foreign currency contracts
$
3.9 $
1.3 $
68.5
Foreign currency option contracts
—
(4.0)
—
$
3.9 $
(2.7) $
68.5
Amount of unrealized (loss) gain recognized in income
Forward foreign currency contracts
$
(20.9) $
(7.5) $
14.7
Foreign currency option contracts
0.8
(5.5)
5.5
$
(20.1) $
(13.0) $
20.2
Amount of gain (loss) recognized in income
Total
$
(16.2) $
(15.7) $
88.7
As of September 28, 2024, the Company had outstanding forward foreign currency contracts that were not designated for
hedge accounting and are used to hedge forecasted transactions denominated in the Euro, U.K. pound, Australian dollar,
Canadian dollar, Chinese Yuan and Japanese Yen with an aggregate notional amount of $378.5 million.
Financial Instrument Presentation
The table below presents the fair value of the Company's derivative financial instruments as well as their classification on
the balance sheet as of September 28, 2024:
Balance Sheet Location
September 28, 2024
September 30, 2023
Assets:
Derivative instrument designated as a cash flow hedge:
Interest rate swap contracts
Prepaid expenses and
other current assets
$
3.1 $
16.2
Interest rate swap contracts
Other assets
—
10.7
$
3.1 $
26.9
Derivatives not designated as hedging instruments:
Forward foreign currency contracts
Prepaid expenses and
other current assets
$
— $
8.4
Foreign currency option contracts
Prepaid expenses and
other current assets
0.8
—
$
0.8 $
8.4
Liabilities:
Derivative instruments designated as a cash flow hedge:
Interest rate swap contracts
Other long-term
liabilities
0.2
—
Total
$
0.2 $
—
Derivatives not designated as hedging instruments:
Forward foreign currency contracts
Accrued expenses
$
12.6 $
—
F-20
The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest
rate swap for the following reporting periods:
Years Ended
September 28,
2024
September 30,
2023
September 24,
2022
Amount of (loss) gain recognized in other
comprehensive income (loss), net of taxes:
Interest rate swap
$
(18.3) $
(9.2) $
44.0
Total
$
(18.3) $
(9.2) $
44.0
Trade Receivables and Allowance for Credit Losses
The Company applies ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) to its trade receivables and
allowances for credit losses, which requires that financial assets measured at amortized cost be presented at the net amount
expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical
collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported
amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the
balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade
receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its
expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity from new
macroeconomic events, such as pandemics and inflation, must be taken into consideration. To date, the Company has not
experienced significant customer payment defaults, or identified other significant collectability concerns. In connection with
assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability
including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and
financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those
assets from the portfolios of trade receivables evaluated on a collective basis.
The following is a rollforward of the allowance for credit losses for fiscal 2024, 2023 and 2022:
Balance at
Beginning
of Period
Charged to
Costs and
Expenses
Write-
offs and
Payments
Balance at
End of
Period
Period Ended:
September 28, 2024
$
38.5 $
5.7 $
(2.8) $
41.4
September 30, 2023
$
37.7 $
3.7 $
(2.9) $
38.5
September 24, 2022
$
40.5 $
4.2 $
(7.0) $
37.7
Cost of Service and Other Revenues
Cost of service and other revenues primarily represents payroll and related costs associated with the Company’s
professional services, employees, consultants, infrastructure costs and overhead allocations, including depreciation, rent and
materials consumed in providing the service.
Stock-Based Compensation
The Company accounts for share-based payments in accordance with ASC 718, Stock Compensation (ASC 718). As
such, all share-based payments to employees, including grants of stock options, restricted stock units, performance stock units
and market stock units and shares issued under the Company’s employee stock purchase plan, are recognized in the
Consolidated Statements of Income based on their fair values on the date of grant. In addition, all excess tax benefits and
deficiencies are recognized as a component of the provision for income taxes on a discrete basis in the period in which the
equity awards vest and/or are settled.
Net Income Per Share
Basic net income per share is computed by dividing net income by the weighted average number of common shares
outstanding. Diluted net income per share is computed by dividing net income by the weighted average number of common
shares and the dilutive effect of potential future issuances of common stock from outstanding stock options and restricted stock
units for the period outstanding determined by applying the treasury stock method. In accordance with ASC 718, the assumed
proceeds under the treasury stock method include the average unrecognized compensation expense of in-the-money stock
F-21
options and restricted stock units. This results in the assumed buyback of additional shares, thereby reducing the dilutive impact
of equity awards.
A reconciliation of basic and diluted share amounts for fiscal 2024, 2023, and 2022 was as follows:
September 28, 2024
September 30, 2023
September 24, 2022
Basic weighted average common shares outstanding
235,723
246,772
251,527
Weighted average common stock equivalents from
assumed exercise of stock options and restricted stock
units
1,830
2,059
2,318
Diluted weighted average common shares outstanding
237,553
248,831
253,845
Weighted-average anti-dilutive shares related to:
Outstanding stock options and restricted stock units
1,171
981
1,049
Product Warranties
The Company generally offers a one-year warranty for its products. The Company provides for the estimated cost of
product warranties at the time product revenue is recognized. Factors that affect the Company’s warranty reserves include the
number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically
assesses the adequacy of the warranty reserve and adjusts the amount as necessary.
Product warranty activity for fiscal 2024 and 2023 was as follows:
Balance at
Beginning of
Period
Provisions
Acquired
Settlements/
Adjustments
Balance at End
of Period
Period ended:
September 28, 2024
$
8.3 $
9.0 $
0.1 $
(7.5) $
9.9
September 30, 2023
$
8.0 $
6.8 $
0.8 $
(7.3) $
8.3
Advertising Costs
Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising.
Advertising costs, which include trade shows and conventions, were approximately $22.6 million, $31.4 million and $78.1
million for fiscal 2024, 2023 and 2022, respectively, and were included in selling and marketing expense in the Consolidated
Statements of Income. The higher advertising costs in fiscal 2022 was primarily due to the Company's agreement to be a
sponsor of the Women's Tennis Association and related structure of the arrangement and the production and airing of its Super
Bowl commercial in February 2022.
New Accounting Pronouncements
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) Improvements to Reportable
Segment Disclosures. The guidance requires entities to provide enhanced disclosures about significant segment expenses. For
entities that have adopted the amendments in Update 2023-07, the updated guidance is effective for fiscal years beginning after
December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the
Company in fiscal 2025. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU
2023-07 on its consolidated financial position and results of operations.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) Improvements to Income Tax
Disclosures. The FASB issued this Update to enhance income tax disclosures primarily related to the rate reconciliation and
income taxes paid information. The amendments in this Update are effective for fiscal years, and interim periods within those
fiscal years, beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted.
The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its consolidated financial position and
results of operations.
In March 2024, the SEC issued its final climate disclosure rule, which requires the disclosure of Scope 1 and Scope 2
greenhouse gas emissions and other climate-related topics in annual reports and registration statements, when material.
Disclosure requirements were to begin phasing in for fiscal years beginning on or after January 1, 2025, however on April 4,
F-22
2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. The Company is
monitoring SEC developments and evaluating the impact of the new rule to its financial statements.
3. Revenue
The Company accounts for revenue pursuant to ASC 606, Revenue from Contracts with Customer (ASC 606) and
generates revenue from the sale of its products, primarily medical imaging systems and related components and software,
diagnostic tests and assays and surgical disposable products, and related services, which are primarily support and maintenance
services on its medical imaging systems, and to a lesser extent installation, training and repairs. In addition, the Company
generates service revenue from performing laboratory testing services through its Biotheranostics CLIA laboratory, which is
included in its Molecular Diagnostics business. The Company's products are sold primarily through a direct sales force, and
within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The
following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis:
Years Ended
September 28, 2024
September 30, 2023
September 24, 2022
Business (in
millions)
United
States
Intl.
Total
United
States
Intl.
Total
United
States
Intl.
Total
Diagnostics:
Cytology &
Perinatal
$
283.3 $
195.9 $
479.2 $
297.4 $
183.2 $
480.6 $
300.4 $
174.3 $
474.7
Molecular
Diagnostics
999.1
273.4 1,272.5 1,061.0
300.7 1,361.7 1,694.5
816.9 2,511.4
Blood
Screening
30.3
—
30.3
37.8
—
37.8
32.4
—
32.4
Total
1,312.7
469.3 1,782.0 1,396.2
483.9 1,880.1 2,027.3
991.2 3,018.5
Breast Health:
Breast
Imaging
932.9
277.8 1,210.7
884.0
260.2 1,144.2
735.1
216.5
951.6
Interventional
Breast
Solutions
244.6
67.6
312.2
232.6
55.9
288.5
222.1
54.1
276.2
Total
1,177.5
345.4 1,522.9 1,116.6
316.1 1,432.7
957.2
270.6 1,227.8
GYN Surgical
482.5
158.8
641.3
475.3
128.9
604.2
423.8
99.1
522.9
Skeletal Health
51.4
32.7
84.1
69.9
43.5
113.4
59.6
34.0
93.6
Total
$ 3,024.1 $ 1,006.2 $ 4,030.3 $ 3,058.0 $
972.4 $ 4,030.4 $ 3,467.9 $ 1,394.9 $ 4,862.8
Years Ended
Geographic Regions (in millions)
September 28,
2024
September 30,
2023
September 24,
2022
United States
$
3,024.1 $
3,058.0 $
3,467.9
Europe
532.7
520.3
888.5
Asia-Pacific
259.6
255.7
359.7
Rest of World
213.9
196.4
146.7
$
4,030.3 $
4,030.4 $
4,862.8
The following table provides revenue recognized by source:
F-23
Years Ended
Revenue by type (in millions)
September 28,
2024
September 30,
2023
September 24,
2022
Disposables
$
2,490.2 $
2,539.4 $
3,603.6
Capital equipment, components and
software
764.9
740.5
587.6
Service
758.2
730.5
652.4
Other
17.0
20.0
19.2
$
4,030.3 $
4,030.4 $
4,862.8
The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with
a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or
the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure
revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is
determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a
promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. The
transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for
the goods and services expected to be transferred. A contract's transaction price is allocated to each distinct performance
obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for
the Company's products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of
loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of
the remaining benefit of the product. As such, the Company's performance obligation related to product sales is satisfied at a
point in time. Revenue from support and maintenance contracts, extended warranty and professional services for installation,
training and repairs is recognized over time based on the period contracted or as the services are performed as these methods
represent a faithful depiction of the transfer of goods and services.
The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the
Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms are
typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs
performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product
revenue when the corresponding revenue is recognized.
The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer
has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through
the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements
include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue
is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded
lease concurrent with the sale of disposables over the term of the agreement.
Revenue from laboratory testing services, which are generated by the Company's Biotheranostics business, is recognized
based upon contracted amounts with payors and historical cash collection experience for the same test or same payor group.
Revenue is recognized once the laboratory services have been performed, the results have been delivered to the ordering
physician, the payor has been identified, and insurance has been verified. The estimated timeframes for cash collection are three
months for Medicare payors, six months for Medicare Advantage payors, and nine months for commercial payors.
Generally, the contracts for capital equipment include multiple performance obligations. For contracts with multiple
performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of
the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of
standalone selling price using average selling prices over 3- to 12-month periods of data depending on the products or nature of
the services coupled with current market considerations. If the product or service does not have a history of sales or if sales
volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department
adjusted for expected discounts.
Variable Consideration
The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates,
product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability.
The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable
F-24
to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the
Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of
revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer
contracts. The Company's contracts for the sale of capital equipment and related components, and assays and tests typically do
not provide the right to return product, however, its contracts for the sale of its GYN Surgical and Interventional Breast
Solutions surgical handpieces provide for a right of return for a limited period of time. Estimates of variable consideration and
constraints are not material to the Company's financial statements.
Remaining Performance Obligations
As of September 28, 2024, the estimated revenue expected to be recognized in the future related to performance
obligations that are unsatisfied was approximately $861.1 million. These remaining performance obligations primarily relate to
support and maintenance obligations and extended warranty in the Company's Breast Health and Skeletal Health reportable
segments. The Company expects to recognize approximately 47.6% of this amount as revenue in 2025, 28.6% in 2026, 14.5%
in 2027, 6.2% in 2028, and 3.1% thereafter. As permitted, the Company does not include remaining performance obligations
related to contracts with original expected durations of one year or less in the amounts above.
Contract Assets and Liabilities
The Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value.
Contract assets primarily relate to the Company's conditional right to consideration for work completed but not billed at the
reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial.
Contract liabilities primarily relate to payments received from customers in advance of performance under the contract.
The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much
lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily
relates to support and maintenance contracts and extended warranty obligations within the Company's Breast Health and
Skeletal Health reportable segments. Contract liabilities are classified as other current liabilities and other long-term liabilities
on the Consolidated Balance Sheets. The Company recognized revenue of $134.4 million and $132.7 million in the years ended
September 28, 2024 and September 30, 2023, respectively, that was included in the contract liability balance at September 30,
2023 and September 24, 2022, respectively.
Practical Expedients
The Company applies a practical expedient to expense costs to obtain a contract with a customer as incurred when the
amortization period would have been one year or less. These costs solely comprise sales commissions and typically the
commissions are incurred at the time of shipment of product and upon billings for support and maintenance contracts.
4. Leases
The Company accounts for leases pursuant to ASC 842 Leases (ASC 842) and recognizes lease assets and liabilities on
its balance sheet. As a lessee, the Company elected to combine lease and non-lease components together for the majority of its
leases, and as a result accounts for each separate lease component and the non-lease components associated with that lease
component as a single lease component. As a lessor, in instances where the Company places instruments (or equipment) at
customer sites as part of its reagent rental contracts, certain of the Company's reagent rental contracts could be classified as
sales-type leases. Under sales-type leases, there is accelerated expense recognition for the cost of the placed equipment and
potentially up-front revenue in the event there are fixed rental payments, a portion of which would be allocated to the
equipment. The Company does not have a significant amount of sales-type leases.
Lessee Activity - Leases where Hologic is the Lessee
The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates
through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate
the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space,
vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet
and expense for these leases is recognized on a straight-line basis over the lease term. In accordance with ASC 842, for leases
executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single
lease component. The Company's leases have remaining lease terms of one year to approximately 11 years, some of which may
include options to extend the leases for up to 10 years and some include options to terminate early. These options have been
included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company
does not have any leases that include residual value guarantees.
F-25
The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances
present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in
other assets, accrued expenses, and other long-term liabilities in the Consolidated Balance Sheet as of September 28, 2024.
Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities
represent the Company's obligation to make lease payments arising from the lease contract. Operating and finance lease
liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the
expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company
utilizes the incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis
over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average
discount rate utilized on the Company's operating and finance lease liabilities as of September 28, 2024 was 4.92%.
The following table presents supplemental balance sheet information related to the Company's operating and finance
leases:
September 28, 2024
September 30, 2023
Balance Sheet Location
Operating Leases
Finance Leases
Operating Leases
Finance Leases
Assets
Lease right-of-use assets
Other assets
$
92.2 $
— $
62.7 $
—
Finance lease right-of-use
assets (non-current)
Property, plant and
equipment, net
$
— $
5.0 $
— $
5.6
Liabilities
Operating lease liabilities
(current)
Accrued expenses
$
24.0 $
— $
20.4 $
—
Finance lease liabilities
(current)
Finance lease obligations -
short term
$
— $
3.3 $
— $
3.1
Operating lease liabilities
(non-current)
Other long-term liabilities $
83.9 $
— $
47.1 $
—
Finance lease liabilities (non-
current)
Finance lease obligations -
long term
$
— $
12.2 $
— $
15.3
The following table presents the weighted average remaining lease term and discount rate information related to the
Company's operating and finance leases:
As of September 28, 2024
As of September 30, 2023
Operating Leases
Finance Lease
Operating Leases
Finance Lease
Weighted average remaining lease term
5.92
4.83
4.18
5.69
Weighted average discount rate
5.0 %
4.1 %
2.9 %
4.2 %
The following table provides information related to the Company’s operating and finance leases:
Year Ended
September 28, 2024
Year Ended
September 30, 2023
Operating lease cost (a)
$
41.3 $
29.9
Finance lease cost - amortization of right-of-use assets
$
0.7 $
0.7
Finance lease cost - interest cost
$
0.8 $
0.8
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from finance leases
$
0.7 $
0.9
Operating cash flows from operating leases
$
26.1 $
28.3
Financing cash flows from finance leases
$
3.8 $
4.0
Total cash paid for amounts included in the measurement of lease
liabilities
$
30.6 $
33.2
ROU assets arising from entering into new operating lease obligations (b)
$
60.4 $
15.7
ROU assets arising from entering into new finance lease obligations
$
— $
—
(a) Includes short-term lease expense and variable lease costs, which were immaterial for the year ended September 28,
2024. During the first quarter of fiscal 2024, in conjunction with the strategy change to move the Mobidiag development
F-26
activities and operations to the Company’s San Diego, California location, the Company recorded a lease asset impairment
charge of $12.5 million. Please refer to Footnote 8 for additional details.
(b) During fiscal 2024, the Company renewed two leases at the Company’s Marlborough, Massachusetts locations in the
amount of $23.3 million and $8.4 million for a term of 10 years and 5 years, respectively.
The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and
finance leases as of September 28, 2024:
Fiscal Year
Operating Leases
Finance Leases
2025
$
28.7 $
3.8
2026
25.1
3.8
2027
20.8
4.0
2028
14.4
3.0
2029
8.0
0.6
Thereafter
29.6
1.7
Total future minimum lease payments
126.6
16.9
Less: imputed interest
(18.7)
(1.4)
Present value of lease liabilities
$
107.9 $
15.5
Lessor Activity - Leases where Hologic is the Lessor
Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically
include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual
arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting
purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract.
Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable
and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue
between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 3% of
the Company’s consolidated revenue for all periods presented.
In connection with the disposition of the Medical Aesthetics business in fiscal 2020, the Company entered into an
agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized
$10.2 million for the right-of-use asset for the finance lease and recorded a lease receivable, which is $10.4 million as of
September 28, 2024.
The Company leases a portion of a building it owns and subleases some of its rented facilities and received aggregate
rental income of $1.5 million, $1.1 million and $2.8 million in fiscal 2024, 2023 and 2022, respectively, which has been
recorded as an offset to operating lease costs. The future minimum annual rental income payments under these lease and
sublease agreements at September 28, 2024 are as follows:
Fiscal 2025
$
1.2
Fiscal 2026
1.1
Fiscal 2027
1.1
Fiscal 2028
0.8
Fiscal 2029
0.4
Thereafter
0.6
Total
$
5.2
5. Business Combinations
Fiscal 2024 Acquisitions
Endomag
On July 25, 2024, the Company completed the acquisition of Endomagnetics Ltd (“Endomag”) for a purchase price of
$313.9 million. Endomag, located in the U.K., develops and sells breast surgery localization and lymphatic tracing
technologies. Endomag’s results of operations are reported in the Company's Breast Health reportable segment from the date of
F-27
acquisition.
The purchase price was allocated to Endomag's preliminary tangible and identifiable intangible assets and liabilities based
on their preliminary estimated fair values as of July 25, 2024, as set forth below.
Cash
$
16.2
Accounts receivable
5.5
Inventory
14.9
Other assets
7.0
Accounts payable and accrued expenses
(22.6)
Identifiable intangible assets:
Developed technology
180.9
Trade names
7.4
Customer relationship
6.5
In-process research and development
3.0
Deferred income taxes, net
(43.8)
Goodwill
138.9
Purchase Price
$
313.9
In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended
future use of acquired assets, analysis of historical financial performance and estimates of future performance of Endomag’s
business. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the
valuation of acquired assets and liabilities.
As part of the preliminary purchase price allocation, the Company determined the identifiable intangible assets are
developed technology, trade names, customer relationship and in-process research and development project. The preliminary
fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted
using a 15.0% rate. The cash flows were based on estimates used to price the transaction, and the discount rate applied was
benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital.
The developed technology assets are comprised of know-how, patents and technologies embedded in Endomag’s
products and relate to currently marketed products. The developed technology assets comprise the primary product families
under the Sentimag, Magseed and Magtrace technology platforms.
The preliminary estimate of the weighted average life for the developed technology assets was 11 years, for customer
relationships was 12 years and trade name assets was 11 years. The calculation of the excess of the purchase price over the
estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to
the recognition of the amount of goodwill were primarily based on anticipated strategic and synergistic benefits that are
expected to be realized from the Endomag acquisition. These benefits include expanding the Company’s breast care portfolio
and utilizing Breast Health’s sales and regulatory expertise to drive adoption and revenue growth. None of the goodwill is
expected to be deductible for income tax purposes.
Fiscal 2023 Acquisitions
JW Medical
On July 3, 2023, the Company completed the acquisition of assets from JW Medical Corporation (“JW Medical”) for a
purchase price of $6.7 million. JW Medical was a long-standing distributor of the Company’s Breast Health products in South
Korea. The majority of the purchase price was allocated to a customer relationship intangible asset with a useful life of 5 years.
Normedi
On April 3, 2023, the Company completed the acquisition of Normedi Nordic AS (“Normedi”) for a purchase price of
$7.7 million, which included $1.1 million for contingent consideration. Normedi was a long-standing distributor of the
Company’s Surgical products in the Nordics region of Europe. The Company allocated $3.0 million of the purchase price to a
customer relationship intangible asset with a useful life of 5 years, and the excess of the purchase price over the net assets
acquired was recorded to goodwill.
Fiscal 2022 Acquisitions
F-28
Bolder Surgical
On November 29, 2021, the Company completed the acquisition of Bolder Surgical Holdings, Inc. (“Bolder”), for a
purchase price of $160.1 million. Bolder, located in Louisville, Colorado, is a developer and manufacturer of energy vessel
sealing surgical devices used in both laparoscopic and open procedures. Bolder's results of operations are reported in the
Company's GYN Surgical reportable segment from the date of acquisition.
The purchase price was allocated to Bolder’s tangible and identifiable intangible assets and liabilities based on their
estimated fair values as of November 29, 2021, as set forth below.
Cash
$
1.9
Accounts receivable
1.3
Inventory
3.3
Other assets
3.0
Accounts payable and accrued expenses
(3.2)
Identifiable intangible assets:
Developed technology
73.6
Customer relationship
21.7
Trade names
1.4
Deferred income taxes, net
(11.7)
Goodwill
68.8
Purchase Price
$
160.1
In performing the purchase price allocation, the Company considered, among other factors, the intended future use of
acquired assets, analysis of historical financial performance and estimates of future performance of Bolder’s business.
As part of the purchase price allocation, the Company determined the identifiable intangible assets were developed
technology, customer relationships and trade names. The preliminary fair value of the intangible assets was estimated using the
income approach, and the cash flow projections were discounted using a 16.0% rate. The cash flows were based on estimates
used to price the transaction, and the discount rate applied was benchmarked with reference to the implied rate of return from
the transaction model and the weighted average cost of capital.
The developed technology assets are comprised of know-how, patents and technologies embedded in Bolder’s products
and relate to currently marketed products. The developed technology assets comprise the primary product families under the
JustRight and CoolSeal technology platforms.
The estimate of the weighted average life for the developed technology, customer relationship, and trade name assets was
10 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and
intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the amount of goodwill were
primarily based on anticipated strategic and synergistic benefits that are expected to be realized from the Bolder acquisition.
These benefits include expanding the Company’s surgical portfolio and utilizing GYN Surgical’s sales and regulatory expertise
to drive adoption and revenue growth. None of the goodwill is expected to be deductible for income tax purposes.
Contingent Consideration
The Company’s primary contingent consideration liability was related to its acquisition of Acessa Health, Inc.
(“Acessa”), which was acquired in August 2020. Acessa developed the Acessa ProVu laparoscopic radiofrequency ablation
system. The Company estimated the fair value of this liability to be $81.8 million as of the acquisition date. The contingent
payments were based on a multiple of annual incremental revenue growth over a three-year period ending annually in
December of each of 2021, 2022, and 2023. There was no maximum earnout. Pursuant to ASC 805, the Company recorded its
estimate of the fair value of the contingent consideration liability utilizing the Monte Carlo simulation based on future revenue
projections of Acessa, revenue growth rates of comparable companies, implied volatility and applying a risk adjusted discount
rate. Each quarter the Company was required to remeasure the fair value of the liability as assumptions change, and such
adjustments were recorded in operating expenses. This fair value measurement was based on significant inputs not observable
in the market and thus represented a Level 3 measurement as defined in ASC 820. This fair value measurement was directly
impacted by the Company's estimate of future incremental revenue growth of the business. Accordingly, if actual revenue
growth were higher or lower than the estimates within the fair value measurement, the Company would record additional
charges or gains. During the first quarter of fiscal 2024, the third and final measurement period was completed, and the
Company recorded a loss of $1.7 million to increase the contingent consideration liability to fair value based on actual revenue
F-29
results in the final earn-out period. The Company made a final payment of $2.6 million during the second quarter of fiscal 2024.
During 2023, the Company remeasured the contingent consideration liability and recorded a gain of $14.9 million to
record the liability to fair value. The reduction in fair value was due to a decrease in forecasted revenues over the remaining
measurement period. The Company paid $7.6 million for the second earnout period. During fiscal 2022, the Company
remeasured the contingent consideration and recorded a gain of $39.5 million to record the liability at fair value. The reduction
in fair value was primarily due to a decrease in forecasted revenues over the measurement period and to a much lesser extent an
increase in the discount rate driven by market rates. The Company paid $12.2 million for the first earnout period.
6. Strategic Investments
Maverix Medical
On November 13, 2023, the Company entered into an agreement with KKR Comet, LLC, an affiliate of KKR & Co. Inc.
(“KKR Comet”), to form a legal entity to develop and acquire innovative technologies and commercial operations within the
lung cancer space. The new entity, named Maverix Medical LLC (“Maverix”), is managed by Ajax Health. As part of this
strategic investment, the Company contributed $24.5 million in return for 45% ownership in the Class A Common units of
Maverix, and both the Company and KKR Comet have committed to make additional capital contributions in proportion to the
ownership percentages upon meeting certain objectives and as approved by the Maverix board. In accordance with ASC 810,
Consolidation, and ASC 323, Investments - Equity Method and Joint Ventures, the Company determined that Maverix is a VIE
however the Company is not the primary beneficiary but does have significant influence and therefore this investment should be
accounted for under the equity method, which requires the Company to record its proportional share of the entity’s net income
(loss). This investment is recorded within Other assets in the Consolidated Balance Sheets, and the Company’s proportionate
share of Maverix’s net loss for the year ended September 28, 2024 was $3.6 million.
Other
The Company holds other non-marketable equity securities as part of its strategic investments portfolio. Other non-
marketable equity securities are measured at cost, less any impairment, adjusted for observable price changes in orderly
transactions for identical or similar investments of the same issuer. In addition, these investments are assessed for indicators of
impairment, including adverse changes in technological milestones and financial conditions of the investee. Changes in fair
value of these strategic investments are recorded in other income (expense), net in the Consolidated Statements of Income. No
such impairments were recorded in fiscal 2024 and 2023, and in fiscal 2022, the Company recorded a $4.0 million impairment
charge on one investment. At September 28, 2024 and September 30, 2023, the Company’s investments in equity securities
without readily determinable fair values totaled $25.3 million and $15.5 million, respectively, and are included in Other assets
on the Consolidated Balance Sheets.
7. Disposition
Sale of SuperSonic Imagine Ultrasound Imaging Business
On September 28, 2023, the Company executed an agreement to sell its SSI ultrasound imaging business to SSH
Holdings Limited for a sales price of $1.9 million in cash. Under the terms of the contract, the Company agreed to fund the SSI
business with $33.2 million of cash. The sale was completed on October 3, 2023. The Company also agreed to provide certain
transition services for up to one year, depending on the nature of the service. The SSI ultrasound imaging asset group met the
criteria to be classified as assets held-for-sale in the fourth quarter of fiscal 2023. As a result, the Company recorded a charge of
$51.7 million in the fourth quarter of fiscal 2023 to record the asset group to its fair value less costs to sell pursuant to ASC
360.
The assets and liabilities of the disposed business at the date of disposition were as follows:
F-30
Assets:
Cash
$
33.2
Accounts receivable
4.5
Inventory
16.2
Prepaid expenses and other assets
8.6
Valuation allowance
(50.6)
Total assets held-for-sale
$
11.9
Liabilities:
Accounts payable
$
3.1
Accrued expenses
5.1
Total liabilities held-for-sale
$
8.2
The valuation allowance of $50.6 million was recorded to appropriately reflect the assets held-for-sale classification in
the Consolidated Balance Sheet in the fourth quarter of fiscal 2023 relative to the loss recorded and the net tangible assets
disposed.
The Company concluded that this disposal did not qualify as a discontinued operation as the sale of the SSI ultrasound
imaging business was deemed to not be a strategic shift having or that will have a major effect on the Company’s operations
and financial results.
8. Restructuring and Divestiture Charges
The Company evaluates its operations for opportunities to improve operational effectiveness and efficiency, including
facility and operations consolidation, and to better align expenses with revenues. As a result of these assessments, the Company
has undertaken various restructuring actions which are described below. The following table displays charges taken related to
restructuring actions in fiscal 2024, 2023 and 2022 and a rollforward of the charges to the accrued balances as of September 28,
2024:
Restructuring Charges
Fiscal 2022 charges:
Workforce reductions
$
—
$
—
$
2.6
$
(0.7) $
1.9
Facility closure costs
—
—
0.5
—
0.5
Fiscal 2022 restructuring charges
$
—
$
—
$
3.1
$
(0.7) $
2.4
Fiscal 2023 charges:
Workforce reductions
$
—
$
5.5
$
6.0
$
—
$
11.5
Other costs
—
—
0.5
—
0.5
Fiscal 2023 restructuring charges
$
—
$
5.5
$
6.5
$
—
$
12.0
Fiscal 2024 charges:
Lease asset impairment charge
$
12.5
$
—
$
—
$
—
$
12.5
Accelerated depreciation expense
7.2
—
—
—
7.2
Workforce reductions
15.8
—
3.9
—
19.7
Other costs
1.2
—
0.5
—
1.7
Fiscal 2024 restructuring charges
$
36.7
$
—
$
4.4
$
—
$
41.1
Fiscal 2024
Actions
Fiscal 2023
Actions
Fiscal 2022
Actions
Other
Total
F-31
Fiscal 2024
Actions
Fiscal 2023
Actions
Fiscal 2022
Actions
Other
Total
Rollforward of Accrued Restructuring
Balance as of September 25, 2021
$
—
$
—
$
—
$
4.1
$
4.1
Fiscal 2022 restructuring charges
$
—
$
—
$
3.1
$
(0.7) $
2.4
Severance payments and adjustments
—
—
(0.4)
(3.0)
(3.4)
Balance as of September 24, 2022
$
—
$
—
$
2.7
$
0.4
$
3.1
Fiscal 2023 restructuring charges
$
—
$
5.5
$
6.5
$
—
$
12.0
Severance payments and adjustments
—
(3.2)
(2.5)
(0.4)
(6.1)
Balance as of September 30, 2023
$
—
$
2.3
$
6.7
$
—
$
9.0
Fiscal 2024 restructuring charges
$
36.7
$
—
$
4.4
$
—
$
41.1
Non-cash impairment charge
(12.5)
—
—
—
(12.5)
Non-cash accelerated depreciation charge
(7.2)
—
—
—
(7.2)
Severance payments and adjustments
(11.5)
(2.0)
(4.9)
—
(18.4)
Balance as of September 28, 2024
$
5.5
$
0.3
$
6.2
$
—
$
12.0
Fiscal 2024 Actions
During the first quarter of fiscal 2024, the Company further refined its strategy for the Mobidiag business, which is within
the Diagnostics reportable segment. The strategy change included the decision to discontinue the manufacture and sale of
certain products, closure of its facilities in Finland and France, and to move the development activities and operations to the
Company’s San Diego, California location. As such, the Company determined certain fixed assets lives should be shortened and
that lease assets were impaired at the affected facilities and recorded accelerated depreciation of $7.2 million and a lease asset
impairment charge of $12.5 million. In connection with this plan, the Company finalized its decision to terminate the employees
at these locations, totaling 190. The Company initiated discussions with the respective Works Councils at the end of the first
quarter of fiscal 2024. In addition, the Company recorded the minimum statutory severance benefit for the employees located in
France of $1.8 million pursuant to ASC 712, Compensation Nonretirement Postemployment Benefits (ASC 712), at this time.
During the second quarter of fiscal 2024, the Company finalized its negotiations with the respective Works Councils and
communicated the termination and related severance benefits to the affected employees. The Company has estimated the total
severance charges, including accelerated stock compensation, will be approximately $13.9 million. The majority of the
severance benefits will be recorded pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420), which requires the
severance benefits to be recognized ratably over the service period to obtain such benefits. The employees will cease
employment in phases. As a result, the Company recorded total severance charges of $11.9 million in fiscal 2024. This action is
expected to be completed by the second quarter of fiscal 2025.
During fiscal 2024, the Company made various decisions to contain costs and to terminate approximately 34 employees
primarily in Breast Health and Diagnostics, within sales, marketing and research and development. The Company recorded
$3.9 million for severance benefits under these actions pursuant to ASC 420. These actions were completed as of September 28,
2024.
Fiscal 2023 and 2022 Actions
During fiscal 2023 and 2022, the Company made various decisions to terminate approximately 128 employees across all
divisions in multiple departments as well as consolidate and close certain offices in Germany and transfer warehouse
distribution in the United States to a third-party facility. During fiscal 2023 and 2022, the Company recorded $9.4 million and
$0.3 million, respectively, primarily for severance benefits under these actions, and $0.5 million in property closure costs in
fiscal 2022. The charges were recorded pursuant to ASC 712 and ASC 420 depending on the employee and nature of the
severance benefit. These actions were completed as of the end of fiscal 2023.
F-32
During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where
it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment
products and all other support services are in the process of being transferred to the Company's Newark, Delaware facility. The
transition is expected to be completed by the third quarter of fiscal 2025. In addition, research and development, sales and
services support and administrative functions have been transferred to the Newark, Delaware and Marlborough, Massachusetts
facilities. The employees were notified of the closure during the first quarter of fiscal 2022, and the majority of employees
located in Danbury were given the option to relocate to the new locations. The Company is recording severance benefits ratably
over the required service period pursuant to ASC 420. As a result, the Company recorded severance and benefits charges of
$3.9 million, $2.1 million, and $1.6 million during fiscal 2024, 2023 and 2022, respectively. The Company estimates that total
severance and benefits charges, including retention and relocation and outplacement costs, will be approximately $8.6 million.
9. Borrowings and Credit Agreements
The Company’s borrowings consisted of the following:
September 28,
2024
September 30,
2023
Current debt obligations, net of debt discount and deferred issuance costs:
Term Loan
$
37.5 $
287.0
Total current debt obligations
$
37.5 $
287.0
Long-term debt obligations, net of debt discount and issuance costs:
Term Loan
1,158.7
1,195.6
2028 Senior Notes
397.6
396.8
2029 Senior Notes
940.8
938.8
Total long-term debt obligations
2,497.1
2,531.2
Total debt obligations
$
2,534.6 $
2,818.2
The debt maturity schedule for the Company’s obligations as of September 28, 2024 was as follows:
2025
2026
2027
2028
2029
2030 and
Thereafter
Total
Term Loan
$
37.5 $
1,160.0 $
— $
— $
— $
— $
1,197.5
2028 Senior Notes
—
—
—
400.0
—
—
400.0
2029 Senior Notes
—
—
—
—
950.0
—
950.0
$
37.5 $
1,160.0 $
— $
400.0 $
950.0 $
— $
2,547.5
2021 Credit Agreement
On September 27, 2021, the Company and certain of its subsidiaries refinanced its then existing term loan and revolving
credit facility with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and
certain other lenders (the “2018 Credit Agreement”) by entering into Refinancing Amendment No. 2 (the “2021 Credit
Agreement”). Borrowings under the 2021 Credit Agreement are secured by first-priority liens on, and a first-priority security
interest in, substantially all of the Company's U.S. assets and the assets of the Subsidiary Guarantors. These liens are subject to
release during the term of the facilities if the Company is able to achieve certain corporate or corporate family ratings and other
conditions are met. The credit facilities under the 2021 Credit Agreement (the “2021 Credit Facilities”) consist of:
•
A $1.5 billion secured term loan (“2021 Term Loan”) with a maturity date of September 25, 2026; and
•
A secured revolving credit facility (“2021 Revolver”) under which the Company may borrow up to $2.0 billion,
subject to certain sublimits, with a maturity date of September 25, 2026.
On August 22, 2022, the Company and its subsidiaries amended the 2021 Credit Agreement by entering into an
amendment (the “Third Amendment”) related to the planned phase out of LIBOR by the U.K. Financial Conduct Authority.
The interest rate applicable to the loans under the 2021 Credit Agreement denominated in U.S. dollars were converted to a
variant of the secured overnight financing rate (“SOFR”), as established from time to time by the Federal Reserve Bank of New
York, plus a corresponding spread. The Third Amendment converted the Eurocurrency Rate to Term SOFR plus the SOFR
Adjustment of 0.10% and the LIBOR Daily Floating Rate to Daily SOFR Rate plus the SOFR Adjustment of 0.10%, effective
September 23, 2022.
F-33
After giving effect to the Third Amendment, borrowings under the 2021 Credit Agreement, other than Swing Line Loans,
bear interest, at the Company's option, at the Base Rate, at the Term SOFR Rate, at the Alternative Currency Daily Rate, or at
the Daily SOFR Rate, in each case plus the Applicable Rate.
The Applicable Rate in regard to the Base Rate, the Term SOFR Rate, the Alternative Currency Daily Rate, the
Alternative Currency Term Rate, and the Daily SOFR Rate is subject to change depending on the Total Net Leverage Ratio (as
defined in the 2021 Credit Agreement). The borrowings of the Term Loan under the 2021 Credit Facilities bear interest at an
annual rate equal to the Term SOFR Rate plus the SOFR Adjustment of 0.10% for a one-month interest period plus an
Applicable Rate equal to 1.00%. As of September 28, 2024, the interest rate under the 2021 Term Loan was 5.96% per annum.
The Company is also required to pay a quarterly commitment fee calculated on a daily basis equal to the Applicable Rate
as of such day multiplied by the undrawn committed amount available under the 2021 Revolver (taking into account any
outstanding amounts under the LC Sublimit). As of September 28, 2024, this commitment fee was 0.15% per annum for the
2021 Revolver.
The Company is required to make scheduled principal payments under the 2021 Term Loan in increasing amounts, which
is $9.375 million per three-month period through fiscal 2025, and increases to $18.75 million per three-month period in fiscal
2026. The remaining balance of $1.085 billion (or such lesser aggregate principal amount of the Term Loans then outstanding)
on the 2021 Term Loan and any amounts outstanding under the 2021 Revolver are due at maturity. In addition, subject to the
terms and conditions set forth in the 2021 Credit Agreement, the Company is required to make certain mandatory prepayments
from the net proceeds of specified types of asset sales (subject to certain reinvestment rights), debt issuances (excluding
permitted debt) and insurance recoveries (subject to certain reinvestment rights). Certain of the mandatory prepayments are
subject to reduction or elimination if certain financial covenants are met. These mandatory prepayments are required to be
applied by the Company first to the 2021 Term Loan, second to any outstanding amount under any Swing Line Loans, third to
the 2021 Revolver, fourth to prepay any outstanding reimbursement obligations with respect to letters of credit and fifth to cash
collateralize such letters of credit. Subject to certain limitations, the Company may voluntarily prepay any of the 2021 Credit
Facilities without premium or penalty. On October 27, 2023 (the first quarter of fiscal 2024), the Company made a
$250.0 million voluntary prepayment on the 2021 Term Loan. The outstanding principal balance of the 2021 Term Loan was
$1.20 billion, and there were no amounts outstanding under the 2021 Revolver.
The 2021 Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit
facilities, including covenants restricting the ability of the Company, subject to negotiated exceptions, to incur additional
indebtedness and grant additional liens on its assets, engage in mergers or acquisitions or dispose of assets, enter into sale-
leaseback transactions, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions
with affiliated persons, make investments, and change the nature of their businesses. In addition, the 2021 Credit Agreement
requires the Borrowers to maintain certain financial ratios. The 2021 Credit Agreement also contains customary representations
and warranties and events of default, including payment defaults, breach of representations and warranties, covenant defaults,
cross defaults and an event of default upon a change of control of the Company.
The Company evaluated the 2021 Credit Agreement for derivatives pursuant to ASC 815, Derivatives and Hedging (ASC
815), and identified embedded derivatives that required bifurcation as the features are not clearly and closely related to the host
instrument. The embedded derivatives were a default provision, which could require additional interest payments, and a
provision requiring contingent payments to compensate the lenders for changes in tax deductions. The Company determined
that the fair value of these embedded derivatives was immaterial as of September 28, 2024.
Pursuant to ASC 470, Debt (ASC 470), the accounting for the refinancing was evaluated on a creditor-by-creditor basis to
determine whether each transaction should be accounted for as a modification or extinguishment. Certain creditors under the
2018 Credit Agreement did not participate in this refinancing transaction and ceased being creditors of the Company. As a
result, the Company recorded a debt extinguishment loss of $0.7 million in the first quarter of fiscal 2022 to write-off the pro-
rata amount of unamortized debt discount and deferred issuance costs related to these creditors. For the remainder of the
creditors, this transaction was accounted for as a modification. Pursuant to ASC 470, third-party costs of $7.0 million were
recorded as a reduction to debt representing deferred issuance costs and fees paid directly to the lenders.
F-34
Interest expense, non-cash interest expense, the weighted average interest rate, and the interest rate at the end of period
under the 2021 Credit Agreement were as follows:
Years Ended
September 28, 2024
September 30, 2023
September 24, 2022
Interest expense(1)
$
85.8
$
92.4
$
31.8
Non-cash interest expense
$
2.2
$
2.3
$
2.2
Weighted average interest rate
6.39 %
5.84 %
1.74 %
Interest rate at end of period
5.96 %
6.42 %
4.18 %
(1) Interest expense includes non-cash interest expense related to the amortization of the deferred issuance costs and
accretion of the debt discount.
Under the Company’s interest rate swap agreements, it received $16.8 million and $35.4 million in fiscal 2024 and 2023,
respectively, which was recorded as a reduction to interest expense. In fiscal 2022, the Company paid $4.9 million under its
interest rate swaps, which was recorded as an increase to interest expense.
Senior Notes
2028 Senior Notes
On January 19, 2018, the Company completed a private placement of $1.0 billion aggregate principal amount of senior
notes and allocated $400 million in aggregate principal amount to its 4.625% Senior Notes due 2028 (the “2028 Senior Notes”)
at an offering price of 100% of the aggregate principal amount of the 2028 Senior Notes. The 2028 Senior Notes are general
senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries.
The 2028 Senior Notes mature on February 1, 2028 and bear interest at the rate of 4.625% per year, payable semi-annually on
February 1 and August 1 of each year, commencing on August 1, 2018.
The Company has the option to redeem the 2028 Senior Notes on or after: February 1, 2024 through February 1, 2025
at 101.541% of par; February 1, 2025 through February 1, 2026 at 100.770% of par; and February 1, 2026 and thereafter
at 100% of par. In addition, if the Company undergoes a change of control coupled with a decline in ratings, as provided in the
indenture, the Company will be required to make an offer to purchase each holder’s 2028 Senior Notes at a price equal
to 101% of their principal amount, plus accrued and unpaid interest, if any, to the repurchase date.
The Company evaluated the 2028 Senior Notes for derivatives pursuant to ASC 815 and did not identify any embedded
derivatives that require bifurcation. All features were deemed to be clearly and closely related to the host instrument.
2029 Senior Notes
On September 28, 2020, the Company completed a private placement of $950 million aggregate principal amount of its
3.250% Senior Notes due 2029 (the “2029 Senior Notes”) at an offering price of 100% of the aggregate principal amount of the
2029 Senior Notes. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a
senior unsecured basis by certain domestic subsidiaries. The 2029 Senior Notes mature on February 15, 2029 and bear interest
at the rate of 3.250% per year, payable semi-annually on February 15 and August 15 of each year, commencing on February 15,
2021.
The Company has the option to redeem the 2029 Senior Notes on or after: September 28, 2024 through September 27,
2025 at 100.813% of par; and September 28, 2025 and thereafter at 100% of par. In addition, if the Company undergoes a
change of control coupled with a decline in ratings, as provided in the indenture, the Company will be required to make an offer
to purchase each holder’s 2029 Senior Notes at a price equal to 101% of their principal amount, plus accrued and unpaid
interest, if any, to the repurchase date.
The Company evaluated the 2029 Senior Notes for derivatives pursuant to ASC 815 and did not identify any embedded
derivatives that require bifurcation. All features were deemed to be clearly and closely related to the host instrument.
F-35
Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows:
Years Ended
September 28, 2024
September 30, 2023
September 24, 2022
Interest
Rate
Interest
Expense(1)
Non-Cash
Interest
Expense
Interest
Expense (1)
Non-Cash
Interest
Expense
Interest
Expense(1)
Non-Cash
Interest
Expense
2029 Senior Notes
3.250 % $
32.9 $
2.1 $
33.5 $
2.1 $
32.9 $
2.1
2028 Senior Notes
4.625 %
19.2
0.7
19.5
0.7
19.2
0.7
Total
$
52.1 $
2.8 $
53.0 $
2.8 $
52.1 $
2.8
(1) Interest expense includes non-cash interest expense related to the amortization of the deferred issuance costs and
accretion of the debt discount.
10. Fair Value Measurements
The Company applies the provisions of ASC 820 for its financial assets and liabilities that are re-measured and reported
at fair value each reporting period and its nonfinancial assets and liabilities that are re-measured and reported at fair value on a
non-recurring basis. Fair value is the price that would be received from selling an asset or paid to transfer a liability in an
orderly transaction between market participants at the measurement date. When determining fair value, the Company considers
the principal or most advantageous market in which it would transact and considers assumptions that market participants would
use when pricing the asset or liability.
Fair Value Hierarchy
ASC 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and
liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the
measurement of fair value. The three levels of the hierarchy are defined as follows:
•
Level 1—Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•
Level 2—Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar
assets or liabilities and market-corroborated inputs.
•
Level 3—Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs
market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis
The Company has investments in money market funds, United States Treasury securities and commercial paper that are
classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are
classified as Cash and cash equivalents, and Short term and Long term investments on the Consolidated Balance Sheets, which
is determined based on maturities at the time of purchase and re-evaluated at each balance sheet date.
The Company also has investments in derivative instruments comprised of interest rate swaps, forward foreign currency
contracts and foreign currency option contracts (including collars). These instruments were valued using analyses obtained from
independent third-party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of
these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer
to Note 2 for further discussion and information on these derivative contracts. In addition, the Company has a contingent
consideration liability that is recorded at fair value and is based on Level 3 inputs.
Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following:
F-36
Fair Value Measurements at September 28, 2024
Fair Value
Quoted Prices in
Active Market for
Identical Assets
(Level 1)
Significant
Other
Observable
Inputs (Level 2)
Significant
Unobservable
Inputs (Level 3)
Assets:
Money market mutual funds
$
341.7 $
341.7 $
— $
—
U.S. Treasury securities
626.3
626.3
—
—
Commercial paper
24.9
24.9
—
—
Interest rate swaps
3.1
—
3.1
—
Foreign currency option contracts
0.8
—
0.8
—
Total
$
996.8 $
992.9 $
3.9 $
—
Liabilities:
Contingent consideration
$
1.1 $
— $
— $
1.1
Interest rate swaps
0.2
—
0.2
—
Forward foreign currency contracts
12.6
—
12.6
—
Total
$
13.9 $
— $
12.8 $
1.1
Fair Value Measurements at September 30, 2023
Fair Value
Quoted Prices in
Active Market for
Identical Assets
(Level 1)
Significant
Other
Observable
Inputs (Level 2)
Significant
Unobservable
Inputs (Level 3)
Assets:
Interest rate swaps
$
26.9 $
— $
26.9 $
—
Forward foreign currency contracts
8.4
—
8.4
—
Total
$
35.3 $
— $
35.3 $
—
Liabilities:
Contingent consideration
$
2.0 $
— $
— $
2.0
Total
$
2.0 $
— $
— $
2.0
Liabilities Measured and Recorded at Fair Value on a Recurring Basis
Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which
solely consisted of contingent consideration liabilities, during the years ended September 28, 2024, September 30, 2023, and
September 24, 2022 were as follows:
Years Ended
2024
2023
2022
Balance at beginning of period
$
2.0 $
23.4 $
75.1
Contingent consideration recorded at acquisition
—
1.1
—
Fair value adjustments
1.7
(14.9)
(39.5)
Payments
(2.6)
(7.6)
(12.2)
Balance at end of period
$
1.1 $
2.0 $
23.4
Assets Measured and Recorded at Fair Value on a Nonrecurring Basis
The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets
are comprised of equity investments and long-lived assets, primarily comprised of property, plant and equipment, intangible
assets, and goodwill. During the third quarter of fiscal 2024, the Company recorded intangible asset impairment charges of
$13.3 million and $0.4 million, respectively, related to its BioZorb developed technology and trade name intangible assets
acquired in the Focal acquisition, which is within the Breast Health reportable segment, reducing the carrying value of the
assets to zero. During the second quarter of fiscal 2024, the Company recorded intangible asset impairment charges of
$25.9 million and $0.9 million, respectively, related to its BioZorb developed technology and trade name intangible assets
F-37
reducing the carrying value of the assets to $13.9 million and $0.5 million, respectively. See Note 2 for further discussion.
During the first quarter of fiscal 2024, the Company recorded a $12.5 million impairment charge for right-of-use lease assets
related to the closure of its Mobidiag facilities in Finland and France (see Note 8 for further discussion), reducing the carrying
value to zero. In addition, during the first quarter of fiscal 2024, the Company recorded a $4.3 million impairment charge for an
in-process research and development project from the Mobidiag acquisition, reducing the carrying value of this asset to
$22.4 million.
During the fourth quarter of fiscal 2023, the Company’s SSI ultrasound imaging business met the criteria to be classified
as assets held-for-sale, and the Company recorded a $51.7 million loss to record the asset group at its fair value less costs to
sell. During the third quarter of fiscal 2023, the Company identified indicators of impairment related to the long-lived assets of
its Mobidiag business and based on the fair value of the asset group recorded impairment charges aggregating $186.9 million,
of which $174.8 million was allocated to intangible assets and $12.1 million was allocated to property, plant and equipment.
Subsequent to the impairment charges, the carrying value of the definite-lived intangible assets and property, plant and
equipment was $65.8 million and $4.6 million, respectively. In addition, the Company recorded a $10.5 million impairment
charge for the only in-process research and development project from the Mobidiag acquisition, and the resulting carrying value
was $26.5 million. During the third quarter of fiscal 2023, the Company identified indicators of impairment related to the long-
lived assets of its SSI ultrasound imaging business and recorded impairment charges aggregating $26.4 million, of which
$20.6 million was allocated to intangible assets and $5.8 million was allocated to equipment. Subsequent to the impairment
charges, the carrying value of these assets was zero.
During the fourth quarter of fiscal 2022, the Company recorded a $27.7 million impairment charge to record its Mobidiag
IPR&D asset to fair value, which is a Level 3 measurement, and it recorded an $8.2 million impairment charge to write-off a
developed technology asset from its Focal acquisition. In addition, the Company recorded an impairment charge of $4.0 million
to record an equity investment at its estimated fair value. During the third quarter of fiscal 2022, the Company recorded a
$9.2 million impairment charge to write off two developed technology assets from its Faxitron acquisition. During the second
quarter of fiscal 2022, the Company recorded a $4.3 million impairment charge to write-off an equity method investment
acquired in the Mobidiag acquisition.
Disclosure of Fair Value of Financial Instruments
The Company’s financial instruments mainly consist of cash and cash equivalents, United States Treasury securities,
commercial paper, accounts receivable, equity investments, interest rate swaps, forward foreign currency contracts, foreign
currency option contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s
cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of
these instruments. The Company’s United States Treasury securities, commercial paper, interest rate swaps, forward foreign
currency contracts and foreign currency option contracts are recorded at fair value. The carrying amount of the insurance
contracts are recorded at their cash surrender value, as required by U.S. GAAP, which approximates fair value. The Company
believes the carrying amounts of its equity investments approximate fair value.
The Company’s cash and cash equivalents and short and long-term investments as of September 28, 2024 were as
follows:
Valuation
Balance Sheet Classification
in millions
Cost
Unrealized
Gains
Unrealized
Losses
Fair Value
Cash and cash
equivalents
Investments
Cash
$ 1,437.1 $
— $
— $ 1,437.1 $ 1,437.1 $
—
Money market mutual funds
341.7
—
—
341.7
341.7
—
U.S. Treasury debt securities
624.7
1.6
—
626.3
356.5
269.8
Commercial paper
24.9
—
—
24.9
24.9
—
Total
$ 2,428.4 $
1.6 $
— $ 2,430.0 $ 2,160.2 $
269.8
The Company classifies its investments in debt securities as available-for-sale and records them at fair value, with
changes in fair value reported as a component of accumulated other comprehensive income (loss), which was immaterial for the
year ended September 28, 2024. The Company periodically assesses these securities for potential impairment losses and credit
losses. The amount of credit losses, if any, will be determined by comparing the difference between the present value of future
cash flows expected to be collected on these securities and the amortized cost. There were no impairments and credit losses
related to available-for-sale securities for the year ended September 28, 2024.
The Company classifies all highly liquid investments with stated maturities of three months or less from the date of
purchase as cash equivalents. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the
ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.
F-38
There were no transfers into or out of Level 3 during the years ended September 28, 2024 and September 30, 2023,
respectively. There were no sales of available-for-sale securities during the year ended September 28, 2024.
The fair value of the available-for-sale securities by contractual maturity as of September 28, 2024 and September 30,
2023 are as follows:
September 28, 2024
September 30, 2023
in millions
Fair Value
Fair Value
Due in three months or less
$
723.1 $
—
Due after three months through one year
173.4
—
Due after one year through five years
96.4
—
Total available-for-sale securities
$
992.9 $
—
Amounts outstanding under the Company’s 2021 Credit Agreement of $1.20 billion aggregate principal as of
September 28, 2024 are subject to variable rates of interest based on current market rates, and as such, the Company believes
the carrying amount of these obligations approximates fair value. The Company’s 2028 Senior Notes and 2029 Senior Notes
had fair values of approximately $393.1 million and $882.2 million, respectively, as of September 28, 2024 based on their
trading prices, representing a Level 1 measurement. Refer to Note 9 for the carrying amounts of the various components of the
Company's debt.
11. Income Taxes
The Company’s income before income taxes consisted of the following:
Years Ended
September 28,
2024
September 30,
2023
September 24,
2022
Domestic
$
609.4 $
861.4 $
1,340.3
Foreign
255.7
(185.3)
247.9
$
865.1 $
676.1 $
1,588.2
F-39
The provision (benefit) for income taxes contained the following components:
Years Ended
September 28,
2024
September 30,
2023
September 24,
2022
Federal:
Current
$
91.6 $
250.6 $
298.6
Deferred
(50.9)
(72.1)
(129.8)
40.7
178.5
168.8
State:
Current
14.2
45.9
54.8
Deferred
(7.5)
(9.4)
(9.5)
6.7
36.5
45.3
Foreign:
Current
41.9
32.7
99.0
Deferred
(13.7)
(27.6)
(26.9)
28.2
5.1
72.1
$
75.6 $
220.1 $
286.2
The income tax provision differed from the tax provision computed at the U.S. federal statutory rate due to the following:
Years Ended
September 28,
2024
September 30,
2023
September 24,
2022
Income tax provision at federal statutory rate
21.0 %
21.0 %
21.0 %
Increase (decrease) in tax resulting from:
Cynosure loss on sale and carryback
—
—
(1.2)
State income taxes, net of federal benefit
2.5
4.1
2.9
U.S. tax on foreign earnings
0.5
(1.0)
(2.6)
Internal Restructuring
—
—
(0.9)
Tax credits
(1.6)
(1.1)
(0.5)
Unrecognized tax benefits
3.9
3.5
0.2
Compensation
1.0
0.8
0.2
Foreign rate differential
(6.8)
(4.8)
(0.8)
Change in deferred tax
—
—
0.4
Assets held-for-sale charge
—
1.5
—
Change in valuation allowance
2.7
8.2
0.4
Return to provision
(1.2)
(1.9)
(0.7)
Worthless stock deduction
(12.4)
—
—
Other
(0.9)
2.3
(0.4)
8.7 %
32.6 %
18.0 %
The Company’s effective tax rate for fiscal 2024 was lower than the U.S. statutory tax rate primarily due to a one-time
tax benefit of $107.2 million related to a worthless stock deduction on an investment in one of the Company’s international
subsidiaries recorded in the first quarter of fiscal 2024, the U.S. deduction for foreign derived intangible income, and the
geographic mix of income earned by the Company’s international subsidiaries, and federal and state tax credits.
The Company's effective tax rate for fiscal 2023 was higher than the U.S. statutory tax rate primarily due to the tax effect
of the SSI ultrasound imaging assets held-for-sale charge, income tax reserves, the global intangible low-taxed income
inclusion, and state income taxes, partially offset by the impact of the U.S. deduction for foreign derived intangible income, and
the geographic mix of income earned by our international subsidiaries.
The Company's effective tax rate for fiscal 2022 was lower than the U.S. statutory tax rate primarily due to the impact of
the U.S. deduction for foreign derived intangible income, reserve releases resulting from statute of limitations expirations and
favorable audit settlements (net of reserve additions for uncertain tax positions), the geographic mix of income earned by the
F-40
Company's international subsidiaries and a tax benefit related to an internal restructuring, partially offset by state income taxes
and the global intangible low-taxed income inclusion.
The Company obtains tax incentives through the Free Trade Zone Regime offered in Costa Rica which allows 100
percent exemption from income tax in the first eight years of operations and 50 percent exemption in the following four years.
This tax incentive resulted in income tax savings of $79.8 million and $45.5 million, or $0.34 and $0.18 per share to diluted net
income in fiscal years 2024 and 2023, respectively. The tax incentive for 100 percent exemption from income tax expires in
fiscal year 2029, with the 50 percent exemption to expire in fiscal year 2033. The Company’s historical practice has been to
renew, extend, or obtain new tax incentive grants upon expiration of existing tax incentive grants. If the Company is not able to
renew, extend, or obtain new tax incentive grants, the expiration of existing tax incentive grants could have a material impact on
the Company’s financial results in future periods. Incentives in fiscal years prior to 2023 were not material to the Company's
consolidated financial statements.
The Company’s significant deferred tax assets and liabilities were as follows:
September 28,
2024
September 30,
2023
Deferred tax assets
Net operating loss and other tax carryforwards
$
137.1 $
125.8
Capitalized research and development
96.8
70.1
Non-deductible accruals
41.0
32.7
Non-deductible reserves
37.8
42.8
Stock-based compensation
21.9
19.8
Nonqualified deferred compensation plan
15.9
13.5
Lease liability
26.2
14.0
Other temporary differences
21.0
5.9
397.7
324.6
Less: valuation allowance
(143.1)
(114.7)
$
254.6 $
209.9
Deferred tax liabilities
Depreciation and amortization
$
(161.8) $
(160.3)
Right of use asset
(23.4)
(13.2)
$
(185.2) $
(173.5)
$
69.4 $
36.4
Under ASC 740, Accounting for Income Taxes (ASC 740), the Company can only recognize the future benefit of deferred
tax assets to the extent that it is “more likely than not” that these assets will be realized. After considering all available positive
and negative evidence, the Company establishes a valuation allowance against specifically identified deferred tax assets
because it is more-likely-than-not that these assets will not be realized. In making this determination, the Company considers
numerous factors including historical profitability, estimated future taxable income and the character of such income. The
valuation allowance increased $28.4 million in fiscal 2024 from fiscal 2023 primarily due to valuation allowances recorded
against net operating loss carryforwards of certain foreign subsidiaries.
As of September 28, 2024, the Company had $22.5 million, $172.1 million, and $275.2 million in gross federal, state, and
foreign net operating losses, respectively, $4.6 million and $2.1 million in federal and state credit carryforwards, respectively,
and $438.9 million and $134.2 million in gross state and foreign capital loss carryforwards, respectively. These losses, credits,
and capital loss carryforwards expire between 2025 and 2044, except for $97.5 million in losses, $4.2 million in credits, and
$134.2 million in capital loss carryforwards that have unlimited carryforward periods. The state and foreign net operating losses
include $107.7 million and $208.6 million, respectively, and the state capital loss carryforwards include $438.9 million, that the
Company expects will expire unutilized.
The Company has determined that unremitted foreign earnings are not considered indefinitely reinvested to the extent
foreign earnings can be distributed without a significant tax cost. As such, the Company records foreign withholding tax
liabilities related to the future repatriation of such earnings. The Company continues to indefinitely reinvest all other outside
basis differences to the extent reversal would incur a significant tax liability. It is not practicable for the Company to calculate
the unrecognized deferred tax liability related to such incremental tax costs on those outside basis differences.
F-41
The Company’s gross unrecognized tax benefits increased $16.7 million from fiscal 2023 to 2024 and was primarily due
to intercompany transfer pricing for ordinary business operations and increases to prior year positions, which were partially
offset by reserve releases resulting from statute of limitations expirations and audit settlements. The $8.9 million increase in
gross unrecognized tax benefits from fiscal 2022 to 2023 was primarily due to intercompany transfer pricing for ordinary
business operations and other current year positions, partially offset by reserve releases resulting from statute of limitations
expirations and audit settlements. In the next twelve months it is reasonably possible that the Company will reduce its gross
unrecognized tax benefits excluding interest by up to $8.3 million due to expiring statutes of limitations. The timing of the
ultimate resolution of the Company’s examinations with relevant taxing authorities, which can include formal administrative
and legal proceedings, and could have a significant impact on the reversal of unrecognized tax benefits, is difficult to predict.
As a result, the Company is not able to provide a reasonably reliable estimate of the timing for reversals of unrecognized
income tax benefits that are under examination.
The Company’s unrecognized income tax benefits activity for fiscal 2024, 2023 and 2022 was as follows:
2024
2023
2022
Balance at beginning of fiscal year
$
256.5 $
247.6 $
212.8
Tax positions related to current year:
Additions
7.8
6.8
45.9
Tax positions related to prior years:
Additions related to change in estimate
11.8
4.5
21.5
Reductions
(2.1)
—
(6.6)
Lapses in statutes of limitations and settlements
(0.8)
(2.4)
(26.0)
Balance as of the end of the fiscal year
$
273.2 $
256.5 $
247.6
As of fiscal 2024, 2023, and 2022 there were $213.9 million, $240.5 million, and $231.6 million of unrecognized tax
benefits that if recognized would affect the annual effective tax rate.
The Company recognizes interest and penalties accrued related to unrecognized tax benefits as a component of income
tax expense. During fiscal years 2024, 2023, and 2022, the Company recognized $20.3 million, $15.8 million, and $0.7 million
in gross interest. The Company had gross accrued interest of $50.4 million and $30.1 million as of September 28, 2024 and
September 30, 2023, respectively, and accrued penalties were not significant.
The Company and its subsidiaries are subject to examination by U.S. federal, state, and foreign tax authorities. The
Company is currently undergoing several income tax audits including examinations by the U.S. Internal Revenue Service (fiscal
years 2017-2020), U.K. HM Revenue and Customs (fiscal years 2016-2022) and various state tax authorities. Excluding
jurisdictions under audit, the Company’s income tax returns are generally no longer subject to examination prior to fiscal year
2019.
Other Tax Accounting Pronouncements
ASU 2016-16 removes the prohibition in ASC 740 against the immediate recognition of the current and deferred income
tax effects of intra-entity transfers of assets other than inventory. In accordance with ASU 2016-16, the Company recorded a
$77.2 million increase to current income tax expense, and a $90.8 million decrease to deferred tax expense related to an internal
restructuring for the year ended September 24, 2022. The net result was an increase to net income of $13.6 million, or $0.05 to
diluted net income per share for the year ended September 24, 2022.
Non-Income Tax Matters
The Company is subject to tax examinations for value added, sales-based, payroll and other non-income tax items. A
number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the
jurisdictions in which it operates and records loss contingencies pursuant to ASC 450, Contingencies (ASC 450). In the normal
course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged,
resulting in assessments by governmental authorities. While the Company believes estimated losses previously recorded are
reasonable, certain audits are still ongoing and additional charges could be recorded in the future.
12. Stockholders' Equity and Stock-Based Compensation
Stock Repurchase Program
F-42
On September 22, 2022, the Board of Directors authorized a stock repurchase program, with a five-year term, to
repurchase up to $1.0 billion of the Company’s outstanding common stock, effective as of the close of trading September 23,
2022. This repurchase program replaced the previous $1.0 billion authorization. During fiscal 2024 and 2023, the Company
repurchased 4.2 million and 6.8 million shares of its common stock for total consideration of $308.3 million and $501.6 million,
respectively, excluding the 1% excise tax on share repurchases of $7.2 million and $2.9 million, respectively. As of
September 28, 2024, $190.3 million remained available under this authorization. Subsequent to September 28, 2024, the
Company repurchased 2.7 million shares for a total consideration of $217.2 million.
On November 6, 2023, the Board of Directors authorized the Company to repurchase up to $500 million of the
Company’s outstanding shares pursuant to an accelerated share repurchase (ASR) agreement. On November 15, 2023, the
Company executed the ASR agreement with Goldman Sachs & Co. (“Goldman Sachs”) pursuant to which the Company agreed
to repurchase $500 million of the Company’s common stock. In connection with the launch of the ASR, on November 17,
2023, the Company paid Goldman Sachs an aggregate of $500 million and received approximately 5.6 million shares of the
Company’s common stock, representing 80% of the transaction value based on the Company’s closing share price on
November 14, 2023. On February 27, 2024, the ASR agreement was completed, and the Company received an additional
1.4 million shares for the final settlement. This final settlement was based on the total transaction value and the volume-
weighted average share price of the Company’s common stock during the term of the agreement.
On September 12, 2024, the Board of Directors authorized a new stock repurchase program, with a five-year term, to
repurchase up to $1.5 billion of the Company’s outstanding stock. This new stock repurchase authorization is in addition to the
Company’s prior stock repurchase authorization. As of September 28, 2024, $1.5 billion remained unused under this program.
On November 19, 2024, the Company executed an ASR agreement with JPMorgan Chase & Co., (“JP Morgan”) pursuant
to which the Company agreed to repurchase $250.0 million of the Company’s common stock. In connection with the launch of
the ASR, on November 20, 2024, the Company paid JP Morgan an aggregate of $250.0 million and received approximately
2.5 million shares of the Company’s common stock, representing 80% of the transaction value based on the Company’s closing
share price on November 18, 2024. The final number of shares to be received under the ASR agreement will be determined
upon completion of the transaction and will be based on the total transaction value and the volume-weighted average share price
of our common stock during the term of the transaction. Final settlement of the transaction is expected to be completed in the
second quarter of fiscal 2025.
Stock-Based Compensation
Equity Compensation Plans
The Company has one share-based compensation plan pursuant to which awards are currently being issued—the 2008
amended and restated Equity Incentive Plan (“2008 Equity Plan”). The purpose of the 2008 Equity Plan is to provide stock
options, restricted stock units and other equity interests in the Company to employees, officers, directors, consultants and
advisors of the Company and any other person who is determined by the Board of Directors to have made (or is expected to
make) contributions to the Company. The 2008 Equity Plan is administered by the Board of Directors of the Company. On
December 8, 2022, the Board of Directors approved an additional 6.5 million shares of common stock available under the 2008
Equity Plan increasing the total shares reserved for issuance under the plan to 38 million. As of September 28, 2024, the
Company had 7.5 million shares available for future grant under the 2008 Equity Plan.
The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations in
fiscal 2024, 2023 and 2022:
2024
2023
2022
Cost of revenues
$
10.7 $
10.5 $
9.1
Research and development
10.3
10.5
8.8
Selling and marketing
13.4
12.0
10.5
General and administrative
47.8
46.6
38.3
Restructuring
0.1
—
—
$
82.3 $
79.6 $
66.7
Grant-Date Fair Value
The Company uses a binomial model to determine the fair value of its stock options. The Company considers a number of
factors to determine the fair value of options including the assistance of an outside valuation adviser. Information pertaining to
stock options granted during fiscal 2024, 2023 and 2022 and related assumptions are noted in the following table:
F-43
Years Ended
September 28,
2024
September 30,
2023
September 24,
2022
Options granted (in millions)
0.6
0.5
0.7
Weighted-average exercise price
$
72.34
$
74.66
$
71.07
Weighted-average grant date fair value
$
25.07
$
25.95
$
21.01
Assumptions:
Risk-free interest rates
4.4 %
4.3 %
1.1 %
Expected life (in years)
4.8
4.8
4.8
Expected volatility
33.4 %
33.9 %
34.2 %
Dividend yield
—
—
—
The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected life of the stock
options. In projecting expected stock price volatility, the Company uses a combination of historical stock price volatility and
implied volatility from observable market prices of similar equity instruments. The Company estimated the expected life of
stock options based on historical experience using employee exercise and option expiration data.
Stock-Based Compensation Expense Attribution
The Company uses the straight-line attribution method to recognize stock-based compensation expense for stock options
and restricted stock units (“RSUs”), unless the employee meets the plan retirement provision of reaching a certain age and years
of service criteria in which case the expense is accelerated to match the required service period to receive such benefit. The
vesting term of stock options is generally four years with annual vesting of 25% per year on the anniversary of the grant date,
and RSUs generally vest over three years with annual vesting at 33% per year on the anniversary of the grant date.
The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards
that are ultimately expected to vest. Under ASC 718, the Company's accounting policy is to estimate forfeitures at the time
awards are granted and revise, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Based on an
analysis of historical forfeitures, the Company has determined a specific forfeiture rate for certain employee groups and has
applied forfeiture rates ranging from 0% to 6.0% as of September 28, 2024 depending on the specific employee group. This
analysis is re-evaluated annually and the forfeiture rate adjusted as necessary. Ultimately, the actual stock-based compensation
expense recognized will only be for those stock options and RSUs that vest.
Stock-based compensation expense related to stock options was $14.0 million, $14.2 million, and $12.0 million in fiscal
2024, 2023 and 2022, respectively. Stock compensation expense related to stock units, including RSUs, performance stock
units (“PSUs”), free cash flow performance stock units (“FCFs”) and market stock units (“MSUs”) was $61.1 million, $58.5
million, and $48.2 million in fiscal 2024, 2023 and 2022, respectively. The related tax benefit recorded in the Consolidated
Statements of Income was $11.4 million, $10.7 million and $8.6 million in fiscal 2024, 2023 and 2022, respectively. At
September 28, 2024, there was $10.0 million and $45.0 million of unrecognized compensation expense related to stock options
and stock units, respectively, to be recognized over a weighted average period of 2.2 years and 1.7 years, respectively.
Share Based Payment Activity
The following table summarizes all stock option activity under the Company’s stock option plans for the year ended
September 28, 2024:
Number
of Shares
(in millions)
Weighted-
Average
Exercise Price
Weighted-
Average
Remaining
Contractual Life
(in Years)
Aggregate
Intrinsic
Value
(in millions)
Options outstanding at September 30, 2023
4.2 $
51.63
5.6
$
77.6
Granted
0.6
72.34
Canceled/ forfeited
(0.1)
73.09
Exercised
(0.4)
39.89
15.5
Options outstanding at September 28, 2024
4.3 $
55.32
5.3
$
108.8
Options exercisable at September 28, 2024
3.1 $
48.57
4.2
$
98.5
Options vested and expected to vest at September
28, 2024 (1)
4.2 $
55.21
5.3
$
108.6
F-44
(1) This represents the number of vested stock options as of September 28, 2024 plus the unvested outstanding options at
September 28, 2024 expected to vest in the future, adjusted for estimated forfeitures.
During fiscal 2023 and 2022, the total intrinsic value of options exercised (i.e., the difference between the market price on
the date of exercise and the price paid by the employee to exercise the options) was $18.4 million and $11.1 million,
respectively.
A summary of the Company’s RSU, PSU, FCF and MSU activity during the year ended September 28, 2024 is presented
below:
Non-vested Shares
Number of
Shares
(in millions)
Weighted-Average
Grant-Date Fair
Value
Non-vested at September 30, 2023
1.6 $
73.33
Granted
0.9
73.10
Vested
(0.7)
70.87
Forfeited
(0.1)
72.42
Non-vested at September 28, 2024
1.7 $
73.84
The number of RSUs vested includes shares withheld on behalf of employees to satisfy minimum statutory tax
withholding requirements. The Company pays the minimum statutory tax withholding requirement on behalf of its employees.
During fiscal 2024, 2023 and 2022 the total fair value of RSUs vested was $51.5 million, $48.4 million and $43.8 million,
respectively.
The Company granted 0.7 million, 0.7 million and 0.7 million RSUs during fiscal 2024, 2023 and 2022, respectively. In
addition, included in the above chart, the Company also granted 0.1 million, 0.1 million and 0.1 million PSUs during fiscal
2024, 2023, and 2022, respectively, to members of the Company's senior management team, which includes additional shares
issued upon achieving metrics within the performance criteria. Each recipient of the PSUs is eligible to receive between zero
and 200% of the target number of shares of the Company’s common stock at the end of the three year performance period
provided the Company’s defined Return on Invested Capital metrics are achieved. The Company also granted $0.1 million,
$0.1 million and $0.1 million of FCF PSUs based on a three-year cumulative free cash flow measure (FCF) to its senior
management team in fiscal 2024, 2023 and 2022, respectively. Each recipient of FCF PSUs is eligible to receive between zero
and 200% of the target number of shares of the Company's common stock at the end of the three year or one-year measurement
periods. The PSUs and FCF PSUs were valued at $71.94, $74.35 and $71.16 per share based on the ending stock price on the
date of grant in fiscal 2024, 2023 and 2022, respectively. The PSUs and FCF PSUs cliff-vest three years from the date of grant,
and the Company recognizes compensation expense ratably over the required service period based on its estimate of the number
of shares that will vest upon achieving the measurement criteria. If there is a change in the estimate of the number of shares that
are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate
is made. The Company also granted 0.1 million, 0.1 million and 0.1 million MSUs during fiscal 2024, 2023 and 2022,
respectively, to its senior management team. Each recipient of MSUs is eligible to receive between zero and 200% of the target
number of shares of the Company’s common stock at the end of the three year performance period based upon achieving a
certain total shareholder return relative to a defined peer group. The MSUs were valued at $88.06, $97.91 and $75.43 per share
using the Monte Carlo simulation model in fiscal 2024, 2023 and 2022, respectively. These awards cliff-vest three years from
the date of grant, and the Company recognizes compensation expense for the MSUs ratably over the service period regardless
of the measurement criteria being met.
Employee Stock Purchase Plan
The Hologic, Inc. Amended and Restated 2012 Employee Stock Purchase Plan (“2012 ESPP”) provides for the granting
of up to 8.5 million shares of the Company’s common stock to eligible employees. The 2012 ESPP plan period is semi-annual
and allows participants to purchase the Company’s common stock at 85% of the lower of (i) the market price per share of the
common stock on the first day of the offering period or (ii) the market price per share of the common stock on the purchase
date. Stock-based compensation expense in fiscal 2024, 2023 and 2022 was $7.2 million, $6.9 million and $6.5 million,
respectively.
The Company uses the Black-Scholes model to estimate the fair value of shares to be issued as of the grant date using the
following weighted average assumptions:
F-45
September 28,
2024
September 30,
2023
September 24,
2022
Assumptions:
Risk-free interest rates
5.29 %
4.10 %
0.96 %
Expected life (in years)
0.5
0.5
0.5
Expected volatility
33.4 %
34.0 %
34.0 %
Dividend yield
—
—
—
13. 401(k) Plan
The Company's U.S. employees have access to a qualified 401(k) defined contribution plan. The Company made
contributions of $23.3 million, $23.9 million and $21.8 million for fiscal 2024, 2023 and 2022, respectively.
14. Deferred Compensation Plans
Nonqualified Deferred Compensation Plan
The Company has a Nonqualified Deferred Compensation Plan (“DCP”) which provides non-qualified retirement
benefits to a select group of executive officers, senior management and highly compensated employees of the Company.
Eligible employees may elect to contribute up to 75% of their annual base salary and 100% of their annual bonus to the DCP
and such employee contributions are 100% vested. In addition, the Company may elect to make annual discretionary
contributions on behalf of participants in the DCP. Each Company contribution is subject to a three-year vesting schedule, such
that each contribution vests one third annually. Employee contributions are recorded within accrued expenses.
Upon enrollment into the DCP, employees make investment elections for both their voluntary contributions and
discretionary contributions, if any, made by the Company. Earnings and losses on contributions based on these investment
elections are recorded as a component of compensation expense in the period earned.
Annually, the Compensation Committee of the Board of Directors has approved a discretionary cash contribution to the
DCP for each year. Discretionary contributions by the Company to the DCP are held in a Rabbi Trust. The Company records
compensation expense for the DCP discretionary contributions ratably over the three-year vesting period of each annual
contribution, unless the participant meets the plan retirement provision of reaching a certain age and years of service criteria in
which case the expense is accelerated to match the required service period to receive such benefit. Under the DCP, the
Company recorded compensation expense related to Company contributions of $3.5 million, $3.9 million and $4.0 million in
fiscal 2024, 2023 and 2022, respectively. The full amount of the discretionary contribution, net of forfeitures, along with
employee deferrals is recorded within accrued expenses and totaled $82.4 million and $65.4 million at September 28, 2024 and
September 30, 2023, respectively.
The Company has purchased Company-owned group life insurance contracts, in which both voluntary and discretionary
Company DCP contributions are invested, to partially fund payment of the Company’s obligation to the DCP participants. The
total amount invested at September 28, 2024 and September 30, 2023 was $71.0 million and $56.1 million, respectively. The
values of these life insurance contracts are recorded in other long-term assets. Changes in the cash surrender value of life
insurance contracts, which were not significant in fiscal 2024, 2023 and 2022, are recorded within other income (expense), net.
Deferred Equity Plan
Effective September 17, 2015, the Company adopted the Hologic, Inc. Deferred Equity Plan (the “DEP”). The DEP is
designed to allow executives and non-employee Directors to accumulate Company stock in a tax-efficient manner to meet their
long-term equity accumulation goals and shareholder ownership guidelines. Under the DEP, eligible participants may elect to
defer the settlement of stock units granted under the 2008 Equity Plan until separation from service or separation from service
plus a fixed number of years. Participants may defer settlement by vesting tranche. Although the equity will vest on schedule, if
deferral of settlement is elected, no shares are issued until the settlement date. The settlement date is the earlier of death,
disability, change in control of the Company or separation from service plus the number of years of deferral elected by the
participant. While these shares upon vesting are not distributed to the individuals and are not outstanding, these shares are
included in basic weighted average shares outstanding used to calculate earnings per share.
F-46
15. Non-cancelable Purchase Commitments
The Company has certain non-cancelable purchase obligations primarily related to inventory purchases and diagnostics
instruments, primarily Panther systems, and to a lesser extent other operating expense commitments. These obligations are not
recorded in the Consolidated Balance Sheets. For reasons of quality assurance, sole source availability or cost effectiveness,
certain key components and raw materials and instruments are available only from a sole supplier and the Company has certain
long-term supply contracts to assure continuity of supply. At September 28, 2024, non-cancelable purchase commitments were
as follows:
Fiscal 2025
475.9
Fiscal 2026
7.3
Fiscal 2027
3.4
Fiscal 2028
0.9
Fiscal 2029
0.5
Thereafter
0.7
Total
$
488.7
16. Litigation and Related Matters
On November 4, 2022, a product liability complaint was filed against the Company in Massachusetts state court by a
group of plaintiffs who claim they sustained injuries caused by the BioZorb 3D Bioabsorbable Marker, and additional
complaints were subsequently filed alleging similar claims. The BioZorb device is an implantable three-dimensional marker
that helps clinicians overcome certain challenges presented by breast conserving cancer surgery (lumpectomy). The complaints
allege that the plaintiffs suffered side effects that were not disclosed in the BioZorb instructions for use and make various
additional claims related to the design, manufacture and marketing of the device. Complaints have been filed on behalf of
approximately 100 plaintiffs, one pending in Massachusetts state court, and the remainder in United States District Court for the
District of Massachusetts. Discovery is ongoing. While the Company believes it has valid defenses and plans to vigorously
defend its position, litigation can be costly and unpredictable, and at this early stage the Company cannot reasonably assess the
outcome of this matter.
The Company is a party to various other legal proceedings, claims, governmental and/or regulatory inspections, inquiries
and investigations arising out of the ordinary course of its business. The Company believes that except for the matter described
above there are no other proceedings, claims, inspections, inquiries or investigations pending against it, the ultimate resolution
of which are reasonably likely based upon management’s assessment, to have a material adverse effect on its financial condition
or results of operations. It is possible that future results for any particular quarter or annual period may be materially affected by
changes in our assumptions or the effectiveness of our strategies relating to these matters. In all cases, at each reporting period,
the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable
under ASC 450. Legal costs are expensed as incurred.
17. Business Segments and Geographic Information
The Company reports segment information in accordance with ASC 280, Segment Reporting. Operating segments are
identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the
chief operating decision maker, or decision-making group, in making decisions about how to allocate resources and assess
performance. The Company’s chief operating decision maker is its chief executive officer, and the Company’s reportable
segments have been identified based on the types of products manufactured and the end markets to which the products are sold.
Each reportable segment generates revenue from either the sale of medical equipment and related services and/or sale of
disposable products and supplies, primarily used for diagnostic testing and surgical procedures. The Company has four
reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Company measures and evaluates its
reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such
as intangible asset amortization expense and goodwill and intangible asset impairment charges, transaction and integration
expenses for acquisitions, restructuring, consolidation and divestiture charges, litigation charges, and other one-time or unusual
items.
F-47
Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and
equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other
identifiable assets as corporate assets. There were no intersegment revenues. Segment information for fiscal 2024, 2023, and
2022 was as follows:
Years Ended
September 28,
2024
September 30,
2023
September 24,
2022
Total revenues:
Diagnostics
$
1,782.0 $
1,880.1 $
3,018.5
Breast Health
1,522.9
1,432.7
1,227.8
GYN Surgical
641.3
604.2
522.9
Skeletal Health
84.1
113.4
93.6
$
4,030.3 $
4,030.4 $
4,862.8
Operating income (loss):
Diagnostics
$
303.1 $
193.9 $
1,359.4
Breast Health
394.5
273.0
183.2
GYN Surgical
185.5
188.9
104.9
Skeletal Health
(0.5)
12.6
(7.3)
$
882.6 $
668.4 $
1,640.2
Depreciation and amortization:
Diagnostics
$
218.8 $
224.7 $
274.0
Breast Health
41.6
50.0
58.8
GYN Surgical
48.1
48.0
96.6
Skeletal Health
0.5
0.7
0.7
$
309.0 $
323.4 $
430.1
Capital expenditures:
Diagnostics
$
80.2 $
85.2 $
96.8
Breast Health
30.9
41.1
14.6
GYN Surgical
16.6
17.0
12.8
Skeletal Health
1.4
0.8
0.3
Corporate
1.1
6.1
2.7
$
130.2 $
150.2 $
127.2
Identifiable assets:
Diagnostics
$
2,431.3 $
2,596.4 $
2,881.7
Breast Health
1,588.9
1,170.1
1,245.8
GYN Surgical
1,419.9
1,455.4
1,461.5
Skeletal Health
48.3
33.7
27.5
Corporate
3,667.6
3,883.7
3,454.7
$
9,156.0 $
9,139.3 $
9,071.2
The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon
customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The
Company’s sales in Europe are predominantly derived from the United Kingdom, Germany, France, Spain, Italy, and the
Netherlands. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of
world” designation includes Canada, Latin America and the Middle East.
F-48
Revenues by geography as a percentage of total revenues were as follows:
Years Ended
September 28,
2024
September 30,
2023
September 24,
2022
United States
75.0 %
75.9 %
71.3 %
Europe
13.2 %
12.9 %
18.3 %
Asia-Pacific
6.5 %
6.3 %
7.4 %
Rest of world
5.3 %
4.9 %
3.0 %
100.0 %
100.0 %
100.0 %
The Company’s property, plant and equipment were geographically located as follows:
September 28,
2024
September 30,
2023
September 24,
2022
United States
$
379.7 $
367.6 $
332.4
Europe
70.6
67.0
72.1
Costa Rica
40.0
36.0
32.1
United Kingdom
32.0
32.4
31.7
Rest of world
15.5
14.0
13.3
$
537.8 $
517.0 $
481.6
18. Accrued Expenses and Other Long-Term Liabilities
Accrued expenses and other long-term liabilities consisted of the following:
September 28,
2024
September 30,
2023
Accrued Expenses
Compensation and employee benefits
$
289.0 $
280.1
Income and other taxes
69.4
62.3
Operating leases
24.0
20.4
Other
197.3
171.8
$
579.7 $
534.6
September 28,
2024
September 30,
2023
Other Long-Term Liabilities
Reserve for income tax uncertainties
$
311.8 $
274.3
Operating leases
83.9
47.1
Other
10.6
13.2
$
406.3 $
334.6
F-49
Exhibit 21.1
Subsidiaries of Hologic*
Jurisdiction of Incorporation or Organization
Acessa Health Inc.
Delaware
Beijing Hologic Technology Co., Ltd.
China
Benassar Diagnostica-Equipamientos Medicos Unipessoal, Lda.
Portugal
Bioptics, Inc.
Arizona
Biotheranostics, Inc.
Delaware
Bolder Surgical Holdings, Inc.
Delaware
Bolder Surgical, LLC
Colorado
Cytyc Corporation
Delaware
Cytyc Prenatal Products Corp.
Delaware
Cytyc Surgical Products, LLC
Massachusetts
Diagenode Co., Ltd.
Japan
Diagenode SA
Belgium
Diagenode, LLC
Delaware
Emsor, Sociedad de responsabilidad limitada
Spain
Endomagnetics GmbH
Germany
Endomagnetics Ltd.
United Kingdom
Endomagnetics SAS
France
Endomagnetics, Inc.
Delaware
Faxitron Bioptics, LLC
Delaware
Genewave SAS
France
Gen-Probe Incorporated
Delaware
Gen-Probe Prodesse, Inc.
Wisconsin
Health Beacons, Inc.
Washington
Hologic (Australia & New Zealand) Pty Ltd.
Australia
Hologic (Hainan) Medical Co., Ltd.
China
Hologic Asia Pacific Limited
Hong Kong
Hologic Austria GmbH
Austria
Hologic BV
Belgium
Hologic Bermuda Holding Limited
Bermuda
Hologic Bermuda Holding 2 Limited
Bermuda
Hologic Bermuda Limited
Bermuda
Hologic Canada ULC
Canada
Hologic Capital Holdings, Inc.
Delaware
Hologic Denmark ApS
Denmark
Hologic Deutschland GmbH
Germany
Hologic Espana S.A.
Spain
Hologic Finance Ltd.
Bermuda
Hologic France SARL
France
Hologic GGO 2, LLC
Delaware
Hologic GGO 3 LLP
United Kingdom
Hologic GGO 4 LTD
United Kingdom
Hologic Global Holding LTD
United Kingdom
Hologic Hitec-Imaging GmbH
Germany
Hologic Holdings Limited
United Kingdom
Hologic HUB LTD
United Kingdom
Hologic Iberia, S.L.
Spain
Hologic India LLP
India
Hologic International Holdings B.V.
Netherlands
Hologic IP LTD
United Kingdom
Hologic Ireland Limited
Ireland
Hologic Italia S.r.l.
Italy
Hologic Japan KK
Japan
Hologic Korea Ltd.
Korea
Hologic Latin America (Servicos Em Marketing E Negocios) Ltda.
Brazil
Hologic Ltd.
United Kingdom
Hologic Malaysia SDN. BHD.
Malaysia
Hologic (Shanghai) Medical Supplies Co., Ltd.
China
Hologic Medical Technologies (Beijing) Co., Ltd.
China
Hologic Medicor Suisse GmbH
Switzerland
Hologic MENA, Technical and Scientific Office
Saudi Arabia
Hologic Middle East, Dubai
Dubai
Hologic Netherlands B.V.
Netherlands
Hologic Nordic Holdings Oy
Finland
Hologic Sales and Service, LLC
Massachusetts
Hologic Singapore Pte. Ltd
Singapore
Hologic Suisse SA
Switzerland
Hologic Surgical Products Costa Rica, S.R.L.
Costa Rica
Hologic Sweden AB
Sweden
Hologic Swiss Group GmbH
Switzerland
Hologic Taiwan Ltd.
Taiwan
Hologic UK Finance Ltd.
United Kingdom
Hologic US Finance Co LLC
Delaware
Mobidiag Oy
Finland
Mobidiag Sverige AB
Sweden
Mobidiag UK Ltd.
United Kingdom
Navigation Three Limited
Hong Kong
Normedi AB
Sweden
Normedi Danmark ApS
Denmark
Normedi Finland OyAb
Finland
Normedi Nordic AS
Norway
Normedi Norge AS
Norway
Somatex (HK) Limited
China
Somatex Medical Technologies GmbH
Germany
SuperSonic Imagine (Shanghai) Medical Devices Co., Ltd.
China
Suros Surgical Systems, Inc.
Delaware
TCT International Co., Ltd.
British Virgin Islands
*Subsidiaries not included in the list are omitted because, in aggregate, they are insignificant as defined by Item
601(b)(21) of Regulation S-K.
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1)
Registration Statement (Form S-3 ASR No. 333-268392) pertaining to Hologic, Inc.’s shelf registration
statement for common stock, preferred stock, debt securities, rights, warrants, purchase contracts, units or
any combination of the foregoing, and
(2)
Registration Statements (Form S-8 Nos. 333-271581, 333-150796, 333-181126, 333-188468,
333-210968, 333-224613) pertaining to the equity incentive plans and employee stock purchase plan of
Hologic, Inc.;
of our reports dated November 27, 2024, with respect to the consolidated financial statements of Hologic, Inc. and the
effectiveness of internal control over financial reporting of Hologic, Inc. included in this Annual Report (Form 10-K) of
Hologic, Inc. for the year ended September 28, 2024.
/s/ Ernst & Young LLP
Boston, Massachusetts
November 27, 2024
Exhibit 31.1
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Stephen P. MacMillan, certify that:
1.
I have reviewed this annual report on Form 10-K of Hologic, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons
performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report
financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting.
Date: November 27, 2024
/s/ Stephen P. MacMillan
Stephen P. MacMillan
Chairman, President and Chief Executive Officer
Exhibit 31.2
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Karleen M. Oberton, certify that:
1.
I have reviewed this annual report on Form 10-K of Hologic, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons
performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report
financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting.
Date: November 27, 2024
/s/ Karleen M. Oberton
Karleen M. Oberton
Chief Financial Officer
Exhibit 32.1
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
I, Stephen P. MacMillan, Chief Executive Officer of Hologic, Inc., a Delaware corporation (the “Company”), do hereby
certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title
18, United States Code), that:
(1) The Annual Report on Form 10-K for the year ended September 28, 2024 (the “Form 10-K”) of the Company fully
complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Form 10-K fairly presents, in all material respects, the financial condition and
results of operations of the Company.
Dated: November 27, 2024
/s/ Stephen P. MacMillan
Stephen P. MacMillan
Chairman, President and Chief Executive Officer
A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002 HAS BEEN PROVIDED TO HOLOGIC, INC. AND WILL BE RETAINED BY HOLOGIC, INC. AND
FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.
Exhibit 32.2
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
I, Karleen M. Oberton, Chief Financial Officer of Hologic, Inc., a Delaware corporation (the “Company”), do hereby
certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title
18, United States Code), that:
(1) The Annual Report on Form 10-K for the year ended September 28, 2024 (the “Form 10-K”) of the Company fully
complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Form 10-K fairly presents, in all material respects, the financial condition and
results of operations of the Company.
Dated: November 27, 2024
/s/ Karleen M. Oberton
Karleen M. Oberton
Chief Financial Officer
A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002 HAS BEEN PROVIDED TO HOLOGIC, INC. AND WILL BE RETAINED BY HOLOGIC, INC. AND
FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.
BR436440-0125-10K